

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Commissioner
 US Department of Commerce
 United States Patent and Trademark
 Office, PCT
 2011 South Clark Place Room
 CP2/5C24
 Arlington, VA 22202
 ETATS-UNIS D'AMERIQUE
 in its capacity as elected Office

Date of mailing (day/month/year) 17 July 2001 (17.07.01)	
International application No. PCT/US00/26085	Applicant's or agent's file reference PT-1086 PCT
International filing date (day/month/year) 22 September 2000 (22.09.00)	Priority date (day/month/year) 28 September 1999 (28.09.99)
Applicant HODGSON, David, M. et al	

1. The designated Office is hereby notified of its election made:


☒ in the demand filed with the International Preliminary Examining Authority on:
 27 April 2001 (27.04.01)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was
☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer H. Zhou
Facsimile No.: (41-22) 740.14.35	Telephone No.: (41-22) 338.83.38



PATENT COOPERATION TREATY

Incyte Pharmaceuticals, Inc.
Patent Department
Received

AUG 27 2001

From the INTERNATIONAL SEARCHING AUTHORITY

PCT

NOTIFICATION OF TRANSMITTAL OF
THE INTERNATIONAL SEARCH REPORT
OR THE DECLARATION

(PCT Rule 44.1)

To:

INCYTE GENOMICS, INC.
Attn. HAMLET-COX, D.
3160 Porter Drive
Palo Alto, CA 94304
UNITED STATES OF AMERICADate of mailing
(day/month/year)

21/08/2001

Applicant's or agent's file reference

PT-1086 PCT

FOR FURTHER ACTION

See paragraphs 1 and 4 below

International application No.

PCT/US 00/ 26085

International filing date
(day/month/year)

22/09/2000

Applicant

INCYTE GENOMICS, INC. et al.

- 1.
- ☒
- The applicant is hereby notified that the International Search Report has been established and is transmitted herewith.

Filing of amendments and statement under Article 19:

The applicant is entitled, if he so wishes, to amend the claims of the International Application (see Rule 46):

When? The time limit for filing such amendments is normally 2 months from the date of transmittal of the International Search Report; however, for more details, see the notes on the accompanying sheet.**Where?** Directly to the International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland
Facsimile No.: (41-22) 740.14.35**For more detailed instructions,** see the notes on the accompanying sheet.

- 2.
- ☐
- The applicant is hereby notified that no International Search Report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.

- 3.
- ☐
- With regard to the protest**
- against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:

☐ the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.☐ no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

- 4.
- Further action(s):**
- The applicant is reminded of the following:

Shortly after **18 months** from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90bis.1 and 90bis.3, respectively, before the completion of the technical preparations for international publication.Within **19 months** from the priority date, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later).Within **20 months** from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected in the demand or in a later election within 19 months from the priority date or could not be elected because they are not bound by Chapter II.

Name and mailing address of the International Searching Authority

European Patent Office, P.B. 5818 Patentlaan 2
NL-2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Mireille Claudepierre

These Notes are intended to give the basic instructions concerning the filing of amendments under article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these Notes, "Article", "Rule", and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions, respectively.

INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international publication. Furthermore, it should be emphasized that provisional protection is available in some States only.

What parts of the international application may be amended?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

When?

Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been/is filed, see below.

How?

Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

The amendments must be made in the language in which the international application is to be published.

What documents must/may accompany the amendments?

Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must be in English or French, at the choice of the applicant. However, if the language of the international application is English, the letter must be in English; if the language of the international application is French, the letter must be in French.



The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

1. [Where originally there were 48 claims and after amendment of some claims there are 51]:
"Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; claims 30, 33 and 36 unchanged; new claims 49 to 51 added."
2. [Where originally there were 15 claims and after amendment of all claims there are 11]:
"Claims 1 to 15 replaced by amended claims 1 to 11."
3. [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]:
"Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or
"Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
4. [Where various kinds of amendments are made]:
"Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

"Statement under article 19(1)" (Rule 46.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

It must be in the language in which the international application is to be published.

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

Consequence if a demand for international preliminary examination has already been filed

If, at the time of filing any amendments and any accompanying statement, under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the time of filing the amendments (and any statement) with the International Bureau, also file with the International Preliminary Examining Authority a copy of such amendments (and of any statement) and, where required, a translation of such amendments for the procedure before that Authority (see Rules 55.3(a) and 62.2, first sentence). For further information, see the Notes to the demand form (PCT/IPEA/401).

Consequence with regard to translation of the international application for entry into the national phase

The applicant's attention is drawn to the fact that, upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see Volume II of the PCT Applicant's Guide.

PATENT COOPERATION TREATY

PCT

US

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference PT-1086 PCT	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/US 00/ 26085	International filing date (day/month/year) 22/09/2000	(Earliest) Priority Date (day/month/year) 28/09/1999
Applicant INCYTE GENOMICS, INC. et al.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 6 sheets.

☐ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

☒ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☒ furnished subsequently to this Authority in computer readable form.

☒ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☒ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☐ **Certain claims were found unsearchable** (See Box I).

3. ☒ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☒ None of the figures.



INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 00/26085

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-19 (all partially)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.



FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-19 (all partially)

Invention 1

Isolated polynucleotide comprising a polynucleotide sequence with Seq.ID 1, methods, compositions and microarrays using said polynucleotide, as well as a recombinant polynucleotide comprising a promoter sequence operably linked to Seq.ID 1 and a cell and a transgenic organism comprising such a recombinant polynucleotide, a purified polypeptide encoded by Seq.ID 1, a method of producing such a polypeptide, an antibody which specifically binds to this polypeptide as well as methods of identifying a test compound using this polypeptide.

2. Claims: 1-19 (all partially)

Inventions 2-25

Isolated polynucleotide comprising a polynucleotide sequence with Seq.ID 2, methods, compositions and microarrays using said polynucleotide, as well as a recombinant polynucleotide comprising a promoter sequence operably linked to Seq.ID 2 and a cell and a transgenic organism comprising such a recombinant polynucleotide, a purified polypeptide encoded by Seq.ID 2, a method of producing such a polypeptide, an antibody which specifically binds to this polypeptide as well as methods of identifying a test compound using this polypeptide.

..idem for Seq.IDs 3-25



INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/26085

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/00 C12N15/63 C07K14/47 C07K16/00 C12Q1/68
G01N33/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, EMBL, MEDLINE, EMBASE, BIOSIS, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	✓ DATABASE EMBL [Online] ID/AC: AC010645, 17 September 1999 (1999-09-17) DOE JOINT GENOME INSTITUTE: "Homo sapiens chromosome 19 clone LLNR-268A12" XP002167657	1-3
Y	abstract	4-19
X	✓ DATABASE EMBL [Online] ID/AC: AC003006, 29 October 1997 (1997-10-29) LAMERDIN ET AL.: "Human DNA from overlapping chromosome 19-specific cosmid R32543, and F15613 containing ZNF gene family member, genomic sequence, complete sequence" XP002167658	1-3
Y	abstract	4-19

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

17 May 2001

Date of mailing of the international search report

21.08.01

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Hagenmaier, S



INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/26085

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>✓ AGATA Y ET AL: "Rapid and efficient cloning of cDNAs encoding Kruppel-like zinc finger proteins by degenerate PCR" GENE: AN INTERNATIONAL JOURNAL ON GENES AND GENOMES, GB, ELSEVIER SCIENCE PUBLISHERS, BARKING, vol. 213, no. 1-2, 15 June 1998 (1998-06-15), pages 55-64, XP004125003 ISSN: 0378-1119 the whole document</p> <p>---</p>	4-19
Y	<p>✓ OGURI T ET AL: "The Kruppel-type zinc finger family gene, HKR1, is induced in lung cancer by exposure to platinum drugs" GENE, NL, ELSEVIER BIOMEDICAL PRESS. AMSTERDAM, vol. 222, no. 1, 5 November 1998 (1998-11-05), pages 61-67, XP004151164 ISSN: 0378-1119 the whole document</p> <p>---</p>	4-19
A	<p>✓ SHANNON MARK ET AL: "Comparative analysis of a conserved zinc finger gene cluster on human chromosome 19q and mouse chromosome 7." GENOMICS, vol. 33, no. 1, 1996, pages 112-120, XP002167655 ISSN: 0888-7543 the whole document</p> <p>---</p>	
A	<p>✓ PENGUE GINA ET AL: "Krueppel-associated box-mediated repression of RNA polymerase II promoters is influenced by the arrangement of basal promoter elements." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 93, no. 3, 1996, pages 1015-1020, XP002167656 1996 ISSN: 0027-8424 the whole document</p> <p>---</p>	
A	<p>✓ WO 97 33551 A (MILLENNIUM PHARMACEUTICALS) 18 September 1997 (1997-09-18) the whole document</p> <p>---</p>	
A	<p>✓ WO 99 46293 A (FU GANG ; ZHANG QINGHUA (CN); WANG YAXIN (CN); WU JISHENG (CN); SHA) 16 September 1999 (1999-09-16) the whole document</p> <p>---</p>	

-/--



INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/26085

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	✓ WO 98 56951 A (ABBOTT LAB) 17 December 1998 (1998-12-17) the whole document ---	
A	✓ WO 98 25959 A (CHIRON CORP) 18 June 1998 (1998-06-18) the whole document ---	
A	✓ WO 99 02724 A (MOUNT SINAI HOSPITAL CORP ;BERNSTEIN ALAN (CA); CARUANA GEORGINA ()) 21 January 1999 (1999-01-21) the whole document ---	
P,Y	✓ WO 00 00513 A (SHANGHAI SECOND MEDICAL UNIVER) 6 January 2000 (2000-01-06) the whole document -----	4-19



INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/26085

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9733551	A	18-09-1997	AU 2582897 A US 6268470 B US 6100031 A	01-10-1997 31-07-2001 08-08-2000
WO 9946293	A	16-09-1999	NONE	
WO 9856951	A	17-12-1998	EP 0990045 A	05-04-2000
WO 9825959	A	18-06-1998	AU 5796298 A EP 0948531 A	03-07-1998 13-10-1999
WO 9902724	A	21-01-1999	AU 8203598 A	08-02-1999
WO 0000513	A	06-01-2000	NONE	



MOLECULES FOR DISEASE DETECTION AND TREATMENT

This application claims the benefit of U.S. Ser. No. 60/156,565 filed September 28, 1999 and U.S. Ser. No. 60/168,197 filed November 30, 1999.

5

TECHNICAL FIELD

The present invention relates to molecules for disease detection and treatment and to the use of these sequences in the diagnosis, study, prevention, and treatment of diseases associated with, as well as effects of exogenous compounds on, the expression of molecules for disease detection and treatment.

10

BACKGROUND OF THE INVENTION

The human genome is comprised of thousands of genes, many encoding gene products that function in the maintenance and growth of the various cells and tissues in the body. Aberrant expression or mutations in these genes and their products is the cause of, or is associated with, a variety of human diseases such as cancer and other cell proliferative disorders. The identification of these genes and their products is the basis of an ever-expanding effort to find markers for early detection of diseases, and targets for their prevention and treatment.

15

For example, cancer represents a type of cell proliferative disorder that affects nearly every tissue in the body. A wide variety of molecules, either aberrantly expressed or mutated, can be the cause of, or involved with, various cancers because tissue growth involves complex and ordered patterns of cell proliferation, cell differentiation, and apoptosis. Cell proliferation must be regulated to maintain both the number of cells and their spatial organization. This regulation depends upon the appropriate expression of proteins which control cell cycle progression in response to extracellular signals such as growth factors and other mitogens, and intracellular cues such as DNA damage or nutrient starvation. Molecules which directly or indirectly modulate cell cycle progression fall into several categories, including growth factors and their receptors, second messenger and signal transduction proteins, oncogene products, tumor-suppressor proteins, and mitosis-promoting factors. Aberrant expression or mutations in any of these gene products can result in cell proliferative disorders such as cancer. Oncogenes are genes generally derived from normal genes that, through abnormal expression or mutation, can effect the transformation of a normal cell to a malignant one (oncogenesis). Oncoproteins, encoded by oncogenes, can affect cell proliferation in a variety of ways and include growth factors, growth factor receptors, intracellular signal transducers, nuclear transcription factors, and cell-cycle control proteins. In contrast, tumor-suppressor genes are involved in inhibiting cell proliferation. Mutations which cause reduced or loss of function in tumor-suppressor genes result in aberrant cell proliferation and cancer. Thus a wide variety of genes

20

25

30

35

and their products have been found that are associated with cell proliferative disorders such as cancer, but many more may exist that are yet to be discovered.

DNA-based arrays can provide a simple way to explore the expression of a single polymorphic gene or a large number of genes. When the expression of a single gene is explored, DNA-based arrays are employed to detect the expression of specific gene variants. For example, a p53 tumor suppressor gene array is used to determine whether individuals are carrying mutations that predispose them to cancer. A cytochrome p450 gene array is useful to determine whether individuals have one of a number of specific mutations that could result in increased drug metabolism, drug resistance or drug toxicity.

DNA-based array technology is especially relevant for the rapid screening of expression of a large number of genes. There is a growing awareness that gene expression is affected in a global fashion. A genetic predisposition, disease or therapeutic treatment may affect, directly or indirectly, the expression of a large number of genes. In some cases the interactions may be expected, such as when the genes are part of the same signaling pathway. In other cases, such as when the genes participate in separate signaling pathways, the interactions may be totally unexpected. Therefore, DNA-based arrays can be used to investigate how genetic predisposition, disease, or therapeutic treatment affects the expression of a large number of genes.

The discovery of new molecules for disease detection and treatment satisfies a need in the art by providing new compositions which are useful in the diagnosis, study, prevention, and treatment of diseases associated with, as well as effects of exogenous compounds on, the expression of molecules for disease detection and treatment.

SUMMARY OF THE INVENTION

The present invention relates to human disease detection and treatment molecule polynucleotides (mddt) as presented in the Sequence Listing. The mddt uniquely identify genes encoding structural, functional, and regulatory disease detection and treatment molecules.

The invention provides an isolated polynucleotide comprising a polynucleotide sequence selected from the group consisting of a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:1-25; b) a naturally occurring polynucleotide sequence having at least 90% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:1-25; c) a polynucleotide sequence complementary to a); d) a polynucleotide sequence complementary to b); and e) an RNA equivalent of a) through d). In one alternative, the polynucleotide comprises a polynucleotide sequence selected from the group consisting of SEQ ID NO:1-25. In another alternative, the polynucleotide comprises at least 60 contiguous nucleotides of a polynucleotide sequence selected from the group consisting of a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:1-25; b) a naturally occurring polynucleotide sequence having at least 90%

sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:1-25; c) a polynucleotide sequence complementary to a); d) a polynucleotide sequence complementary to b); and e) an RNA equivalent of a) through d). The invention further provides a composition for the detection of expression of disease detection and treatment molecule polynucleotides comprising at least one isolated polynucleotide comprising a polynucleotide sequence selected from the group consisting of a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:1-25; b) a naturally occurring polynucleotide sequence having at least 90% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:1-25; c) a polynucleotide sequence complementary to a); d) a polynucleotide sequence complementary to b); and e) an RNA equivalent of a) through d); and a detectable label.

The invention also provides a method for detecting a target polynucleotide in a sample, said target polynucleotide comprising a polynucleotide sequence selected from the group consisting of a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:1-25; b) a naturally occurring polynucleotide sequence having at least 90% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:1-25; c) a polynucleotide sequence complementary to a); d) a polynucleotide sequence complementary to b); and e) an RNA equivalent of a) through d). The method comprises a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide, and b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof. In one alternative, the probe comprises at least 30 contiguous nucleotides. In another alternative, the probe comprises at least 60 contiguous nucleotides.

The invention further provides a recombinant polynucleotide comprising a promoter sequence operably linked to an isolated polynucleotide comprising a polynucleotide sequence selected from the group consisting of a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:1-25; b) a naturally occurring polynucleotide sequence having at least 90% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:1-25; c) a polynucleotide sequence complementary to a); d) a polynucleotide sequence complementary to b); and e) an RNA equivalent of a) through d). In one alternative, the invention provides a cell transformed with the recombinant polynucleotide. In another alternative, the invention provides a transgenic organism comprising the recombinant polynucleotide. In a further alternative, the invention provides a method for producing a disease detection and treatment molecule polypeptide, the method comprising a) culturing a cell under conditions suitable for expression of the disease detection and treatment molecule polypeptide, wherein said cell is transformed with the recombinant polynucleotide, and b)

recovering the disease detection and treatment molecule polypeptide so expressed.

The invention also provides a purified disease detection and treatment molecule polypeptide (MDDT) encoded by at least one polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:1-25. Additionally, the invention provides an isolated antibody
5 which specifically binds to the disease detection and treatment molecule polypeptide. The invention further provides a method of identifying a test compound which specifically binds to the disease detection and treatment molecule polypeptide, the method comprising the steps of a) providing a test compound; b) combining the disease detection and treatment molecule polypeptide with the test compound for a sufficient time and under suitable conditions for binding; and c) detecting binding of
10 the disease detection and treatment molecule polypeptide to the test compound, thereby identifying the test compound which specifically binds the disease detection and treatment molecule polypeptide.

The invention further provides a microarray wherein at least one element of the microarray is an isolated polynucleotide comprising at least 60 contiguous nucleotides of a polynucleotide comprising a polynucleotide sequence selected from the group consisting of a) a polynucleotide
15 sequence selected from the group consisting of SEQ ID NO:1-25; b) a naturally occurring polynucleotide sequence having at least 90% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:1-25; c) a polynucleotide sequence complementary to a); d) a polynucleotide sequence complementary to b); and e) an RNA equivalent of a) through d). The invention also provides a method for generating a transcript image of a sample which contains
20 polynucleotides. The method comprises a) labeling the polynucleotides of the sample, b) contacting the elements of the microarray with the labeled polynucleotides of the sample under conditions suitable for the formation of a hybridization complex, and c) quantifying the expression of the polynucleotides in the sample.

Additionally, the invention provides a method for screening a compound for effectiveness in
25 altering expression of a target polynucleotide, wherein said target polynucleotide comprises a polynucleotide sequence selected from the group consisting of a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:1-25; b) a naturally occurring polynucleotide sequence having at least 90% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:1-25; c) a polynucleotide sequence complementary to a); d) a
30 polynucleotide sequence complementary to b); and e) an RNA equivalent of a) through d). The method comprises a) exposing a sample comprising the target polynucleotide to a compound, and b) detecting altered expression of the target polynucleotide.

The invention further provides a method for assessing toxicity of a test compound, said method comprising a) treating a biological sample containing nucleic acids with the test compound;
35 b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide comprising a polynucleotide sequence selected from the

group consisting of i) a polynucleotide sequence selected from the group consisting of SEQ ID NO:1-25; ii) a naturally occurring polynucleotide sequence having at least 90% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:1-25; iii) a polynucleotide sequence complementary to i), iv) a polynucleotide sequence complementary to ii), and v) an RNA equivalent of i)-iv). Hybridization occurs under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence selected from the group consisting of i) a polynucleotide sequence selected from the group consisting of SEQ ID NO:1-25; ii) a naturally occurring polynucleotide sequence having at least 90% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:1-25; iii) a polynucleotide sequence complementary to i), iv) a polynucleotide sequence complementary to ii), and v) an RNA equivalent of i)-iv), and alternatively, the target polynucleotide comprises a fragment of a polynucleotide sequence selected from the group consisting of i-v above; c) quantifying the amount of hybridization complex; and d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

DESCRIPTION OF THE TABLES

Table 1 shows the sequence identification numbers (SEQ ID NO:s) and template identification numbers (template IDs) corresponding to the polynucleotides of the present invention, along with their GenBank hits (GI Numbers), probability scores, and functional annotations corresponding to the GenBank hits.

Table 2 shows the sequence identification numbers (SEQ ID NO:s) and template identification numbers (template IDs) corresponding to the polynucleotides of the present invention, along with polynucleotide segments of each template sequence as defined by the indicated "start" and "stop" nucleotide positions. The reading frames of the polynucleotide segments and the Pfam hits, Pfam descriptions, and E-values corresponding to the polypeptide domains encoded by the polynucleotide segments are indicated.

Table 3 shows the sequence identification numbers (SEQ ID NO:s) and template identification numbers (template IDs) corresponding to the polynucleotides of the present invention, along with polynucleotide segments of each template sequence as defined by the indicated "start" and "stop" nucleotide positions. The reading frames of the polynucleotide segments are shown, and the polypeptides encoded by the polynucleotide segments constitute either signal peptide (SP) or transmembrane (TM) domains, as indicated.

Table 4A and Table 4B show the sequence identification numbers (SEQ ID NO:s) and

template identification numbers (template IDs) corresponding to the polynucleotides of the present invention, along with component sequence identification numbers (component IDs) corresponding to each template. The component sequences, which were used to assemble the template sequences, are defined by the indicated "start" and "stop" nucleotide positions along each template.

5 Table 5 shows the tissue distribution profiles for the templates of the invention.

Table 6 summarizes the bioinformatics tools which are useful for analysis of the polynucleotides of the present invention. The first column of Table 6 lists analytical tools, programs, and algorithms, the second column provides brief descriptions thereof, the third column presents appropriate references, all of which are incorporated by reference herein in their entirety, and the
10 fourth column presents, where applicable, the scores, probability values, and other parameters used to evaluate the strength of a match between two sequences (the higher the score, the greater the homology between two sequences).

DETAILED DESCRIPTION OF THE INVENTION

15 Before the nucleic acid sequences and methods are presented, it is to be understood that this invention is not limited to the particular machines, methods, and materials described. Although particular embodiments are described, machines, methods, and materials similar or equivalent to these embodiments may be used to practice the invention. The preferred machines, methods, and materials set forth are not intended to limit the scope of the invention which is limited only by the
20 appended claims.

The singular forms "a", "an", and "the" include plural reference unless the context clearly dictates otherwise. All technical and scientific terms have the meanings commonly understood by one of ordinary skill in the art. All publications are incorporated by reference for the purpose of describing and disclosing the cell lines, vectors, and methodologies which are presented and which
25 might be used in connection with the invention. Nothing in the specification is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

Definitions

As used herein, the lower case "mddt" refers to a nucleic acid sequence, while the upper case
30 "MDDT" refers to an amino acid sequence encoded by mddt. A "full-length" mddt refers to a nucleic acid sequence containing the entire coding region of a gene endogenously expressed in human tissue.

"Adjuvants" are materials such as Freund's adjuvant, mineral gels (aluminum hydroxide), and surface active substances (lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol) which may be administered to increase a host's
35 immunological response.

"Allele" refers to an alternative form of a nucleic acid sequence. Alleles result from a

"mutation," a change or an alternative reading of the genetic code. Any given gene may have none, one, or many allelic forms. Mutations which give rise to alleles include deletions, additions, or substitutions of nucleotides. Each of these changes may occur alone, or in combination with the others, one or more times in a given nucleic acid sequence. The present invention encompasses allelic mddt.

"Amino acid sequence" refers to a peptide, a polypeptide, or a protein of either natural or synthetic origin. The amino acid sequence is not limited to the complete, endogenous amino acid sequence and may be a fragment, epitope, variant, or derivative of a protein expressed by a nucleic acid sequence.

"Amplification" refers to the production of additional copies of a sequence and is carried out using polymerase chain reaction (PCR) technologies well known in the art.

"Antibody" refers to intact molecules as well as to fragments thereof, such as Fab, F(ab')₂, and Fv fragments, which are capable of binding the epitopic determinant. Antibodies that bind MDDT polypeptides can be prepared using intact polypeptides or using fragments containing small peptides of interest as the immunizing antigen. The polypeptide or peptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize the animal.

"Antisense sequence" refers to a sequence capable of specifically hybridizing to a target sequence. The antisense sequence may include DNA, RNA, or any nucleic acid mimic or analog such as peptide nucleic acid (PNA); oligonucleotides having modified backbone linkages such as phosphorothioates, methylphosphonates, or benzylphosphonates; oligonucleotides having modified sugar groups such as 2'-methoxyethyl sugars or 2'-methoxyethoxy sugars; or oligonucleotides having modified bases such as 5-methyl cytosine, 2'-deoxyuracil, or 7-deaza-2'-deoxyguanosine.

"Antisense sequence" refers to a sequence capable of specifically hybridizing to a target sequence. The antisense sequence can be DNA, RNA, or any nucleic acid mimic or analog.

"Antisense technology" refers to any technology which relies on the specific hybridization of an antisense sequence to a target sequence.

A "bin" is a portion of computer memory space used by a computer program for storage of data, and bounded in such a manner that data stored in a bin may be retrieved by the program.

"Biologically active" refers to an amino acid sequence having a structural, regulatory, or biochemical function of a naturally occurring amino acid sequence.

"Clone joining" is a process for combining gene bins based upon the bins' containing sequence information from the same clone. The sequences may assemble into a primary gene transcript as well as one or more splice variants.

"Complementary" describes the relationship between two single-stranded nucleic acid sequences that anneal by base-pairing (5'-A-G-T-3' pairs with its complement 3'-T-C-A-5').

A "component sequence" is a nucleic acid sequence selected by a computer program such as PHRED and used to assemble a consensus or template sequence from one or more component sequences.

A "consensus sequence" or "template sequence" is a nucleic acid sequence which has been assembled from overlapping sequences, using a computer program for fragment assembly such as the GELVIEW fragment assembly system (Genetics Computer Group (GCG), Madison WI) or using a relational database management system (RDMS).

"Conservative amino acid substitutions" are those substitutions that, when made, least interfere with the properties of the original protein, i.e., the structure and especially the function of the protein is conserved and not significantly changed by such substitutions. The table below shows amino acids which may be substituted for an original amino acid in a protein and which are regarded as conservative substitutions.

15

	Original Residue	Conservative Substitution
	Ala	Gly, Ser
	Arg	His, Lys
	Asn	Asp, Gln, His
20	Asp	Asn, Glu
	Cys	Ala, Ser
	Gln	Asn, Glu, His
	Glu	Asp, Gln, His
	Gly	Ala
25	His	Asn, Arg, Gln, Glu
	Ile	Leu, Val
	Leu	Ile, Val
	Lys	Arg, Gln, Glu
	Met	Leu, Ile
30	Phe	His, Met, Leu, Trp, Tyr
	Ser	Cys, Thr
	Thr	Ser, Val
	Trp	Phe, Tyr
	Tyr	His, Phe, Trp
35	Val	Ile, Leu, Thr

Conservative substitutions generally maintain (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a beta sheet or alpha helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain.

40

"Deletion" refers to a change in either a nucleic or amino acid sequence in which at least one nucleotide or amino acid residue, respectively, is absent.

"Derivative" refers to the chemical modification of a nucleic acid sequence, such as by replacement of hydrogen by an alkyl, acyl, amino, hydroxyl, or other group.

The terms "element" and "array element" refer to a polynucleotide, polypeptide, or other chemical compound having a unique and defined position on a microarray.

5 "E-value" refers to the statistical probability that a match between two sequences occurred by chance.

A "fragment" is a unique portion of mddt or MDDT which is identical in sequence to but shorter in length than the parent sequence. A fragment may comprise up to the entire length of the defined sequence, minus one nucleotide/amino acid residue. For example, a fragment may comprise
10 from 10 to 1000 contiguous amino acid residues or nucleotides. A fragment used as a probe, primer, antigen, therapeutic molecule, or for other purposes, may be at least 5, 10, 15, 16, 20, 25, 30, 40, 50, 60, 75, 100, 150, 250 or at least 500 contiguous amino acid residues or nucleotides in length. Fragments may be preferentially selected from certain regions of a molecule. For example, a polypeptide fragment may comprise a certain length of contiguous amino acids selected from the first
15 250 or 500 amino acids (or first 25% or 50%) of a polypeptide as shown in a certain defined sequence. Clearly these lengths are exemplary, and any length that is supported by the specification, including the Sequence Listing and the figures, may be encompassed by the present embodiments.

A fragment of mddt comprises a region of unique polynucleotide sequence that specifically identifies mddt, for example, as distinct from any other sequence in the same genome. A fragment of
20 mddt is useful, for example, in hybridization and amplification technologies and in analogous methods that distinguish mddt from related polynucleotide sequences. The precise length of a fragment of mddt and the region of mddt to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

A fragment of MDDT is encoded by a fragment of mddt. A fragment of MDDT comprises a
25 region of unique amino acid sequence that specifically identifies MDDT. For example, a fragment of MDDT is useful as an immunogenic peptide for the development of antibodies that specifically recognize MDDT. The precise length of a fragment of MDDT and the region of MDDT to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

30 A "full length" nucleotide sequence is one containing at least a start site for translation to a protein sequence, followed by an open reading frame and a stop site, and encoding a "full length" polypeptide.

"Hit" refers to a sequence whose annotation will be used to describe a given template. Criteria for selecting the top hit are as follows: if the template has one or more exact nucleic acid
35 matches, the top hit is the exact match with highest percent identity. If the template has no exact matches but has significant protein hits, the top hit is the protein hit with the lowest E-value. If the

template has no significant protein hits, but does have significant non-exact nucleotide hits, the top hit is the nucleotide hit with the lowest E-value.

“Homology” refers to sequence similarity either between a reference nucleic acid sequence and at least a fragment of an mddt or between a reference amino acid sequence and a fragment of an MDDT.

“Hybridization” refers to the process by which a strand of nucleotides anneals with a complementary strand through base pairing. Specific hybridization is an indication that two nucleic acid sequences share a high degree of identity. Specific hybridization complexes form under defined annealing conditions, and remain hybridized after the “washing” step. The defined-hybridization conditions include the annealing conditions and the washing step(s), the latter of which is particularly important in determining the stringency of the hybridization process, with more stringent conditions allowing less non-specific binding, i.e., binding between pairs of nucleic acid probes that are not perfectly matched. Permissive conditions for annealing of nucleic acid sequences are routinely determinable and may be consistent among hybridization experiments, whereas wash conditions may be varied among experiments to achieve the desired stringency.

Generally, stringency of hybridization is expressed with reference to the temperature under which the wash step is carried out. Generally, such wash temperatures are selected to be about 5°C to 20°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. An equation for calculating T_m and conditions for nucleic acid hybridization is well known and can be found in Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; specifically see volume 2, chapter 9.

High stringency conditions for hybridization between polynucleotides of the present invention include wash conditions of 68°C in the presence of about 0.2 x SSC and about 0.1% SDS, for 1 hour. Alternatively, temperatures of about 65°C, 60°C, or 55°C may be used. SSC concentration may be varied from about 0.2 to 2 x SSC, with SDS being present at about 0.1%. Typically, blocking reagents are used to block non-specific hybridization. Such blocking reagents include, for instance, denatured salmon sperm DNA at about 100-200 µg/ml. Useful variations on these conditions will be readily apparent to those skilled in the art. Hybridization, particularly under high stringency conditions, may be suggestive of evolutionary similarity between the nucleotides. Such similarity is strongly indicative of a similar role for the nucleotides and their resultant proteins.

Other parameters, such as temperature, salt concentration, and detergent concentration may be varied to achieve the desired stringency. Denaturants, such as formamide at a concentration of about 35-50% v/v, may also be used under particular circumstances, such as RNA:DNA hybridizations. Appropriate hybridization conditions are routinely determinable by one of ordinary

"Immunogenic" describes the potential for a natural, recombinant, or synthetic peptide, epitope, polypeptide, or protein to induce antibody production in appropriate animals, cells, or cell lines.

5 "Insertion" or "addition" refers to a change in either a nucleic or amino acid sequence in which at least one nucleotide or residue, respectively, is added to the sequence.

"Labeling" refers to the covalent or noncovalent joining of a polynucleotide, polypeptide, or antibody with a reporter molecule capable of producing a detectable or measurable signal.

10 "Microarray" is any arrangement of nucleic acids, amino acids, antibodies, etc., on a substrate. The substrate may be a solid support such as beads, glass, paper, nitrocellulose, nylon, or an appropriate membrane.

"Linkers" are short stretches of nucleotide sequence which may be added to a vector or an mddt to create restriction endonuclease sites to facilitate cloning. "Polylinkers" are engineered to incorporate multiple restriction enzyme sites and to provide for the use of enzymes which leave 5' or
15 3' overhangs (e.g., BamHI, EcoRI, and HindIII) and those which provide blunt ends (e.g., EcoRV, SnaBI, and StuI).

"Naturally occurring" refers to an endogenous polynucleotide or polypeptide that may be isolated from viruses or prokaryotic or eukaryotic cells.

20 "Nucleic acid sequence" refers to the specific order of nucleotides joined by phosphodiester bonds in a linear, polymeric arrangement. Depending on the number of nucleotides, the nucleic acid sequence can be considered an oligomer, oligonucleotide, or polynucleotide. The nucleic acid can be DNA, RNA, or any nucleic acid analog, such as PNA, may be of genomic or synthetic origin, may be either double-stranded or single-stranded, and can represent either the sense or antisense (complementary) strand.

25 "Oligomer" refers to a nucleic acid sequence of at least about 6 nucleotides and as many as about 60 nucleotides, preferably about 15 to 40 nucleotides, and most preferably between about 20 and 30 nucleotides, that may be used in hybridization or amplification technologies. Oligomers may be used as, e.g., primers for PCR, and are usually chemically synthesized.

30 "Operably linked" refers to the situation in which a first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Generally, operably linked DNA sequences may be in close proximity or contiguous and, where necessary to join two protein coding regions, in the same reading frame.

35 "Peptide nucleic acid" (PNA) refers to a DNA mimic in which nucleotide bases are attached to a pseudopeptide backbone to increase stability. PNAs, also designated antigene agents, can prevent gene expression by targeting complementary messenger RNA.

The phrases "percent identity" and "% identity", as applied to polynucleotide sequences, refer to the percentage of residue matches between at least two polynucleotide sequences aligned using a standardized algorithm. Such an algorithm may insert, in a standardized and reproducible way, gaps in the sequences being compared in order to optimize alignment between two sequences, and therefore achieve a more meaningful comparison of the two sequences.

Percent identity between polynucleotide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program. This program is part of the LASERGENE software package, a suite of molecular biological analysis programs (DNASTAR, Madison WI). CLUSTAL V is described in Higgins, D.G. and Sharp, P.M. (1989) CABIOS 5:151-153 and in Higgins, D.G. et al. (1992) CABIOS 8:189-191. For pairwise alignments of polynucleotide sequences, the default parameters are set as follows: Ktuple=2, gap penalty=5, window=4, and "diagonals saved"=4. The "weighted" residue weight table is selected as the default. Percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polynucleotide sequence pairs.

Alternatively, a suite of commonly used and freely available sequence comparison algorithms is provided by the National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST) (Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410), which is available from several sources, including the NCBI, Bethesda, MD, and on the Internet at <http://www.ncbi.nlm.nih.gov/BLAST/>. The BLAST software suite includes various sequence analysis programs including "blastn," that is used to determine alignment between a known polynucleotide sequence and other sequences on a variety of databases. Also available is a tool called "BLAST 2 Sequences" that is used for direct pairwise comparison of two nucleotide sequences. "BLAST 2 Sequences" can be accessed and used interactively at <http://www.ncbi.nlm.nih.gov/gorf/bl2/>. The "BLAST 2 Sequences" tool can be used for both blastn and blastp (discussed below). BLAST programs are commonly used with gap and other parameters set to default settings. For example, to compare two nucleotide sequences, one may use blastn with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such default parameters may be, for example:

Matrix: BLOSUM62

Reward for match: 1

Penalty for mismatch: -2

Open Gap: 5 and Extension Gap: 2 penalties

Gap x drop-off: 50

Expect: 10

Word Size: 11

Filter: on

Percent identity may be measured over the length of an entire defined sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined sequence, for instance, a fragment of at least 20, at least 30, at least 40, at least 50, at least 70, at least 100, or at least 200 contiguous nucleotides. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in figures or Sequence Listings, may be used to describe a length over which percentage identity may be measured.

Nucleic acid sequences that do not show a high degree of identity may nevertheless encode similar amino acid sequences due to the degeneracy of the genetic code. It is understood that changes in nucleic acid sequence can be made using this degeneracy to produce multiple nucleic acid sequences that all encode substantially the same protein.

The phrases "percent identity" and "% identity", as applied to polypeptide sequences, refer to the percentage of residue matches between at least two polypeptide sequences aligned using a standardized algorithm. Methods of polypeptide sequence alignment are well-known. Some alignment methods take into account conservative amino acid substitutions. Such conservative substitutions, explained in more detail above, generally preserve the hydrophobicity and acidity of the substituted residue, thus preserving the structure (and therefore function) of the folded polypeptide.

Percent identity between polypeptide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program (described and referenced above). For pairwise alignments of polypeptide sequences using CLUSTAL V, the default parameters are set as follows: Ktuple=1, gap penalty=3, window=5, and "diagonals saved"=5. The PAM250 matrix is selected as the default residue weight table. As with polynucleotide alignments, the percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polypeptide sequence pairs.

Alternatively the NCBI BLAST software suite may be used. For example, for a pairwise comparison of two polypeptide sequences, one may use the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) with blastp set at default parameters. Such default parameters may be, for example:

Matrix: BLOSUM62

Open Gap: 11 and Extension Gap: 1 penalty

Gap x drop-off: 50

Expect: 10

Word Size: 3

Filter: on

Percent identity may be measured over the length of an entire defined polypeptide sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for

example, over the length of a fragment taken from a larger, defined polypeptide sequence. for instance, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least 150 contiguous residues. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in figures or Sequence Listings, may be used to describe a length over which percentage identity may be measured.

"Post-translational modification" of an MDDT may involve lipidation, glycosylation, phosphorylation, acetylation, racemization, proteolytic cleavage, and other modifications known in the art. These processes may occur synthetically or biochemically. Biochemical modifications will vary by cell type depending on the enzymatic milieu and the MDDT.

"Probe" refers to mddt or fragments thereof, which are used to detect identical, allelic or related nucleic acid sequences. Probes are isolated oligonucleotides or polynucleotides attached to a detectable label or reporter molecule. Typical labels include radioactive isotopes, ligands, chemiluminescent agents, and enzymes. "Primers" are short nucleic acids, usually DNA oligonucleotides, which may be annealed to a target polynucleotide by complementary base-pairing. The primer may then be extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification (and identification) of a nucleic acid sequence, e.g., by the polymerase chain reaction (PCR).

Probes and primers as used in the present invention typically comprise at least 15 contiguous nucleotides of a known sequence. In order to enhance specificity, longer probes and primers may also be employed, such as probes and primers that comprise at least 20, 30, 40, 50, 60, 70, 80, 90, 100, or at least 150 consecutive nucleotides of the disclosed nucleic acid sequences. Probes and primers may be considerably longer than these examples, and it is understood that any length supported by the specification, including the figures and Sequence Listing, may be used.

Methods for preparing and using probes and primers are described in the references, for example Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; Ausubel et al., 1987, Current Protocols in Molecular Biology, Greene Publ. Assoc. & Wiley-Intersciences, New York NY; Innis et al., 1990, PCR Protocols, A Guide to Methods and Applications, Academic Press, San Diego CA. PCR primer pairs can be derived from a known sequence, for example, by using computer programs intended for that purpose such as Primer (Version 0.5, 1991, Whitehead Institute for Biomedical Research, Cambridge MA).

Oligonucleotides for use as primers are selected using software known in the art for such purpose. For example, OLIGO 4.06 software is useful for the selection of PCR primer pairs of up to 100 nucleotides each, and for the analysis of oligonucleotides and larger polynucleotides of up to 5,000 nucleotides from an input polynucleotide sequence of up to 32 kilobases. Similar primer selection programs have incorporated additional features for expanded capabilities. For example, the PrimOU primer selection program (available to the public from the Genome Center at University of

Texas South West Medical Center, Dallas TX) is capable of choosing specific primers from megabase sequences and is thus useful for designing primers on a genome-wide scope. The Primer3 primer selection program (available to the public from the Whitehead Institute/MIT Center for Genome Research, Cambridge MA) allows the user to input a "mispriming library," in which sequences to avoid as primer binding sites are user-specified. Primer3 is useful, in particular, for the selection of oligonucleotides for microarrays. (The source code for the latter two primer selection programs may also be obtained from their respective sources and modified to meet the user's specific needs.) The PrimeGen program (available to the public from the UK Human Genome Mapping Project Resource Centre, Cambridge UK) designs primers based on multiple sequence alignments, thereby allowing selection of primers that hybridize to either the most conserved or least conserved regions of aligned nucleic acid sequences. Hence, this program is useful for identification of both unique and conserved oligonucleotides and polynucleotide fragments. The oligonucleotides and polynucleotide fragments identified by any of the above selection methods are useful in hybridization technologies, for example, as PCR or sequencing primers, microarray elements, or specific probes to identify fully or partially complementary polynucleotides in a sample of nucleic acids. Methods of oligonucleotide selection are not limited to those described above.

"Purified" refers to molecules, either polynucleotides or polypeptides that are isolated or separated from their natural environment and are at least 60% free, preferably at least 75% free, and most preferably at least 90% free from other compounds with which they are naturally associated.

A "recombinant nucleic acid" is a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two or more otherwise separated segments of sequence. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques such as those described in Sambrook, *supra*. The term recombinant includes nucleic acids that have been altered solely by addition, substitution, or deletion of a portion of the nucleic acid. Frequently, a recombinant nucleic acid may include a nucleic acid sequence operably linked to a promoter sequence. Such a recombinant nucleic acid may be part of a vector that is used, for example, to transform a cell.

Alternatively, such recombinant nucleic acids may be part of a viral vector, e.g., based on a vaccinia virus, that could be used to vaccinate a mammal wherein the recombinant nucleic acid is expressed, inducing a protective immunological response in the mammal.

"Regulatory element" refers to a nucleic acid sequence from nontranslated regions of a gene, and includes enhancers, promoters, introns, and 3' untranslated regions, which interact with host proteins to carry out or regulate transcription or translation.

"Reporter" molecules are chemical or biochemical moieties used for labeling a nucleic acid, an amino acid, or an antibody. They include radionuclides; enzymes; fluorescent, chemiluminescent,

or chromogenic agents; substrates; cofactors; inhibitors; magnetic particles; and other moieties known in the art.

An "RNA equivalent," in reference to a DNA sequence, is composed of the same linear sequence of nucleotides as the reference DNA sequence with the exception that all occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

"Sample" is used in its broadest sense. Samples may contain nucleic or amino acids, antibodies, or other materials, and may be derived from any source (e.g., bodily fluids including, but not limited to, saliva, blood, and urine; chromosome(s), organelles, or membranes isolated from a cell; genomic DNA, RNA, or cDNA in solution or bound to a substrate; and cleared cells or tissues or blots or imprints from such cells or tissues).

"Specific binding" or "specifically binding" refers to the interaction between a protein or peptide and its agonist, antibody, antagonist, or other binding partner. The interaction is dependent upon the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope "A," the presence of a polypeptide containing epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the antibody.

"Substitution" refers to the replacement of at least one nucleotide or amino acid by a different nucleotide or amino acid.

"Substrate" refers to any suitable rigid or semi-rigid support including, e.g., membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers, microparticles or capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.

A "transcript image" refers to the collective pattern of gene expression by a particular tissue or cell type under given conditions at a given time.

"Transformation" refers to a process by which exogenous DNA enters a recipient cell. Transformation may occur under natural or artificial conditions using various methods well known in the art. Transformation may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method is selected based on the host cell being transformed.

"Transformants" include stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome, as well as cells which transiently express inserted DNA or RNA.

A "transgenic organism," as used herein, is any organism, including but not limited to animals and plants, in which one or more of the cells of the organism contains heterologous nucleic acid

introduced by way of human intervention, such as by transgenic techniques well known in the art. The nucleic acid is introduced into the cell, directly or indirectly by introduction into a precursor of the cell, by way of deliberate genetic manipulation, such as by microinjection or by infection with a recombinant virus. The term genetic manipulation does not include classical cross-breeding, or in
5 vitro fertilization, but rather is directed to the introduction of a recombinant DNA molecule. The transgenic organisms contemplated in accordance with the present invention include bacteria, cyanobacteria, fungi, and plants and animals. The isolated DNA of the present invention can be introduced into the host by methods known in the art, for example infection, transfection, transformation or transconjugation. Techniques for transferring the DNA of the present invention
10 into such organisms are widely known and provided in references such as Sambrook et al. (1989), supra.

A "variant" of a particular nucleic acid sequence is defined as a nucleic acid sequence having at least 25% sequence identity to the particular nucleic acid sequence over a certain length of one of the nucleic acid sequences using blastn with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-
15 1999) set at default parameters. Such a pair of nucleic acids may show, for example, at least 30%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or even at least 98% or greater sequence identity over a certain defined length. The variant may result in "conservative" amino acid changes which do not affect structural and/or chemical properties. A variant may be described as, for example, an "allelic" (as defined above), "splice," "species," or "polymorphic"
20 variant. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternate splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or lack domains that are present in the reference molecule. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides generally will have significant
25 amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass "single nucleotide polymorphisms" (SNPs) in which the polynucleotide sequence varies by one base. The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.

30 In an alternative, variants of the polynucleotides of the present invention may be generated through recombinant methods. One possible method is a DNA shuffling technique such as MOLECULARBREEDING (Maxygen Inc., Santa Clara CA; described in U.S. Patent Number 5,837,458; Chang, C.-C. et al. (1999) Nat. Biotechnol. 17:793-797; Christians, F.C. et al. (1999) Nat. Biotechnol. 17:259-264; and Cramer, A. et al. (1996) Nat. Biotechnol. 14:315-319) to alter or
35 improve the biological properties of MDDT, such as its biological or enzymatic activity or its ability to bind to other molecules or compounds. DNA shuffling is a process by which a library of gene

variants is produced using PCR-mediated recombination of gene fragments. The library is then subjected to selection or screening procedures that identify those gene variants with the desired properties. These preferred variants may then be pooled and further subjected to recursive rounds of DNA shuffling and selection/screening. Thus, genetic diversity is created through "artificial" breeding and rapid molecular evolution. For example, fragments of a single gene containing random point mutations may be recombined, screened, and then reshuffled until the desired properties are optimized. Alternatively, fragments of a given gene may be recombined with fragments of homologous genes in the same gene family, either from the same or different species, thereby maximizing the genetic diversity of multiple naturally occurring genes in a directed and controllable manner.

A "variant" of a particular polypeptide sequence is defined as a polypeptide sequence having at least 40% sequence identity to the particular polypeptide sequence over a certain length of one of the polypeptide sequences using blastp with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of polypeptides may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98% or greater sequence identity over a certain defined length of one of the polypeptides.

THE INVENTION

In a particular embodiment, cDNA sequences derived from human tissues and cell lines were aligned based on nucleotide sequence identity and assembled into "consensus" or "template" sequences which are designated by the template identification numbers (template IDs) in column 2 of Table 1. The sequence identification numbers (SEQ ID NO:s) corresponding to the template IDs are shown in column 1. The template sequences have similarity to GenBank sequences, or "hits," as designated by the GI Numbers in column 3. The statistical probability of each GenBank hit is indicated by a probability score in column 4, and the functional annotation corresponding to each GenBank hit is listed in column 5.

The invention incorporates the nucleic acid sequences of these templates as disclosed in the Sequence Listing and the use of these sequences in the diagnosis and treatment of disease states characterized by defects in disease detection and treatment molecule molecules. The invention further utilizes these sequences in hybridization and amplification technologies, and in particular, in technologies which assess gene expression patterns correlated with specific cells or tissues and their responses in vivo or in vitro to pharmaceutical agents, toxins, and other treatments. In this manner, the sequences of the present invention are used to develop a transcript image for a particular cell or tissue.

Derivation of Nucleic Acid Sequences

cDNA was isolated from libraries constructed using RNA derived from normal and diseased human tissues and cell lines. The human tissues and cell lines used for cDNA library construction were selected from a broad range of sources to provide a diverse population of cDNAs representative of gene transcription throughout the human body. Descriptions of the human tissues and cell lines used for cDNA library construction are provided in the LIFESEQ database (Incyte Genomics, Inc. (Incyte), Palo Alto CA). Human tissues were broadly selected from, for example, cardiovascular, dermatologic, endocrine, gastrointestinal, hematopoietic/immune system, musculoskeletal, neural, reproductive, and urologic sources.

Cell lines used for cDNA library construction were derived from, for example, leukemic cells, teratocarcinomas, neuroepitheliomas, cervical carcinoma, lung fibroblasts, and endothelial cells. Such cell lines include, for example, THP-1, Jurkat, HUVEC, hNT2, WI38, HeLa, and other cell lines commonly used and available from public depositories (American Type Culture Collection, Manassas VA). Prior to mRNA isolation, cell lines were untreated, treated with a pharmaceutical agent such as 5'-aza-2'-deoxycytidine, treated with an activating agent such as lipopolysaccharide in the case of leukocytic cell lines, or, in the case of endothelial cell lines, subjected to shear stress.

Sequencing of the cDNAs

Methods for DNA sequencing are well known in the art. Conventional enzymatic methods employ the Klenow fragment of DNA polymerase I, SEQUENASE DNA polymerase (U.S. Biochemical Corporation, Cleveland OH), Taq polymerase (PE Biosystems, Foster City CA), thermostable T7 polymerase (Amersham Pharmacia Biotech, Inc. (Amersham Pharmacia Biotech), Piscataway NJ), or combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE amplification system (Life Technologies Inc. (Life Technologies), Gaithersburg MD), to extend the nucleic acid sequence from an oligonucleotide primer annealed to the DNA template of interest. Methods have been developed for the use of both single-stranded and double-stranded templates. Chain termination reaction products may be electrophoresed on urea-polyacrylamide gels and detected either by autoradiography (for radioisotope-labeled nucleotides) or by fluorescence (for fluorophore-labeled nucleotides). Automated methods for mechanized reaction preparation, sequencing, and analysis using fluorescence detection methods have been developed. Machines used to prepare cDNAs for sequencing can include the MICROLAB 2200 liquid transfer system (Hamilton Company (Hamilton), Reno NV), Peltier thermal cycler (PTC200; MJ Research, Inc. (MJ Research), Watertown MA), and ABI CATALYST 800 thermal cycler (PE Biosystems). Sequencing can be carried out using, for example, the ABI 373 or 377 (PE Biosystems) or MEGABACE 1000 (Molecular Dynamics, Inc. (Molecular Dynamics), Sunnyvale CA) DNA sequencing systems, or other automated and manual sequencing systems well known in the art.

The nucleotide sequences of the Sequence Listing have been prepared by current, state-of-the-art, automated methods and, as such, may contain occasional sequencing errors or unidentified nucleotides. Such unidentified nucleotides are designated by an N. These infrequent unidentified bases do not represent a hindrance to practicing the invention for those skilled in the art. Several methods employing standard recombinant techniques may be used to correct errors and complete the missing sequence information. (See, e.g., those described in Ausubel, F.M. et al. (1997) Short Protocols in Molecular Biology, John Wiley & Sons, New York NY; and Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview NY.)

10 Assembly of cDNA Sequences

Human polynucleotide sequences may be assembled using programs or algorithms well known in the art. Sequences to be assembled are related, wholly or in part, and may be derived from a single or many different transcripts. Assembly of the sequences can be performed using such programs as PHRAP (Phils Revised Assembly Program) and the GELVIEW fragment assembly system (GCG), or other methods known in the art.

Alternatively, cDNA sequences are used as "component" sequences that are assembled into "template" or "consensus" sequences as follows. Sequence chromatograms are processed, verified, and quality scores are obtained using PHRED. Raw sequences are edited using an editing pathway known as Block 1 (See, e.g., the LIFESEQ Assembled User Guide, Incyte Genomics, Palo Alto, CA). A series of BLAST comparisons is performed and low-information segments and repetitive elements (e.g., dinucleotide repeats, Alu repeats, etc.) are replaced by "n's", or masked, to prevent spurious matches. Mitochondrial and ribosomal RNA sequences are also removed. The processed sequences are then loaded into a relational database management system (RDMS) which assigns edited sequences to existing templates, if available. When additional sequences are added into the RDMS, a process is initiated which modifies existing templates or creates new templates from works in progress (i.e., nonfinal assembled sequences) containing queued sequences or the sequences themselves. After the new sequences have been assigned to templates, the templates can be merged into bins. If multiple templates exist in one bin, the bin can be split and the templates reannotated.

Once gene bins have been generated based upon sequence alignments, bins are "clone joined" based upon clone information. Clone joining occurs when the 5' sequence of one clone is present in one bin and the 3' sequence from the same clone is present in a different bin, indicating that the two bins should be merged into a single bin. Only bins which share at least two different clones are merged.

A resultant template sequence may contain either a partial or a full length open reading frame, or all or part of a genetic regulatory element. This variation is due in part to the fact that the full length cDNAs of many genes are several hundred, and sometimes several thousand, bases in

length. With current technology, cDNAs comprising the coding regions of large genes cannot be cloned because of vector limitations, incomplete reverse transcription of the mRNA, or incomplete "second strand" synthesis. Template sequences may be extended to include additional contiguous sequences derived from the parent RNA transcript using a variety of methods known to those of skill in the art. Extension may thus be used to achieve the full length coding sequence of a gene.

Analysis of the cDNA Sequences

The cDNA sequences are analyzed using a variety of programs and algorithms which are well known in the art. (See, e.g., Ausubel, 1997, supra, Chapter 7.7; Meyers, R.A. (Ed.) (1995) Molecular Biology and Biotechnology, Wiley VCH, New York NY, pp. 856-853; and Table 6.) These analyses comprise both reading frame determinations, e.g., based on triplet codon periodicity for particular organisms (Fickett, J.W. (1982) *Nucleic Acids Res.* 10:5303-5318); analyses of potential start and stop codons; and homology searches.

Computer programs known to those of skill in the art for performing computer-assisted searches for amino acid and nucleic acid sequence similarity, include, for example, Basic Local Alignment Search Tool (BLAST; Altschul, S.F. (1993) *J. Mol. Evol.* 36:290-300; Altschul, S.F. et al. (1990) *J. Mol. Biol.* 215:403-410). BLAST is especially useful in determining exact matches and comparing two sequence fragments of arbitrary but equal lengths, whose alignment is locally maximal and for which the alignment score meets or exceeds a threshold or cutoff score set by the user (Karlin, S. et al. (1988) *Proc. Natl. Acad. Sci. USA* 85:841-845). Using an appropriate search tool (e.g., BLAST or HMM), GenBank, SwissProt, BLOCKS, PFAM and other databases may be searched for sequences containing regions of homology to a query mddt or MDDT of the present invention.

Other approaches to the identification, assembly, storage, and display of nucleotide and polypeptide sequences are provided in "Relational Database for Storing Biomolecule Information," U.S.S.N. 08/947,845, filed October 9, 1997; "Project-Based Full-Length Biomolecular Sequence Database," U.S.S.N. 08/811,758, filed March 6, 1997; and "Relational Database and System for Storing Information Relating to Biomolecular Sequences," U.S.S.N. 09/034,807, filed March 4, 1998, all of which are incorporated by reference herein in their entirety.

Protein hierarchies can be assigned to the putative encoded polypeptide based on, e.g., motif, BLAST, or biological analysis. Methods for assigning these hierarchies are described, for example, in "Database System Employing Protein Function Hierarchies for Viewing Biomolecular Sequence Data," U.S.S.N. 08/812,290, filed March 6, 1997, incorporated herein by reference.

Human Disease Detection and Treatment Molecule Sequences

The mddt of the present invention may be used for a variety of diagnostic and therapeutic

purposes. For example, an mddt may be used to diagnose a particular condition, disease, or disorder associated with disease detection and treatment molecules. Such conditions, diseases, and disorders include, but are not limited to, a cell proliferative disorder, such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, a cancer of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; and an autoimmune/inflammatory disorder, such as actinic keratosis, acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, arteriosclerosis, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, bronchitis, bursitis, cholecystitis, cirrhosis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, paroxysmal nocturnal hemoglobinuria, hepatitis, hypereosinophilia, irritable bowel syndrome, episodic lymphopenia with lymphocytotoxins, mixed connective tissue disease (MCTD), multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, myelofibrosis, osteoarthritis, osteoporosis, pancreatitis, polycythemia vera, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, primary thrombocythemia, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, trauma, and hematopoietic cancer including lymphoma, leukemia, and myeloma. The mddt can be used to detect the presence of, or to quantify the amount of, an mddt-related polynucleotide in a sample. This information is then compared to information obtained from appropriate reference samples, and a diagnosis is established. Alternatively, a polynucleotide complementary to a given mddt can inhibit or inactivate a therapeutically relevant gene related to the mddt.

Analysis of mddt Expression Patterns

The expression of mddt may be routinely assessed by hybridization-based methods to determine, for example, the tissue-specificity, disease-specificity, or developmental stage-specificity of mddt expression. For example, the level of expression of mddt may be compared among different cell types or tissues, among diseased and normal cell types or tissues, among cell types or tissues at different developmental stages, or among cell types or tissues undergoing various treatments. This type of analysis is useful, for example, to assess the relative levels of mddt expression in fully or

partially differentiated cells or tissues, to determine if changes in mddt expression levels are correlated with the development or progression of specific disease states, and to assess the response of a cell or tissue to a specific therapy, for example, in pharmacological or toxicological studies.

Methods for the analysis of mddt expression are based on hybridization and amplification

technologies and include membrane-based procedures such as northern blot analysis, high-throughput procedures that utilize, for example, microarrays, and PCR-based procedures.

Hybridization and Genetic Analysis

The mddt, their fragments, or complementary sequences, may be used to identify the presence of and/or to determine the degree of similarity between two (or more) nucleic acid sequences. The mddt may be hybridized to naturally occurring or recombinant nucleic acid sequences under appropriately selected temperatures and salt concentrations. Hybridization with a probe based on the nucleic acid sequence of at least one of the mddt allows for the detection of nucleic acid sequences, including genomic sequences, which are identical or related to the mddt of the Sequence Listing.

Probes may be selected from non-conserved or unique regions of at least one of the polynucleotides of SEQ ID NO:1-25 and tested for their ability to identify or amplify the target nucleic acid sequence using standard protocols.

Polynucleotide sequences that are capable of hybridizing, in particular, to those shown in SEQ ID NO:1-25 and fragments thereof, can be identified using various conditions of stringency. (See, e.g., Wahl, G.M. and S.L. Berger (1987) *Methods Enzymol.* 152:399-407; Kimmel, A.R. (1987) *Methods Enzymol.* 152:507-511.) Hybridization conditions are discussed in "Definitions."

A probe for use in Southern or northern hybridization may be derived from a fragment of an mddt sequence, or its complement, that is up to several hundred nucleotides in length and is either single-stranded or double-stranded. Such probes may be hybridized in solution to biological materials such as plasmids, bacterial, yeast, or human artificial chromosomes, cleared or sectioned tissues, or to artificial substrates containing mddt. Microarrays are particularly suitable for identifying the presence of and detecting the level of expression for multiple genes of interest by examining gene expression correlated with, e.g., various stages of development, treatment with a drug or compound, or disease progression. An array analogous to a dot or slot blot may be used to arrange and link polynucleotides to the surface of a substrate using one or more of the following: mechanical (vacuum), chemical, thermal, or UV bonding procedures. Such an array may contain any number of mddt and may be produced by hand or by using available devices, materials, and machines.

Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g., Brennan, T.M. et al. (1995) U.S. Patent No. 5,474,796; Schena, M. et al. (1996) *Proc. Natl. Acad. Sci. USA* 93:10614-10619; Baldeschweiler et al. (1995) PCT application WO95/251116; Shalon, D. et al. (1995) PCT application WO95/35505; Heller, R.A. et al. (1997) *Proc. Natl. Acad. Sci. USA* 94:2150-

Probes may be labeled by either PCR or enzymatic techniques using a variety of commercially available reporter molecules. For example, commercial kits are available for radioactive and chemiluminescent labeling (Amersham Pharmacia Biotech) and for alkaline phosphatase labeling (Life Technologies). Alternatively, mddt may be cloned into commercially available vectors for the production of RNA probes. Such probes may be transcribed in the presence of at least one labeled nucleotide (e.g., ^{32}P -ATP, Amersham Pharmacia Biotech).

Additionally the polynucleotides of SEQ ID NO:1-25 or suitable fragments thereof can be used to isolate full length cDNA sequences utilizing hybridization and/or amplification procedures well known in the art, e.g., cDNA library screening, PCR amplification, etc. The molecular cloning of such full length cDNA sequences may employ the method of cDNA library screening with probes using the hybridization, stringency, washing, and probing strategies described above and in Ausubel, supra, Chapters 3, 5, and 6. These procedures may also be employed with genomic libraries to isolate genomic sequences of mddt in order to analyze, e.g., regulatory elements.

Genetic Mapping

Gene identification and mapping are important in the investigation and treatment of almost all conditions, diseases, and disorders. Cancer, cardiovascular disease, Alzheimer's disease, arthritis, diabetes, and mental illnesses are of particular interest. Each of these conditions is more complex than the single gene defects of sickle cell anemia or cystic fibrosis, with select groups of genes being predictive of predisposition for a particular condition, disease, or disorder. For example, cardiovascular disease may result from malfunctioning receptor molecules that fail to clear cholesterol from the bloodstream, and diabetes may result when a particular individual's immune system is activated by an infection and attacks the insulin-producing cells of the pancreas. In some studies, Alzheimer's disease has been linked to a gene on chromosome 21; other studies predict a different gene and location. Mapping of disease genes is a complex and reiterative process and generally proceeds from genetic linkage analysis to physical mapping.

As a condition is noted among members of a family, a genetic linkage map traces parts of chromosomes that are inherited in the same pattern as the condition. Statistics link the inheritance of particular conditions to particular regions of chromosomes, as defined by RFLP or other markers. (See, for example, Lander, E. S. and Botstein, D. (1986) Proc. Natl. Acad. Sci. USA 83:7353-7357.) Occasionally, genetic markers and their locations are known from previous studies. More often, however, the markers are simply stretches of DNA that differ among individuals. Examples of genetic linkage maps can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) World Wide Web site.

In another embodiment of the invention, mddt sequences may be used to generate

hybridization probes useful in chromosomal mapping of naturally occurring genomic sequences.

Either coding or noncoding sequences of mddt may be used, and in some instances, noncoding sequences may be preferable over coding sequences. For example, conservation of an mddt coding sequence among members of a multi-gene family may potentially cause undesired cross hybridization during chromosomal mapping. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries. (See, e.g., Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355; Price, C.M. (1993) Blood Rev. 7:127-134; and Trask, B.J. (1991) Trends Genet. 7:149-154.)

Fluorescent in situ hybridization (FISH) may be correlated with other physical chromosome mapping techniques and genetic map data. (See, e.g., Meyers, supra, pp. 965-968.) Correlation between the location of mddt on a physical chromosomal map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder. The mddt sequences may also be used to detect polymorphisms that are genetically linked to the inheritance of a particular condition, disease, or disorder.

In situ hybridization of chromosomal preparations and genetic mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending existing genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the number or arm of the corresponding human chromosome is not known. These new marker sequences can be mapped to human chromosomes and may provide valuable information to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once a disease or syndrome has been crudely correlated by genetic linkage with a particular genomic region, e.g., ataxia-telangiectasia to 11q22-23, any sequences mapping to that area may represent associated or regulatory genes for further investigation. (See, e.g., Gatti, R.A. et al. (1988) Nature 336:577-580.) The nucleotide sequences of the subject invention may also be used to detect differences in chromosomal architecture due to translocation, inversion, etc., among normal, carrier, or affected individuals.

Once a disease-associated gene is mapped to a chromosomal region, the gene must be cloned in order to identify mutations or other alterations (e.g., translocations or inversions) that may be correlated with disease. This process requires a physical map of the chromosomal region containing the disease-gene of interest along with associated markers. A physical map is necessary for determining the nucleotide sequence of and order of marker genes on a particular chromosomal region. Physical mapping techniques are well known in the art and require the generation of overlapping sets of cloned DNA fragments from a particular organelle, chromosome, or genome. These clones are analyzed to reconstruct and catalog their order. Once the position of a marker is

determined, the DNA from that region is obtained by consulting the catalog and selecting clones from that region. The gene of interest is located through positional cloning techniques using hybridization or similar methods.

5 Diagnostic Uses

The mddt of the present invention may be used to design probes useful in diagnostic assays. Such assays, well known to those skilled in the art, may be used to detect or confirm conditions, disorders, or diseases associated with abnormal levels of mddt expression. Labeled probes developed from mddt sequences are added to a sample under hybridizing conditions of desired stringency. In
10 some instances, mddt, or fragments or oligonucleotides derived from mddt, may be used as primers in amplification steps prior to hybridization. The amount of hybridization complex formed is quantified and compared with standards for that cell or tissue. If mddt expression varies significantly from the standard, the assay indicates the presence of the condition, disorder, or disease. Qualitative or
15 quantitative diagnostic methods may include northern, dot blot, or other membrane or dip-stick based technologies or multiple-sample format technologies such as PCR, enzyme-linked immunosorbent assay (ELISA)-like, pin, or chip-based assays.

The probes described above may also be used to monitor the progress of conditions, disorders, or diseases associated with abnormal levels of mddt expression, or to evaluate the efficacy of a particular therapeutic treatment. The candidate probe may be identified from the mddt that are
20 specific to a given human tissue and have not been observed in GenBank or other genome databases. Such a probe may be used in animal studies, preclinical tests, clinical trials, or in monitoring the treatment of an individual patient. In a typical process, standard expression is established by methods well known in the art for use as a basis of comparison, samples from patients affected by the disorder or disease are combined with the probe to evaluate any deviation from the standard profile, and a
25 therapeutic agent is administered and effects are monitored to generate a treatment profile. Efficacy is evaluated by determining whether the expression progresses toward or returns to the standard normal pattern. Treatment profiles may be generated over a period of several days or several months. Statistical methods well known to those skilled in the art may be use to determine the significance of such therapeutic agents.

30 The polynucleotides are also useful for identifying individuals from minute biological samples, for example, by matching the RFLP pattern of a sample's DNA to that of an individual's DNA. The polynucleotides of the present invention can also be used to determine the actual base-by-base DNA sequence of selected portions of an individual's genome. These sequences can be used to prepare PCR primers for amplifying and isolating such selected DNA, which can then be
35 sequenced. Using this technique, an individual can be identified through a unique set of DNA sequences. Once a unique ID database is established for an individual, positive identification of that

individual can be made from extremely small tissue samples.

In a particular aspect, oligonucleotide primers derived from the mddt of the invention may be used to detect single nucleotide polymorphisms (SNPs). SNPs are substitutions, insertions and deletions that are a frequent cause of inherited or acquired genetic disease in humans. Methods of SNP detection include, but are not limited to, single-stranded conformation polymorphism (SSCP) and fluorescent SSCP (fSSCP) methods. In SSCP, oligonucleotide primers derived from mddt are used to amplify DNA using the polymerase chain reaction (PCR). The DNA may be derived, for example, from diseased or normal tissue, biopsy samples, bodily fluids, and the like. SNPs in the DNA cause differences in the secondary and tertiary structures of PCR products in single-stranded form, and these differences are detectable using gel electrophoresis in non-denaturing gels. In fSSCP, the oligonucleotide primers are fluorescently labeled, which allows detection of the amplimers in high-throughput equipment such as DNA sequencing machines. Additionally, sequence database analysis methods, termed in silico SNP (isSNP), are capable of identifying polymorphisms by comparing the sequences of individual overlapping DNA fragments which assemble into a common consensus sequence. These computer-based methods filter out sequence variations due to laboratory preparation of DNA and sequencing errors using statistical models and automated analyses of DNA sequence chromatograms. In the alternative, SNPs may be detected and characterized by mass spectrometry using, for example, the high throughput MASSARRAY system (Sequenom, Inc., San Diego CA).

DNA-based identification techniques are critical in forensic technology. DNA sequences taken from very small biological samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, semen, etc., can be amplified using, e.g., PCR, to identify individuals. (See, e.g., Erlich, H. (1992) PCR Technology, Freeman and Co., New York, NY). Similarly, polynucleotides of the present invention can be used as polymorphic markers.

There is also a need for reagents capable of identifying the source of a particular tissue. Appropriate reagents can comprise, for example, DNA probes or primers prepared from the sequences of the present invention that are specific for particular tissues. Panels of such reagents can identify tissue by species and/or by organ type. In a similar fashion, these reagents can be used to screen tissue cultures for contamination.

The polynucleotides of the present invention can also be used as molecular weight markers on nucleic acid gels or Southern blots, as diagnostic probes for the presence of a specific mRNA in a particular cell type, in the creation of subtracted cDNA libraries which aid in the discovery of novel polynucleotides, in selection and synthesis of oligomers for attachment to an array or other support, and as an antigen to elicit an immune response.

The mddt of the invention or their mammalian homologs may be "knocked out" in an animal model system using homologous recombination in embryonic stem (ES) cells. Such techniques are well known in the art and are useful for the generation of animal models of human disease. (See, e.g.,
5 U.S. Patent Number 5,175,383 and U.S. Patent Number 5,767,337.) For example, mouse ES cells, such as the mouse 129/SvJ cell line, are derived from the early mouse embryo and grown in culture. The ES cells are transformed with a vector containing the gene of interest disrupted by a marker gene, e.g., the neomycin phosphotransferase gene (neo; Capecchi, M.R. (1989) Science 244:1288-1292). The vector integrates into the corresponding region of the host genome by homologous
10 recombination. Alternatively, homologous recombination takes place using the Cre-loxP system to knockout a gene of interest in a tissue- or developmental stage-specific manner (Marth, J.D. (1996) Clin. Invest. 97:1999-2002; Wagner, K.U. et al. (1997) Nucleic Acids Res. 25:4323-4330). Transformed ES cells are identified and microinjected into mouse cell blastocysts such as those from the C57BL/6 mouse strain. The blastocysts are surgically transferred to pseudopregnant dams, and
15 the resulting chimeric progeny are genotyped and bred to produce heterozygous or homozygous strains. Transgenic animals thus generated may be tested with potential therapeutic or toxic agents.

The mddt of the invention may also be manipulated in vitro in ES cells derived from human blastocysts. Human ES cells have the potential to differentiate into at least eight separate cell lineages including endoderm, mesoderm, and ectodermal cell types. These cell lineages differentiate
20 into, for example, neural cells, hematopoietic lineages, and cardiomyocytes (Thomson, J.A. et al. (1998) Science 282:1145-1147).

The mddt of the invention can also be used to create "knockin" humanized animals (pigs) or transgenic animals (mice or rats) to model human disease. With knockin technology, a region of mddt is injected into animal ES cells, and the injected sequence integrates into the animal cell
25 genome. Transformed cells are injected into blastulae, and the blastulae are implanted as described above. Transgenic progeny or inbred lines are studied and treated with potential pharmaceutical agents to obtain information on treatment of a human disease. Alternatively, a mammal inbred to overexpress mddt, resulting, e.g., in the secretion of MDDT in its milk, may also serve as a convenient source of that protein (Janne, J. et al. (1998) Biotechnol. Annu. Rev. 4:55-74).

30

Screening Assays

MDDT encoded by polynucleotides of the present invention may be used to screen for molecules that bind to or are bound by the encoded polypeptides. The binding of the polypeptide and the molecule may activate (agonist), increase, inhibit (antagonist), or decrease activity of the
35 polypeptide or the bound molecule. Examples of such molecules include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

Preferably, the molecule is closely related to the natural ligand of the polypeptide, e.g., a ligand or fragment thereof, a natural substrate, or a structural or functional mimetic. (See, Coligan et al., (1991) Current Protocols in Immunology 1(2): Chapter 5.) Similarly, the molecule can be closely related to the natural receptor to which the polypeptide binds, or to at least a fragment of the receptor, e.g., the active site. In either case, the molecule can be rationally designed using known techniques. Preferably, the screening for these molecules involves producing appropriate cells which express the polypeptide, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, Drosophila, or E. coli. Cells expressing the polypeptide or cell membrane fractions which contain the expressed polypeptide are then contacted with a test compound and binding, stimulation, or inhibition of activity of either the polypeptide or the molecule is analyzed.

An assay may simply test binding of a candidate compound to the polypeptide, wherein binding is detected by a fluorophore, radioisotope, enzyme conjugate, or other detectable label. Alternatively, the assay may assess binding in the presence of a labeled competitor.

Additionally, the assay can be carried out using cell-free preparations, polypeptide/molecule affixed to a solid support, chemical libraries, or natural product mixtures. The assay may also simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide, measuring polypeptide/molecule activity or binding, and comparing the polypeptide/molecule activity or binding to a standard.

Preferably, an ELISA assay using, e.g., a monoclonal or polyclonal antibody, can measure polypeptide level in a sample. The antibody can measure polypeptide level by either binding, directly or indirectly, to the polypeptide or by competing with the polypeptide for a substrate.

All of the above assays can be used in a diagnostic or prognostic context. The molecules discovered using these assays can be used to treat disease or to bring about a particular result in a patient (e.g., blood vessel growth) by activating or inhibiting the polypeptide/molecule. Moreover, the assays can discover agents which may inhibit or enhance the production of the polypeptide from suitably manipulated cells or tissues.

Transcript Imaging and Toxicological Testing

Another embodiment relates to the use of mddt to develop a transcript image of a tissue or cell type. A transcript image represents the global pattern of gene expression by a particular tissue or cell type. Global gene expression patterns are analyzed by quantifying the number of expressed genes and their relative abundance under given conditions and at a given time. (See Seilhamer et al., "Comparative Gene Transcript Analysis," U.S. Patent Number 5,840,484, expressly incorporated by reference herein.) Thus a transcript image may be generated by hybridizing the polynucleotides of the present invention or their complements to the totality of transcripts or reverse transcripts of a particular tissue or cell type. In one embodiment, the hybridization takes place in high-throughput

format, wherein the polynucleotides of the present invention or their complements comprise a subset of a plurality of elements on a microarray. The resultant transcript image would provide a profile of gene activity pertaining to disease detection and treatment molecules.

Transcript images which profile mddt expression may be generated using transcripts isolated from tissues, cell lines, biopsies, or other biological samples. The transcript image may thus reflect mddt expression in vivo, as in the case of a tissue or biopsy sample, or in vitro, as in the case of a cell line.

Transcript images which profile mddt expression may also be used in conjunction with in vitro model systems and preclinical evaluation of pharmaceuticals, as well as toxicological testing of industrial and naturally-occurring environmental compounds. All compounds induce characteristic gene expression patterns, frequently termed molecular fingerprints or toxicant signatures, which are indicative of mechanisms of action and toxicity (Nuwaysir, E. F. et al. (1999) Mol. Carcinog. 24:153-159; Steiner, S. and Anderson, N. L. (2000) Toxicol. Lett. 112-113:467-71, expressly incorporated by reference herein). If a test compound has a signature similar to that of a compound with known toxicity, it is likely to share those toxic properties. These fingerprints or signatures are most useful and refined when they contain expression information from a large number of genes and gene families. Ideally, a genome-wide measurement of expression provides the highest quality signature. Even genes whose expression is not altered by any tested compounds are important as well, as the levels of expression of these genes are used to normalize the rest of the expression data. The normalization procedure is useful for comparison of expression data after treatment with different compounds. While the assignment of gene function to elements of a toxicant signature aids in interpretation of toxicity mechanisms, knowledge of gene function is not necessary for the statistical matching of signatures which leads to prediction of toxicity. (See, for example, Press Release 00-02 from the National Institute of Environmental Health Sciences, released February 29, 2000, available at <http://www.niehs.nih.gov/oc/news/toxchip.htm>.) Therefore, it is important and desirable in toxicological screening using toxicant signatures to include all expressed gene sequences.

In one embodiment, the toxicity of a test compound is assessed by treating a biological sample containing nucleic acids with the test compound. Nucleic acids that are expressed in the treated biological sample are hybridized with one or more probes specific to the polynucleotides of the present invention, so that transcript levels corresponding to the polynucleotides of the present invention may be quantified. The transcript levels in the treated biological sample are compared with levels in an untreated biological sample. Differences in the transcript levels between the two samples are indicative of a toxic response caused by the test compound in the treated sample.

Another particular embodiment relates to the use of MDDT encoded by polynucleotides of the present invention to analyze the proteome of a tissue or cell type. The term proteome refers to the global pattern of protein expression in a particular tissue or cell type. Each protein component of a

proteome can be subjected individually to further analysis. Proteome expression patterns, or profiles, are analyzed by quantifying the number of expressed proteins and their relative abundance under given conditions and at a given time. A profile of a cell's proteome may thus be generated by separating and analyzing the polypeptides of a particular tissue or cell type. In one embodiment, the separation is achieved using two-dimensional gel electrophoresis, in which proteins from a sample are separated by isoelectric focusing in the first dimension, and then according to molecular weight by sodium dodecyl sulfate slab gel electrophoresis in the second dimension (Steiner and Anderson, supra). The proteins are visualized in the gel as discrete and uniquely positioned spots, typically by staining the gel with an agent such as Coomassie Blue or silver or fluorescent stains. The optical density of each protein spot is generally proportional to the level of the protein in the sample. The optical densities of equivalently positioned protein spots from different samples, for example, from biological samples either treated or untreated with a test compound or therapeutic agent, are compared to identify any changes in protein spot density related to the treatment. The proteins in the spots are partially sequenced using, for example, standard methods employing chemical or enzymatic cleavage followed by mass spectrometry. The identity of the protein in a spot may be determined by comparing its partial sequence, preferably of at least 5 contiguous amino acid residues, to the polypeptide sequences of the present invention. In some cases, further sequence data may be obtained for definitive protein identification.

A proteomic profile may also be generated using antibodies specific for MDDT to quantify the levels of MDDT expression. In one embodiment, the antibodies are used as elements on a microarray, and protein expression levels are quantified by exposing the microarray to the sample and detecting the levels of protein bound to each array element (Lueking, A. et al. (1999) Anal. Biochem. 270:103-11; Mendoz, L. G. et al. (1999) Biotechniques 27:778-88). Detection may be performed by a variety of methods known in the art, for example, by reacting the proteins in the sample with a thiol- or amino-reactive fluorescent compound and detecting the amount of fluorescence bound at each array element.

Toxicant signatures at the proteome level are also useful for toxicological screening, and should be analyzed in parallel with toxicant signatures at the transcript level. There is a poor correlation between transcript and protein abundances for some proteins in some tissues (Anderson, N. L. and Seilhamer, J. (1997) Electrophoresis 18:533-537), so proteome toxicant signatures may be useful in the analysis of compounds which do not significantly affect the transcript image, but which alter the proteomic profile. In addition, the analysis of transcripts in body fluids is difficult, due to rapid degradation of mRNA, so proteomic profiling may be more reliable and informative in such cases.

In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins that are expressed in the treated

biological sample are separated so that the amount of each protein can be quantified. The amount of each protein is compared to the amount of the corresponding protein in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample. Individual proteins are identified by sequencing the amino acid residues of the individual proteins and comparing these partial sequences to the MDDT encoded by polynucleotides of the present invention.

In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins from the biological sample are incubated with antibodies specific to the MDDT encoded by polynucleotides of the present invention. The amount of protein recognized by the antibodies is quantified. The amount of protein in the treated biological sample is compared with the amount in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample.

Transcript images may be used to profile mddt expression in distinct tissue types. This process can be used to determine disease detection and treatment molecule activity in a particular tissue type relative to this activity in a different tissue type. Transcript images may be used to generate a profile of mddt expression characteristic of diseased tissue. Transcript images of tissues before and after treatment may be used for diagnostic purposes, to monitor the progression of disease, and to monitor the efficacy of drug treatments for diseases which affect the activity of disease detection and treatment molecules.

Transcript images of cell lines can be used to assess disease detection and treatment molecule activity and/or to identify cell lines that lack or misregulate this activity. Such cell lines may then be treated with pharmaceutical agents, and a transcript image following treatment may indicate the efficacy of these agents in restoring desired levels of this activity. A similar approach may be used to assess the toxicity of pharmaceutical agents as reflected by undesirable changes in disease detection and treatment molecule activity. Candidate pharmaceutical agents may be evaluated by comparing their associated transcript images with those of pharmaceutical agents of known effectiveness.

Antisense Molecules

The polynucleotides of the present invention are useful in antisense technology. Antisense technology or therapy relies on the modulation of expression of a target protein through the specific binding of an antisense sequence to a target sequence encoding the target protein or directing its expression. (See, e.g., Agrawal, S., ed. (1996) Antisense Therapeutics, Humana Press Inc., Totawa NJ; Alama, A. et al. (1997) *Pharmacol. Res.* 36(3):171-178; Crooke, S.T. (1997) *Adv. Pharmacol.* 40:1-49; Sharma, H.W. and R. Narayanan (1995) *Bioessays* 17(12):1055-1063; and Lavrosky, Y. et al. (1997) *Biochem. Mol. Med.* 62(1):11-22.) An antisense sequence is a polynucleotide sequence

capable of specifically hybridizing to at least a portion of the target sequence. Antisense sequences bind to cellular mRNA and/or genomic DNA, affecting translation and/or transcription. Antisense sequences can be DNA, RNA, or nucleic acid mimics and analogs. (See, e.g., Rossi, J.J. et al. (1991) *Antisense Res. Dev.* 1(3):285-288; Lee, R. et al. (1998) *Biochemistry* 37(3):900-1010; Pardridge, W.M. et al. (1995) *Proc. Natl. Acad. Sci. USA* 92(12):5592-5596; and Nielsen, P. E. and Haaima, G. (1997) *Chem. Soc. Rev.* 96:73-78.) Typically, the binding which results in modulation of expression occurs through hybridization or binding of complementary base pairs. Antisense sequences can also bind to DNA duplexes through specific interactions in the major groove of the double helix.

The polynucleotides of the present invention and fragments thereof can be used as antisense sequences to modify the expression of the polypeptide encoded by mddt. The antisense sequences can be produced ex vivo, such as by using any of the ABI nucleic acid synthesizer series (PE Biosystems) or other automated systems known in the art. Antisense sequences can also be produced biologically, such as by transforming an appropriate host cell with an expression vector containing the sequence of interest. (See, e.g., Agrawal, supra.)

In therapeutic use, any gene delivery system suitable for introduction of the antisense sequences into appropriate target cells can be used. Antisense sequences can be delivered intracellularly in the form of an expression plasmid which, upon transcription, produces a sequence complementary to at least a portion of the cellular sequence encoding the target protein. (See, e.g., Slater, J.E., et al. (1998) *J. Allergy Clin. Immunol.* 102(3):469-475; and Scanlon, K.J., et al. (1995) *J. Allergy Clin. Immunol.* 9(13):1288-1296.) Antisense sequences can also be introduced intracellularly through the use of viral vectors, such as retrovirus and adeno-associated virus vectors. (See, e.g., Miller, A.D. (1990) *Blood* 76:271; Ausubel, F.M. et al. (1995) Current Protocols in Molecular Biology, John Wiley & Sons, New York NY; Uckert, W. and W. Walther (1994) *Pharmacol. Ther.* 63(3):323-347.) Other gene delivery mechanisms include liposome-derived systems, artificial viral envelopes, and other systems known in the art. (See, e.g., Rossi, J.J. (1995) *Br. Med. Bull.* 51(1):217-225; Boado, R.J. et al. (1998) *J. Pharm. Sci.* 87(11):1308-1315; and Morris, M.C. et al. (1997) *Nucleic Acids Res.* 25(14):2730-2736.)

Expression

In order to express a biologically active MDDT, the nucleotide sequences encoding MDDT or fragments thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding MDDT and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook, supra, Chapters 4, 8,

A variety of expression vector/host systems may be utilized to contain and express sequences encoding MDDT. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal (mammalian) cell systems. (See, e.g., Sambrook, supra; Ausubel, 1995, supra, Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509; Bitter, G.A. et al. (1987) Methods Enzymol. 153:516-544; Scorer, C.A. et al. (1994) Bio/Technology 12:181-184; Engelhard, E.K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945; Takamatsu, N. (1987) EMBO J. 6:307-311; Coruzzi, G. et al. (1984) EMBO J. 3:1671-1680; Broglie, R. et al. (1984) Science 224:838-843; Winter, J. et al. (1991) Results Probl. Cell Differ. 17:85-105; The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York NY, pp. 191-196; Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. USA 81:3655-3659; and Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355.) Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. (See, e.g., Di Nicola, M. et al. (1998) Cancer Gen. Ther. 5(6):350-356; Yu, M. et al., (1993) Proc. Natl. Acad. Sci. USA 90(13):6340-6344; Buller, R.M. et al. (1985) Nature 317(6040):813-815; McGregor, D.P. et al. (1994) Mol. Immunol. 31(3):219-226; and Verma, I.M. and N. Somia (1997) Nature 389:239-242.) The invention is not limited by the host cell employed.

For long term production of recombinant proteins in mammalian systems, stable expression of MDDT in cell lines is preferred. For example, sequences encoding MDDT can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Any number of selection systems may be used to recover transformed cell lines. (See, e.g., Wigler, M. et al. (1977) Cell 11:223-232; Lowy, I. et al. (1980) Cell 22:817-823.; Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. USA 77:3567-3570; Colbere-Garapin, F. et al. (1981) J. Mol. Biol. 150:1-14; Hartman, S.C. and R.C. Mulligan (1988) Proc. Natl. Acad. Sci. USA 85:8047-8051; Rhodes, C.A. (1995) Methods Mol. Biol. 55:121-131.)

Therapeutic Uses of mddt

The mddt of the invention may be used for somatic or germline gene therapy. Gene therapy may be performed to (i) correct a genetic deficiency (e.g., in the cases of severe combined immunodeficiency (SCID)-X1 disease characterized by X-linked inheritance (Cavazzana-Calvo, M. et

al. (2000) Science 288:669-672), severe combined immunodeficiency syndrome associated with an inherited adenosine deaminase (ADA) deficiency (Blaese, R.M. et al. (1995) Science 270:475-480; Bordignon, C. et al. (1995) Science 270:470-475), cystic fibrosis (Zabner, J. et al. (1993) Cell 75:207-216; Crystal, R.G. et al. (1995) Hum. Gene Therapy 6:643-666; Crystal, R.G. et al. (1995) Hum. Gene Therapy 6:667-703), thalassemias, familial hypercholesterolemia, and hemophilia resulting from Factor VIII or Factor IX deficiencies (Crystal, R.G. (1995) Science 270:404-410; Verma, I.M. and Somia, N. (1997) Nature 389:239-242)), (ii) express a conditionally lethal gene product (e.g., in the case of cancers which result from unregulated cell proliferation), or (iii) express a protein which affords protection against intracellular parasites (e.g., against human retroviruses, such as human immunodeficiency virus (HIV) (Baltimore, D. (1988) Nature 335:395-396; Poeschla, E. et al. (1996) Proc. Natl. Acad. Sci. USA. 93:11395-11399), hepatitis B or C virus (HBV, HCV); fungal parasites, such as Candida albicans and Paracoccidioides brasiliensis; and protozoan parasites such as Plasmodium falciparum and Trypanosoma cruzi). In the case where a genetic deficiency in mddt expression or regulation causes disease, the expression of mddt from an appropriate population of transduced cells may alleviate the clinical manifestations caused by the genetic deficiency.

In a further embodiment of the invention, diseases or disorders caused by deficiencies in mddt are treated by constructing mammalian expression vectors comprising mddt and introducing these vectors by mechanical means into mddt-deficient cells. Mechanical transfer technologies for use with cells in vivo or ex vitro include (i) direct DNA microinjection into individual cells, (ii) ballistic gold particle delivery, (iii) liposome-mediated transfection, (iv) receptor-mediated gene transfer, and (v) the use of DNA transposons (Morgan, R.A. and Anderson, W.F. (1993) Annu. Rev. Biochem. 62:191-217; Ivics, Z. (1997) Cell 91:501-510; Boulay, J-L. and Récipon, H. (1998) Curr. Opin. Biotechnol. 9:445-450).

Expression vectors that may be effective for the expression of mddt include, but are not limited to, the PCDNA 3.1, EPITAG, PRCCMV2, PREP, PVAX vectors (Invitrogen, Carlsbad CA), PCMV-SCRIPT, PCMV-TAG, PEGSH/PERV (Stratagene, La Jolla CA), and PTET-OFF, PTET-ON, PTRE2, PTRE2-LUC, PTK-HYG (Clontech, Palo Alto CA). The mddt of the invention may be expressed using (i) a constitutively active promoter, (e.g., from cytomegalovirus (CMV), Rous sarcoma virus (RSV), SV40 virus, thymidine kinase (TK), or β -actin genes), (ii) an inducible promoter (e.g., the tetracycline-regulated promoter (Gossen, M. and Bujard, H. (1992) Proc. Natl. Acad. Sci. U.S.A. 89:5547-5551; Gossen, M. et al., (1995) Science 268:1766-1769; Rossi, F.M.V. and Blau, H.M. (1998) Curr. Opin. Biotechnol. 9:451-456), commercially available in the T-REX plasmid (Invitrogen); the ecdysone-inducible promoter (available in the plasmids PVGRXR and PIND; Invitrogen); the FK506/rapamycin inducible promoter; or the RU486/mifepristone inducible promoter (Rossi, F.M.V. and Blau, H.M. supra), or (iii) a tissue-specific promoter or the native promoter of the endogenous gene encoding MDDT from a normal individual.

Commercially available liposome transformation kits (e.g., the PERFECT LIPID

TRANSFECTION KIT, available from Invitrogen) allow one with ordinary skill in the art to deliver polynucleotides to target cells in culture and require minimal effort to optimize experimental parameters. In the alternative, transformation is performed using the calcium phosphate method (Graham, F.L. and Eb, A.J. (1973) *Virology* 52:456-467), or by electroporation (Neumann, E. et al. (1982) *EMBO J.* 1:841-845). The introduction of DNA to primary cells requires modification of these standardized mammalian transfection protocols.

In another embodiment of the invention, diseases or disorders caused by genetic defects with respect to mddt expression are treated by constructing a retrovirus vector consisting of (i) mddt under the control of an independent promoter or the retrovirus long terminal repeat (LTR) promoter, (ii) appropriate RNA packaging signals, and (iii) a Rev-responsive element (RRE) along with additional retrovirus *cis*-acting RNA sequences and coding sequences required for efficient vector propagation. Retrovirus vectors (e.g., PFB and PFBNEO) are commercially available (Stratagene) and are based on published data (Riviere, I. et al. (1995) *Proc. Natl. Acad. Sci. U.S.A.* 92:6733-6737), incorporated by reference herein. The vector is propagated in an appropriate vector producing cell line (VPCL) that expresses an envelope gene with a tropism for receptors on the target cells or a promiscuous envelope protein such as VSVg (Armentano, D. et al. (1987) *J. Virol.* 61:1647-1650; Bender, M.A. et al. (1987) *J. Virol.* 61:1639-1646; Adam, M.A. and Miller, A.D. (1988) *J. Virol.* 62:3802-3806; Dull, T. et al. (1998) *J. Virol.* 72:8463-8471; Zufferey, R. et al. (1998) *J. Virol.* 72:9873-9880). U.S. Patent Number 5,910,434 to Rigg ("Method for obtaining retrovirus packaging cell lines producing high transducing efficiency retroviral supernatant") discloses a method for obtaining retrovirus packaging cell lines and is hereby incorporated by reference. Propagation of retrovirus vectors, transduction of a population of cells (e.g., CD4⁺ T-cells), and the return of transduced cells to a patient are procedures well known to persons skilled in the art of gene therapy and have been well documented (Ranga, U. et al. (1997) *J. Virol.* 71:7020-7029; Bauer, G. et al. (1997) *Blood* 89:2259-2267; Bonyhadi, M.L. (1997) *J. Virol.* 71:4707-4716; Ranga, U. et al. (1998) *Proc. Natl. Acad. Sci. U.S.A.* 95:1201-1206; Su, L. (1997) *Blood* 89:2283-2290).

In the alternative, an adenovirus-based gene therapy delivery system is used to deliver mddt to cells which have one or more genetic abnormalities with respect to the expression of mddt. The construction and packaging of adenovirus-based vectors are well known to those with ordinary skill in the art. Replication defective adenovirus vectors have proven to be versatile for importing genes encoding immunoregulatory proteins into intact islets in the pancreas (Csete, M.E. et al. (1995) *Transplantation* 27:263-268). Potentially useful adenoviral vectors are described in U.S. Patent Number 5,707,618 to Armentano ("Adenovirus vectors for gene therapy"), hereby incorporated by reference. For adenoviral vectors, see also Antinozzi, P.A. et al. (1999) *Annu. Rev. Nutr.* 19:511-544 and Verma, I.M. and Somia, N. (1997) *Nature* 18:389:239-242, both incorporated by reference herein.

In another alternative, a herpes-based, gene therapy delivery system is used to deliver mddt to target cells which have one or more genetic abnormalities with respect to the expression of mddt. The use of herpes simplex virus (HSV)-based vectors may be especially valuable for introducing mddt to cells of the central nervous system, for which HSV has a tropism. The construction and packaging of herpes-based vectors are well known to those with ordinary skill in the art. A replication-competent herpes simplex virus (HSV) type 1-based vector has been used to deliver a reporter gene to the eyes of primates (Liu, X. et al. (1999) Exp. Eye Res. 169:385-395). The construction of a HSV-1 virus vector has also been disclosed in detail in U.S. Patent Number 5,804,413 to DeLuca ("Herpes simplex virus strains for gene transfer"), which is hereby incorporated by reference. U.S. Patent Number 5,804,413 teaches the use of recombinant HSV d92 which consists of a genome containing at least one exogenous gene to be transferred to a cell under the control of the appropriate promoter for purposes including human gene therapy. Also taught by this patent are the construction and use of recombinant HSV strains deleted for ICP4, ICP27 and ICP22. For HSV vectors, see also Goins, W. F. et al. 1999 J. Virol. 73:519-532 and Xu, H. et al., (1994) Dev. Biol. 163:152-161, hereby incorporated by reference. The manipulation of cloned herpesvirus sequences, the generation of recombinant virus following the transfection of multiple plasmids containing different segments of the large herpesvirus genomes, the growth and propagation of herpesvirus, and the infection of cells with herpesvirus are techniques well known to those of ordinary skill in the art.

In another alternative, an alphavirus (positive, single-stranded RNA virus) vector is used to deliver mddt to target cells. The biology of the prototypic alphavirus, Semliki Forest Virus (SFV), has been studied extensively and gene transfer vectors have been based on the SFV genome (Garoff, H. and Li, K-J. (1998) Curr. Opin. Biotech. 9:464-469). During alphavirus RNA replication, a subgenomic RNA is generated that normally encodes the viral capsid proteins. This subgenomic RNA replicates to higher levels than the full-length genomic RNA, resulting in the overproduction of capsid proteins relative to the viral proteins with enzymatic activity (e.g., protease and polymerase). Similarly, inserting mddt into the alphavirus genome in place of the capsid-coding region results in the production of a large number of mddt RNAs and the synthesis of high levels of MDDT in vector transduced cells. While alphavirus infection is typically associated with cell lysis within a few days, the ability to establish a persistent infection in hamster normal kidney cells (BHK-21) with a variant of Sindbis virus (SIN) indicates that the lytic replication of alphaviruses can be altered to suit the needs of the gene therapy application (Dryga, S.A. et al. (1997) Virology 228:74-83). The wide host range of alphaviruses will allow the introduction of mddt into a variety of cell types. The specific transduction of a subset of cells in a population may require the sorting of cells prior to transduction. The methods of manipulating infectious cDNA clones of alphaviruses, performing alphavirus cDNA and RNA transfections, and performing alphavirus infections, are well known to those with ordinary skill in the art.

Anti-MDDT antibodies may be used to analyze protein expression levels. Such antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, and Fab fragments. For descriptions of and protocols of antibody technologies, see, e.g., Pound J.D. (1998)

5 Immunochemical Protocols, Humana Press, Totowa, NJ.

The amino acid sequence encoded by the mddt of the Sequence Listing may be analyzed by appropriate software (e.g., LASERGENE NAVIGATOR software, DNASTAR) to determine regions of high immunogenicity. The optimal sequences for immunization are selected from the C-terminus, the N-terminus, and those intervening, hydrophilic regions of the polypeptide which are likely to be
10 exposed to the external environment when the polypeptide is in its natural conformation. Analysis used to select appropriate epitopes is also described by Ausubel (1997, supra, Chapter 11.7). Peptides used for antibody induction do not need to have biological activity; however, they must be antigenic. Peptides used to induce specific antibodies may have an amino acid sequence consisting of at five amino acids, preferably at least 10 amino acids, and most preferably 15 amino acids. A
15 peptide which mimics an antigenic fragment of the natural polypeptide may be fused with another protein such as keyhole limpet cyanin (KLH; Sigma, St. Louis MO) for antibody production. A peptide encompassing an antigenic region may be expressed from an mddt, synthesized as described above, or purified from human cells.

Procedures well known in the art may be used for the production of antibodies. Various hosts
20 including mice, goats, and rabbits, may be immunized by injection with a peptide. Depending on the host species, various adjuvants may be used to increase immunological response.

In one procedure, peptides about 15 residues in length may be synthesized using an ABI 431A peptide synthesizer (PE Biosystems) using fmoc-chemistry and coupled to KLH (Sigma) by reaction with M-maleimidobenzoyl-N-hydroxysuccinimide ester (Ausubel, 1995, supra). Rabbits are
25 immunized with the peptide-KLH complex in complete Freund's adjuvant. The resulting antisera are tested for antipeptide activity by binding the peptide to plastic, blocking with 1% bovine serum albumin (BSA), reacting with rabbit antisera, washing, and reacting with radioiodinated goat anti-rabbit IgG. Antisera with antipeptide activity are tested for anti-MDDT activity using protocols well known in the art, including ELISA, radioimmunoassay (RIA), and immunoblotting.

30 In another procedure, isolated and purified peptide may be used to immunize mice (about 100 µg of peptide) or rabbits (about 1 mg of peptide). Subsequently, the peptide is radioiodinated and used to screen the immunized animals' B-lymphocytes for production of antipeptide antibodies. Positive cells are then used to produce hybridomas using standard techniques. About 20 mg of peptide is sufficient for labeling and screening several thousand clones. Hybridomas of interest are
35 detected by screening with radioiodinated peptide to identify those fusions producing peptide-specific monoclonal antibody. In a typical protocol, wells of a multi-well plate (FAST, Becton-Dickinson,

Palo Alto, CA) are coated with affinity-purified, specific rabbit-anti-mouse (or suitable anti-species IgG) antibodies at 10 mg/ml. The coated wells are blocked with 1% BSA and washed and exposed to supernatants from hybridomas. After incubation, the wells are exposed to radiolabeled peptide at 1 mg/ml.

5 Clones producing antibodies bind a quantity of labeled peptide that is detectable above background. Such clones are expanded and subjected to 2 cycles of cloning. Cloned hybridomas are injected into pristane-treated mice to produce ascites, and monoclonal antibody is purified from the ascitic fluid by affinity chromatography on protein A (Amersham Pharmacia Biotech). Several procedures for the production of monoclonal antibodies, including in vitro production, are described
10 in Pound (supra). Monoclonal antibodies with antipeptide activity are tested for anti-MDDT activity using protocols well known in the art, including ELISA, RIA, and immunoblotting.

Antibody fragments containing specific binding sites for an epitope may also be generated. For example, such fragments include, but are not limited to, the F(ab')₂ fragments produced by pepsin digestion of the antibody molecule, and the Fab fragments generated by reducing the disulfide bridges
15 of the F(ab')₂ fragments. Alternatively, construction of Fab expression libraries in filamentous bacteriophage allows rapid and easy identification of monoclonal fragments with desired specificity (Pound, supra, Chaps. 45-47). Antibodies generated against polypeptide encoded by mddt can be used to purify and characterize full-length MDDT protein and its activity, binding partners, etc.

20 Assays Using Antibodies

Anti-MDDT antibodies may be used in assays to quantify the amount of MDDT found in a particular human cell. Such assays include methods utilizing the antibody and a label to detect expression level under normal or disease conditions. The peptides and antibodies of the invention may be used with or without modification or labeled by joining them, either covalently or
25 noncovalently, with a reporter molecule.

Protocols for detecting and measuring protein expression using either polyclonal or monoclonal antibodies are well known in the art. Examples include ELISA, RIA, and fluorescent activated cell sorting (FACS). Such immunoassays typically involve the formation of complexes between the MDDT and its specific antibody and the measurement of such complexes. These and
30 other assays are described in Pound (supra).

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

35 The disclosures of all patents, applications, and publications mentioned above and below, in particular U.S. Ser. No. 60/156,565 and U.S. Ser. No. 60/168,197 are hereby expressly incorporated

EXAMPLES

I. Construction of cDNA Libraries

5 RNA was purchased from CLONTECH Laboratories, Inc. (Palo Alto CA) or isolated from various tissues. Some tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL (Life Technologies), a monophasic solution of phenol and guanidine isothiocyanate. The resulting lysates were centrifuged over CsCl cushions or extracted with chloroform. RNA was
10 precipitated with either isopropanol or sodium acetate and ethanol, or by other routine methods.

Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA purity. In most cases, RNA was treated with DNase. For most libraries, poly(A⁺) RNA was isolated using oligo d(T)-coupled paramagnetic particles (Promega Corporation (Promega), Madison WI), OLIGOTEX latex particles (QIAGEN, Inc. (QIAGEN), Valencia CA), or an OLIGOTEX mRNA
15 purification kit (QIAGEN). Alternatively, RNA was isolated directly from tissue lysates using other RNA isolation kits, e.g., the POLY(A)PURE mRNA purification kit (Ambion, Inc., Austin TX).

In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the UNIZAP vector system (Stratagene Cloning Systems, Inc. (Stratagene), La Jolla CA) or SUPERScript
20 plasmid system (Life Technologies), using the recommended procedures or similar methods known in the art. (See, e.g., Ausubel, 1997, *supra*, Chapters 5.1 through 6.6.) Reverse transcription was initiated using oligo d(T) or random primers. Synthetic oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the appropriate restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-1000 bp) using SEPHACRYL S1000,
25 SEPHAROSE CL2B, or SEPHAROSE CL4B column chromatography (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis. cDNAs were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g., PBLUESCRIPT plasmid (Stratagene), pSPORT1 plasmid (Life Technologies), or pINCY (Incyte). Recombinant plasmids were transformed into competent *E. coli* cells including XL1-Blue, XL1-BlueMRF, or SOLR from Stratagene or DH5 α ,
30 DH10B, or ElectroMAX DH10B from Life Technologies.

II. Isolation of cDNA Clones

Plasmids were recovered from host cells by *in vivo* excision using the UNIZAP vector system (Stratagene) or by cell lysis. Plasmids were purified using at least one of the following: the Magic or
35 WIZARD Minipreps DNA purification system (Promega); the AGTC Miniprep purification kit (Edge BioSystems, Gaithersburg MD); and the QIAWELL 8, QIAWELL 8 Plus, and QIAWELL 8 Ultra

plasmid purification systems or the R.E.A.L. PREP 96 plasmid purification kit (QIAGEN).

Following precipitation, plasmids were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4°C.

Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format. (Rao, V.B. (1994) Anal. Biochem. 216:1-14.) Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using PICOGREEN dye (Molecular Probes, Inc. (Molecular Probes), Eugene OR) and a FLUOROSKAN II fluorescence scanner (Labsystems Oy, Helsinki, Finland).

III. Sequencing and Analysis

cDNA sequencing reactions were processed using standard methods or high-throughput instrumentation such as the ABI CATALYST 800 thermal cycler (PE Biosystems) or the PTC-200 thermal cycler (MJ Research) in conjunction with the HYDRA microdispenser (Robbins Scientific Corp., Sunnyvale CA) or the MICROLAB 2200 liquid transfer system (Hamilton). cDNA sequencing reactions were prepared using reagents provided by Amersham Pharmacia Biotech or supplied in ABI sequencing kits such as the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (PE Biosystems). Electrophoretic separation of cDNA sequencing reactions and detection of labeled polynucleotides were carried out using the MEGABACE 1000 DNA sequencing system (Molecular Dynamics); the ABI PRISM 373 or 377 sequencing system (PE Biosystems) in conjunction with standard ABI protocols and base calling software; or other sequence analysis systems known in the art. Reading frames within the cDNA sequences were identified using standard methods (reviewed in Ausubel, 1997, supra, Chapter 7.7). Some of the cDNA sequences were selected for extension using the techniques disclosed in Example VIII.

IV. Assembly and Analysis of Sequences

Component sequences from chromatograms were subject to PHRED analysis and assigned a quality score. The sequences having at least a required quality score were subject to various pre-processing editing pathways to eliminate, e.g., low quality 3' ends, vector and linker sequences, polyA tails, Alu repeats, mitochondrial and ribosomal sequences, bacterial contamination sequences, and sequences smaller than 50 base pairs. In particular, low-information sequences and repetitive elements (e.g., dinucleotide repeats, Alu repeats, etc.) were replaced by "n's", or masked, to prevent spurious matches.

Processed sequences were then subject to assembly procedures in which the sequences were assigned to gene bins (bins). Each sequence could only belong to one bin. Sequences in each gene bin were assembled to produce consensus sequences (templates). Subsequent new sequences were

added to existing bins using BLASTn (v.1.4 WashU) and CROSSMATCH. Candidate pairs were identified as all BLAST hits having a quality score greater than or equal to 150. Alignments of at least 82% local identity were accepted into the bin. The component sequences from each bin were assembled using a version of PHRAP. Bins with several overlapping component sequences were assembled using DEEP PHRAP. The orientation (sense or antisense) of each assembled template was determined based on the number and orientation of its component sequences. Template sequences as disclosed in the sequence listing correspond to sense strand sequences (the "forward" reading frames), to the best determination. The complementary (antisense) strands are inherently disclosed herein. The component sequences which were used to assemble each template consensus sequence are listed in Tables 4A and 4B, along with their positions along the template nucleotide sequences.

Bins were compared against each other and those having local similarity of at least 82% were combined and reassembled. Reassembled bins having templates of insufficient overlap (less than 95% local identity) were re-split. Assembled templates were also subject to analysis by STITCHER/EXON MAPPER algorithms which analyze the probabilities of the presence of splice variants, alternatively spliced exons, splice junctions, differential expression of alternative spliced genes across tissue types or disease states, etc. These resulting bins were subject to several rounds of the above assembly procedures.

Once gene bins were generated based upon sequence alignments, bins were clone joined based upon clone information. If the 5' sequence of one clone was present in one bin and the 3' sequence from the same clone was present in a different bin, it was likely that the two bins actually belonged together in a single bin. The resulting combined bins underwent assembly procedures to regenerate the consensus sequences.

The final assembled templates were subsequently annotated using the following procedure. Template sequences were analyzed using BLASTn (v2.0, NCBI) versus gbpri (GenBank version 118). "Hits" were defined as an exact match having from 95% local identity over 200 base pairs through 100% local identity over 100 base pairs, or a homolog match having an E-value, i.e. a probability score, of $\leq 1 \times 10^{-8}$. The hits were subject to frameshift FASTx versus GENPEPT (GenBank version 118). (See Table 6). In this analysis, a homolog match was defined as having an E-value of $\leq 1 \times 10^{-8}$. The assembly method used above was described in "System and Methods for Analyzing Biomolecular Sequences," U.S.S.N. 09/276,534, filed March 25, 1999, and the LIFESEQ Gold user manual (Incyte) both incorporated by reference herein.

Following assembly, template sequences were subjected to motif, BLAST, and functional analyses, and categorized in protein hierarchies using methods described in, e.g., "Database System Employing Protein Function Hierarchies for Viewing Biomolecular Sequence Data," U.S.S.N. 08/812,290, filed March 6, 1997; "Relational Database for Storing Biomolecule Information," U.S.S.N. 08/947,845, filed October 9, 1997; "Project-Based Full-Length Biomolecular Sequence

Database," U.S.S.N. 08/811,758, filed March 6, 1997; and "Relational Database and System for Storing Information Relating to Biomolecular Sequences," U.S.S.N. 09/034,807, filed March 4, 1998, all of which are incorporated by reference herein.

The template sequences were further analyzed by translating each template in all three forward reading frames and searching each translation against the Pfam database of hidden Markov model-based protein families and domains using the HMMER software package (available to the public from Washington University School of Medicine, St. Louis MO). Regions of templates which, when translated, contain similarity to Pfam consensus sequences are reported in Table 2, along with descriptions of Pfam protein domains and families. Only those Pfam hits with an E-value of $\leq 1 \times 10^{-3}$ are reported. (See also World Wide Web site <http://pfam.wustl.edu/> for detailed descriptions of Pfam protein domains and families.)

Additionally, the template sequences were translated in all three forward reading frames, and each translation was searched against hidden Markov models for signal peptide and transmembrane domains using the HMMER software package. Construction of hidden Markov models and their usage in sequence analysis has been described. (See, for example, Eddy, S.R. (1996) Curr. Opin. Str. Biol. 6:361-365.) Regions of templates which, when translated, contain similarity to signal peptide or transmembrane domain consensus sequences are reported in Table 3. Only those signal peptide or transmembrane hits with a cutoff score of 11 bits or greater are reported. A cutoff score of 11 bits or greater corresponds to at least about 91-94% true-positives in signal peptide prediction, and at least about 75% true-positives in transmembrane domain prediction.

The results of HMMER analysis as reported in Tables 2 and 3 may support the results of BLAST analysis as reported in Table 1 or may suggest alternative or additional properties of template-encoded polypeptides not previously uncovered by BLAST or other analyses.

Template sequences are further analyzed using the bioinformatics tools listed in Table 6, or using sequence analysis software known in the art such as MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco CA) and LASERGENE software (DNASTAR). Template sequences may be further queried against public databases such as the GenBank rodent, mammalian, vertebrate, prokaryote, and eukaryote databases.

V. Analysis of Polynucleotide Expression

Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound. (See, e.g., Sambrook, *supra*, ch. 7; Ausubel, 1995, *supra*, ch. 4 and 16.)

Analogous computer techniques applying BLAST were used to search for identical or related molecules in cDNA databases such as GenBank or LIFESEQ (Incyte Genomics). This analysis is

much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or similar. The basis of the search is the product score, which is defined as:

$$\frac{\text{BLAST Score} \times \text{Percent Identity}}{5 \times \text{minimum \{length(Seq. 1), length(Seq. 2)\}}}$$

The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. The product score is a normalized value between 0 and 100, and is calculated as follows: the BLAST score is multiplied by the percent nucleotide identity and the product is divided by (5 times the length of the shorter of the two sequences). The BLAST score is calculated by assigning a score of +5 for every base that matches in a high-scoring segment pair (HSP), and -4 for every mismatch. Two sequences may share more than one HSP (separated by gaps). If there is more than one HSP, then the pair with the highest BLAST score is used to calculate the product score. The product score represents a balance between fractional overlap and quality in a BLAST alignment. For example, a product score of 100 is produced only for 100% identity over the entire length of the shorter of the two sequences being compared. A product score of 70 is produced either by 100% identity and 70% overlap at one end, or by 88% identity and 100% overlap at the other. A product score of 50 is produced either by 100% identity and 50% overlap at one end, or 79% identity and 100% overlap.

VI. Tissue Distribution Profiling

A tissue distribution profile is determined for each template by compiling the cDNA library tissue classifications of its component cDNA sequences. Each component sequence, is derived from a cDNA library constructed from a human tissue. Each human tissue is classified into one of the following categories: cardiovascular system; connective tissue; digestive system; embryonic structures; endocrine system; exocrine glands; genitalia, female; genitalia, male; germ cells; hemic and immune system; liver; musculoskeletal system; nervous system; pancreas; respiratory system; sense organs; skin; stomatognathic system; unclassified/mixed; or urinary tract. Template sequences, component sequences, and cDNA library/tissue information are found in the LIFESEQ GOLD database (Incyte Genomics, Palo Alto CA).

Table 5 shows the tissue distribution profile for the templates of the invention. For each template, the three most frequently observed tissue categories are shown in column 3, along with the percentage of component sequences belonging to each category. Only tissue categories with percentage values of $\geq 10\%$ are shown. A tissue distribution of "widely distributed" in column 3 indicates percentage values of $<10\%$ in all tissue categories.

VII. Transcript Image Analysis

Transcript images are generated as described in Seilhamer et al., "Comparative Gene Transcript Analysis," U.S. Patent Number 5,840,484, incorporated herein by reference.

VIII. Extension of Polynucleotide Sequences and Isolation of a Full-length cDNA

Oligonucleotide primers designed using an mddt of the Sequence Listing are used to extend the nucleic acid sequence. One primer is synthesized to initiate 5' extension of the template, and the other primer, to initiate 3' extension of the template. The initial primers may be designed using OLIGO 4.06 software (National Biosciences, Inc. (National Biosciences), Plymouth MN), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68°C to about 72°C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations are avoided. Selected human cDNA libraries are used to extend the sequence. If more than one extension is necessary or desired, additional or nested sets of primers are designed.

High fidelity amplification is obtained by PCR using methods well known in the art. PCR is performed in 96-well plates using the PTC-200 thermal cycler (MJ Research). The reaction mix contains DNA template, 200 nmol of each primer, reaction buffer containing Mg^{2+} , $(NH_4)_2SO_4$, and β -mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech), ELONGASE enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C. In the alternative, the parameters for primer pair T7 and SK+ are as follows: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 57°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C.

The concentration of DNA in each well is determined by dispensing 100 μ l PICOGREEN quantitation reagent (0.25% (v/v); Molecular Probes) dissolved in 1X Tris-EDTA (TE) and 0.5 μ l of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Incorporated (Corning), Corning NY), allowing the DNA to bind to the reagent. The plate is scanned in a FLUOROSKAN II (Labsystems Oy) to measure the fluorescence of the sample and to quantify the concentration of DNA. A 5 μ l to 10 μ l aliquot of the reaction mixture is analyzed by electrophoresis on a 1 % agarose mini-gel to determine which reactions are successful in extending the sequence.

The extended nucleotides are desalted and concentrated, transferred to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison WI), and sonicated or sheared prior to religation into pUC 18 vector (Amersham Pharmacia Biotech). For shotgun sequencing, the digested nucleotides are separated on low concentration (0.6 to 0.8%) agarose gels, fragments are excised, and agar digested with AGAR ACE (Promega). Extended clones

are religated using T4 ligase (New England Biolabs, Inc., Beverly MA) into pUC 18 vector (Amersham Pharmacia Biotech), treated with Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transfected into competent *E. coli* cells. Transformed cells are selected on antibiotic-containing media, individual colonies are picked and cultured overnight at 37°C in 384-well plates in LB/2x carbenicillin liquid media.

The cells are lysed, and DNA is amplified by PCR using Taq DNA polymerase (Amersham Pharmacia Biotech) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 72°C, 2 min; Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72°C, 5 min; Step 7: storage at 4°C. DNA is quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA recoveries are reamplified using the same conditions as described above. Samples are diluted with 20% dimethylsulfoxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (PE Biosystems).

In like manner, the mddt is used to obtain regulatory sequences (promoters, introns, and enhancers) using the procedure above, oligonucleotides designed for such extension, and an appropriate genomic library.

IX. Labeling of Probes and Southern Hybridization Analyses

Hybridization probes derived from the mddt of the Sequence Listing are employed for screening cDNAs, mRNAs, or genomic DNA. The labeling of probe nucleotides between 100 and 1000 nucleotides in length is specifically described, but essentially the same procedure may be used with larger cDNA fragments. Probe sequences are labeled at room temperature for 30 minutes using a T4 polynucleotide kinase, $\gamma^{32}\text{P}$ -ATP, and 0.5X One-Phor-All Plus (Amersham Pharmacia Biotech) buffer and purified using a ProbeQuant G-50 Microcolumn (Amersham Pharmacia Biotech). The probe mixture is diluted to 10^7 dpm/ $\mu\text{g/ml}$ hybridization buffer and used in a typical membrane-based hybridization analysis.

The DNA is digested with a restriction endonuclease such as Eco RV and is electrophoresed through a 0.7% agarose gel. The DNA fragments are transferred from the agarose to nylon membrane (NYTRAN Plus, Schleicher & Schuell, Inc., Keene NH) using procedures specified by the manufacturer of the membrane. Prehybridization is carried out for three or more hours at 68°C, and hybridization is carried out overnight at 68°C. To remove non-specific signals, blots are sequentially washed at room temperature under increasingly stringent conditions, up to 0.1x saline sodium citrate (SSC) and 0.5% sodium dodecyl sulfate. After the blots are placed in a PHOSPHORIMAGER cassette (Molecular Dynamics) or are exposed to autoradiography film, hybridization patterns of standard and experimental lanes are compared. Essentially the same procedure is employed when

X. Chromosome Mapping of mddt

The cDNA sequences which were used to assemble SEQ ID NO:1-25 are compared with
5 sequences from the Incyte LIFESEQ database and public domain databases using BLAST and other
implementations of the Smith-Waterman algorithm. Sequences from these databases that match SEQ
ID NO:1-25 are assembled into clusters of contiguous and overlapping sequences using assembly
algorithms such as PHRAP (Table 6). Radiation hybrid and genetic mapping data available from
public resources such as the Stanford Human Genome Center (SHGC), Whitehead Institute for
10 Genome Research (WIGR), and Généthon are used to determine if any of the clustered sequences
have been previously mapped. Inclusion of a mapped sequence in a cluster will result in the
assignment of all sequences of that cluster, including its particular SEQ ID NO:, to that map location.
The genetic map locations of SEQ ID NO:1-25 are described as ranges, or intervals, of human
chromosomes. The map position of an interval, in centiMorgans, is measured relative to the terminus
15 of the chromosome's p-arm. (The centiMorgan (cM) is a unit of measurement based on
recombination frequencies between chromosomal markers. On average, 1 cM is roughly equivalent
to 1 megabase (Mb) of DNA in humans, although this can vary widely due to hot and cold spots of
recombination.) The cM distances are based on genetic markers mapped by Généthon which provide
boundaries for radiation hybrid markers whose sequences were included in each of the clusters.

20

XI. Microarray Analysis

Probe Preparation from Tissue or Cell Samples

Total RNA is isolated from tissue samples using the guanidinium thiocyanate method and
polyA⁺ RNA is purified using the oligo (dT) cellulose method. Each polyA⁺ RNA sample is reverse
25 transcribed using MMLV reverse-transcriptase, 0.05 pg/μl oligo-dT primer (21mer), 1X first strand
buffer, 0.03 units/μl RNase inhibitor, 500 μM dATP, 500 μM dGTP, 500 μM dTTP, 40 μM dCTP,
40 μM dCTP-Cy3 (BDS) or dCTP-Cy5 (Amersham Pharmacia Biotech). The reverse transcription
reaction is performed in a 25 ml volume containing 200 ng polyA⁺ RNA with GEMBRIGHT kits
(Incyte). Specific control polyA⁺ RNAs are synthesized by in vitro transcription from non-coding
30 yeast genomic DNA (W. Lei, unpublished). As quantitative controls, the control mRNAs at 0.002 ng,
0.02 ng, 0.2 ng, and 2 ng are diluted into reverse transcription reaction at ratios of 1:100,000,
1:10,000, 1:1000, 1:100 (w/w) to sample mRNA respectively. The control mRNAs are diluted into
reverse transcription reaction at ratios of 1:3, 3:1, 1:10, 10:1, 1:25, 25:1 (w/w) to sample mRNA
differential expression patterns. After incubation at 37°C for 2 hr, each reaction sample (one with
35 Cy3 and another with Cy5 labeling) is treated with 2.5 ml of 0.5M sodium hydroxide and incubated
for 20 minutes at 85°C to stop the reaction and degrade the RNA. Probes are purified using two

successive CHROMA SPIN 30 gel filtration spin columns (CLONTECH Laboratories, Inc.

(CLONTECH), Palo Alto CA) and after combining, both reaction samples are ethanol precipitated using 1 ml of glycogen (1 mg/ml), 60 ml sodium acetate, and 300 ml of 100% ethanol. The probe is then dried to completion using a SpeedVAC (Savant Instruments Inc., Holbrook NY) and

5 resuspended in 14 μ l 5X SSC/0.2% SDS.

Microarray Preparation

Sequences of the present invention are used to generate array elements. Each array element is amplified from bacterial cells containing vectors with cloned cDNA inserts. PCR amplification
10 uses primers complementary to the vector sequences flanking the cDNA insert. Array elements are amplified in thirty cycles of PCR from an initial quantity of 1-2 ng to a final quantity greater than 5 μ g. Amplified array elements are then purified using SEPHACRYL-400 (Amersham Pharmacia Biotech).

Purified array elements are immobilized on polymer-coated glass slides. Glass microscope
15 slides (Corning) are cleaned by ultrasound in 0.1% SDS and acetone, with extensive distilled water washes between and after treatments. Glass slides are etched in 4% hydrofluoric acid (VWR Scientific Products Corporation (VWR), West Chester, PA), washed extensively in distilled water, and coated with 0.05% aminopropyl silane (Sigma) in 95% ethanol. Coated slides are cured in a 110°C oven.

20 Array elements are applied to the coated glass substrate using a procedure described in US Patent No. 5,807,522, incorporated herein by reference. 1 μ l of the array element DNA, at an average concentration of 100 ng/ μ l, is loaded into the open capillary printing element by a high-speed robotic apparatus. The apparatus then deposits about 5 nl of array element sample per slide.

Microarrays are UV-crosslinked using a STRATALINKER UV-crosslinker (Stratagene).
25 Microarrays are washed at room temperature once in 0.2% SDS and three times in distilled water. Non-specific binding sites are blocked by incubation of microarrays in 0.2% casein in phosphate buffered saline (PBS) (Tropix, Inc., Bedford, MA) for 30 minutes at 60°C followed by washes in 0.2% SDS and distilled water as before.

Hybridization

30 Hybridization reactions contain 9 μ l of probe mixture consisting of 0.2 μ g each of Cy3 and Cy5 labeled cDNA synthesis products in 5X SSC, 0.2% SDS hybridization buffer. The probe mixture is heated to 65°C for 5 minutes and is aliquoted onto the microarray surface and covered with an 1.8 cm² coverslip. The arrays are transferred to a waterproof chamber having a cavity just slightly
35 larger than a microscope slide. The chamber is kept at 100% humidity internally by the addition of 140 μ l of 5x SSC in a corner of the chamber. The chamber containing the arrays is incubated for

about 6.5 hours at 60°C. The arrays are washed for 10 min at 45°C in a first wash buffer (1X SSC, 0.1% SDS), three times for 10 minutes each at 45°C in a second wash buffer (0.1X SSC), and dried.

Detection

5 Reporter-labeled hybridization complexes are detected with a microscope equipped with an Innova 70 mixed gas 10 W laser (Coherent, Inc., Santa Clara CA) capable of generating spectral lines at 488 nm for excitation of Cy3 and at 632 nm for excitation of Cy5. The excitation laser light is focused on the array using a 20X microscope objective (Nikon, Inc., Melville NY). The slide containing the array is placed on a computer-controlled X-Y stage on the microscope and raster-
10 scanned past the objective. The 1.8 cm x 1.8 cm array used in the present example is scanned with a resolution of 20 micrometers.

In two separate scans, a mixed gas multiline laser excites the two fluorophores sequentially. Emitted light is split, based on wavelength, into two photomultiplier tube detectors (PMT R1477, Hamamatsu Photonics Systems, Bridgewater NJ) corresponding to the two fluorophores. Appropriate
15 filters positioned between the array and the photomultiplier tubes are used to filter the signals. The emission maxima of the fluorophores used are 565 nm for Cy3 and 650 nm for Cy5. Each array is typically scanned twice, one scan per fluorophore using the appropriate filters at the laser source, although the apparatus is capable of recording the spectra from both fluorophores simultaneously.

The sensitivity of the scans is typically calibrated using the signal intensity generated by a
20 cDNA control species added to the probe mix at a known concentration. A specific location on the array contains a complementary DNA sequence, allowing the intensity of the signal at that location to be correlated with a weight ratio of hybridizing species of 1:100,000. When two probes from different sources (e.g., representing test and control cells), each labeled with a different fluorophore, are hybridized to a single array for the purpose of identifying genes that are differentially expressed,
25 the calibration is done by labeling samples of the calibrating cDNA with the two fluorophores and adding identical amounts of each to the hybridization mixture.

The output of the photomultiplier tube is digitized using a 12-bit RTI-835H analog-to-digital (A/D) conversion board (Analog Devices, Inc., Norwood, MA) installed in an IBM-compatible PC computer. The digitized data are displayed as an image where the signal intensity is mapped using a
30 linear 20-color transformation to a pseudocolor scale ranging from blue (low signal) to red (high signal). The data is also analyzed quantitatively. Where two different fluorophores are excited and measured simultaneously, the data are first corrected for optical crosstalk (due to overlapping emission spectra) between the fluorophores using each fluorophore's emission spectrum.

A grid is superimposed over the fluorescence signal image such that the signal from each spot
35 is centered in each element of the grid. The fluorescence signal within each element is then integrated to obtain a numerical value corresponding to the average intensity of the signal. The

software used for signal analysis is the GEMTOOLS gene expression analysis program (Incyte).

XII. Complementary Nucleic Acids

Sequences complementary to the mddt are used to detect, decrease, or inhibit expression of the naturally occurring nucleotide. The use of oligonucleotides comprising from about 15 to 30 base pairs is typical in the art. However, smaller or larger sequence fragments can also be used.

Appropriate oligonucleotides are designed from the mddt using OLIGO 4.06 software (National Biosciences) or other appropriate programs and are synthesized using methods standard in the art or ordered from a commercial supplier. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5' sequence and used to prevent transcription factor binding to the promoter sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding and processing of the transcript.

XIII. Expression of MDDT

Expression and purification of MDDT is accomplished using bacterial or virus-based expression systems. For expression of MDDT in bacteria, cDNA is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription. Examples of such promoters include, but are not limited to, the *trp-lac (tac)* hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the *lac* operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3). Antibiotic resistant bacteria express MDDT upon induction with isopropyl beta-D-thiogalactopyranoside (IPTG). Expression of MDDT in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant Autographica californica nuclear polyhedrosis virus (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding MDDT by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to infect Spodoptera frugiperda (Sf9) insect cells in most cases, or human hepatocytes, in some cases. Infection of the latter requires additional genetic modifications to baculovirus. (See e.g., Engelhard, supra; and Sandig, supra.)

In most expression systems, MDDT is synthesized as a fusion protein with, e.g., glutathione S-transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step, affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-kilodalton enzyme from Schistosoma japonicum, enables the purification of fusion proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Amersham Pharmacia Biotech). Following purification, the GST moiety can be proteolytically cleaved from

MDDT at specifically engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffinity purification using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak Company, Rochester NY). 6-His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel (1995, *supra*, Chapters 10 and 16). Purified MDDT obtained by these methods can be used directly in the following activity assay.

XIV. Demonstration of MDDT Activity

MDDT, or biologically active fragments thereof, are labeled with ^{125}I Bolton-Hunter reagent. (See, e.g., Bolton, A.E. and W.M. Hunter (1973) *Biochem. J.* 133:529-539.) Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled MDDT, washed, and any wells with labeled MDDT complex are assayed. Data obtained using different concentrations of MDDT are used to calculate values for the number, affinity, and association of MDDT with the candidate molecules.

Alternatively, molecules interacting with MDDT are analyzed using the yeast two-hybrid system as described in Fields, S. and O. Song (1989) *Nature* 340:245-246, or using commercially available kits based on the two-hybrid system, such as the MATCHMAKER system (CLONTECH).

MDDT may also be used in the PATHCALLING process (CuraGen Corp., New Haven CT) which employs the yeast two-hybrid system in a high-throughput manner to determine all interactions between the proteins encoded by two large libraries of genes (Nandabalan, K. et al. (2000) U.S. Patent No. 6,057,101).

XV. Functional Assays

MDDT function is assessed by expressing mddt at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a mammalian expression vector containing a strong promoter that drives high levels of cDNA expression. Vectors of choice include pCMV SPORT (Life Technologies) and pCR3.1 (Invitrogen Corporation, Carlsbad CA), both of which contain the cytomegalovirus promoter. 5-10 μg of recombinant vector are transiently transfected into a human cell line, preferably of endothelial or hematopoietic origin, using either liposome formulations or electroporation. 1-2 μg of an additional plasmid containing sequences encoding a marker protein are co-transfected.

Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP; CLONTECH), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated laser optics-based technique, is used to identify transfected cells expressing GFP or CD64-GFP and to evaluate the apoptotic state of

the cells and other cellular properties.

FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are discussed in Ormerod, M. G. (1994) Flow

10 Cytometry, Oxford, New York NY.

The influence of MDDT on gene expression can be assessed using highly purified populations of cells transfected with sequences encoding MDDT and either CD64 or CD64-GFP. CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Inc., Lake Success NY). mRNA can be purified from the cells using methods well known by those of skill in the art. Expression of mRNA encoding MDDT and other genes of interest can be analyzed by northern analysis or microarray techniques.

20 **XVI. Production of Antibodies**

MDDT substantially purified using polyacrylamide gel electrophoresis (PAGE; see, e.g., Harrington, M.G. (1990) *Methods Enzymol.* 182:488-495), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols.

Alternatively, the MDDT amino acid sequence is analyzed using LASERGENE software (DNASTAR) to determine regions of high immunogenicity, and a corresponding peptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well described in the art. (See, e.g., Ausubel, 1995, supra, Chapter 11.)

Typically, peptides 15 residues in length are synthesized using an ABI 431A peptide synthesizer (PE Biosystems) using fmoc-chemistry and coupled to KLH (Sigma) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to increase immunogenicity. (See, e.g., Ausubel, supra.) Rabbits are immunized with the peptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for anti-peptide activity by, for example, binding the peptide to plastic, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radioiodinated goat anti-rabbit IgG. Antisera with anti-peptide activity are tested for anti-MDDT activity using protocols well known in the art, including ELISA, RIA, and immunoblotting.

XVII. Purification of Naturally Occurring MDDT Using Specific Antibodies

Naturally occurring or recombinant MDDT is substantially purified by immunoaffinity chromatography using antibodies specific for MDDT. An immunoaffinity column is constructed by covalently coupling anti-MDDT antibody to an activated chromatographic resin, such as
5 CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

Media containing MDDT are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of MDDT (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt
10 antibody/MDDT binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and MDDT is collected.

All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described method and system of the invention
15 will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the above-described modes for carrying out the invention which are obvious to those skilled in the field of molecular biology or related fields
20 are intended to be within the scope of the following claims.

TABLE 1

SEQ ID NO:	Template ID	GI Number	Probability Score	Annotation
16	233624.11.dec	g1314560	9.00E-31	amyloid precursor protein-binding protein 1
7	246526.2.dec	g7542723	1.00E-168	DHHC1 protein (Homo sapiens)
5	345638.1.oct	g7406641	2.00E-90	EMeg32 protein (Mus musculus)
18	198840.3.dec	g643590	0	Human alternatively spliced mRNA for NACP (precursor of non-A beta component
4	197170.1.oct	g4389513	8.00E-45	Human homolog of Mus musculus wizL protein (AA 4-1561) (Homo sapiens)
11	040422.12.dec	g3341980	4.00E-66	huntingtin-interacting protein HYPA/FBP11
21	349415.4.dec	g533523	1.00E-159	MAGE-6 antigen (Homo sapiens)
22	474778.3.dec	g2077825	7.00E-62	MNK1 (Homo sapiens)
15	196774.3.dec	g6457278	1.00E-59	pre-B lymphocyte protein 3 (Homo sapiens)
14	059263.6.dec	g1694682	1.00E-116	Src-like adapter protein (Homo sapiens)
13	012432.5.dec	g1314316	2.00E-13	WD-40 motifs; up-regulated by thyroid hormone in tadpoles (Xenopus laevis)

TABLE 2

SEQ ID

NO:	Template ID	Start	Stop	Frame	Pfam Hit	Pfam Description	E-value
1	348736.2.oct	265	450	forward 1	KRAB	PF01352 KRAB box	2.50E-07
2	025119.6.oct	179	367	forward 2	KRAB	PF01352 KRAB box	1.80E-28
3	474539.1.oct	2	280	forward 2	PH	PF00169 PH (pleckstrin homology) domain	2.10E-08
4	197170.1.oct	194	262	forward 2	zf-C2H2	PF00096 Zinc finger, C2H2 type	3.10E-08
5	345638.1.oct	248	640	forward 2	Acetyltransf	PF00583 Acetyltransferase (GNAT) family	0.00033
6	408784.1.dec	207	335	forward 3	UBA	UBA-domain	1.90E-06
7	246526.2.dec	570	764	forward 3	zf-DHHC	DHHC zinc finger domain	2.60E-34
8	200488.5.dec	89	619	forward 2	Peptidase_C15	Pyroglutamyl	3.30E-04
9	474878.1.dec	1003	1116	forward 1	zf-C3HC4	Zinc finger, C3HC4 type (RING finger)	1.50E-05
10	335916.2.dec	1053	1151	forward 3	ank	Ank repeat	1.10E-06
11	340422.12.dec	478	567	forward 1	WW_rsp5_WWP	WW domain	2.40E-12
12	977651.2.dec	718	924	forward 1	NifU-like	NifU-like domain	3.60E-30
13	012432.5.dec	280	396	forward 1	WD40	WD domain, G-beta repeat	7.00E-05
14	059263.6.dec	645	875	forward 3	SH2	Src homology domain	1.30E-33
15	196774.3.dec	695	949	forward 2	ig	Immunoglobulin	2.10E-09
16	233624.11.dec	345	656	forward 3	ThiF_family	ThiF family	4.00E-05
16	233624.11.dec	245	730	forward 2	ThiF_family	ThiF family	4.90E-04
17	228585.3.dec	927	1250	forward 3	PH	PH domain	1.50E-06
17	228585.3.dec	294	833	forward 3	RhoGEF	RhoGEF domain	7.00E-39
17	228585.3.dec	21	185	forward 3	SH3	Src homology domain	1.20E-08
18	198840.3.dec	137	502	forward 2	Synuclein	Synuclein	2.40E-72
19	082154.5.dec	50	340	forward 2	FCH	Fes/CIP4 homology domain	7.60E-05
20	368396.5.dec	3391	3555	forward 1	SH3	Src homology domain	2.40E-21
21	349415.4.dec	2408	3094	forward 2	MAGE	MAGE family	1.20E-134
22	474778.3.dec	297	542	forward 3	pkinase	Eukaryotic protein kinase domain	6.50E-13
23	330933.5.dec	209	604	forward 2	DAGKc	Diacylglycerol kinase catalytic domain (presumed)	4.80E-04
24	998036.2.dec	168	332	forward 3	SH3	Src homology domain	9.60E-20
24	998036.2.dec	956	1126	forward 2	SH3	Src homology domain	2.00E-17
25	999304.1.dec	78	218	forward 3	KRAB	KRAB box	2.30E-17

TABLE 3

SEQ ID NO:	Template ID	Start	Stop	Frame	Domain Type
5	345638.1.oct	1601	1657	forward 2	TM
5	345638.1.oct	243	296	forward 3	TM
7	246526.2.dec	366	419	forward 3	TM
7	246526.2.dec	738	812	forward 3	TM
7	246526.2.dec	738	797	forward 3	TM
7	246526.2.dec	375	452	forward 3	TM
7	246526.2.dec	855	911	forward 3	TM
7	246526.2.dec	849	923	forward 3	TM
7	246526.2.dec	861	938	forward 3	TM
7	246526.2.dec	735	797	forward 3	TM
7	246526.2.dec	855	908	forward 3	TM
7	246526.2.dec	2714	2797	forward 2	TM
9	474878.1.dec	1493	1561	forward 2	SP
9	474878.1.dec	126	194	forward 3	SP
9	474878.1.dec	852	902	forward 3	TM
9	474878.1.dec	2092	2163	forward 1	SP
9	474878.1.dec	1514	1573	forward 2	TM
10	335916.2.dec	579	638	forward 3	SP
10	335916.2.dec	555	638	forward 3	SP
10	335916.2.dec	1306	1389	forward 1	SP
11	040422.12.dec	865	933	forward 1	SP
11	040422.12.dec	945	1001	forward 3	SP
11	040422.12.dec	939	1007	forward 3	SP
11	040422.12.dec	939	1001	forward 3	TM
11	040422.12.dec	939	986	forward 3	SP
11	040422.12.dec	939	1001	forward 3	SP
11	040422.12.dec	945	1055	forward 3	SP
15	196774.3.dec	84	158	forward 3	SP
15	196774.3.dec	111	164	forward 3	TM
15	196774.3.dec	84	146	forward 3	SP
16	233624.11.dec	508	585	forward 1	SP
17	228585.3.dec	2343	2396	forward 3	TM
17	228585.3.dec	4942	4998	forward 1	SP
17	228585.3.dec	4975	5019	forward 1	SP
17	228585.3.dec	5218	5298	forward 1	SP
17	228585.3.dec	1633	1713	forward 1	SP
17	228585.3.dec	4417	4491	forward 1	SP
17	228585.3.dec	4942	5010	forward 1	SP
17	228585.3.dec	4942	5016	forward 1	SP
17	228585.3.dec	4975	5034	forward 1	SP
17	228585.3.dec	4942	5034	forward 1	SP
20	368396.5.dec	597	680	forward 3	SP
20	368396.5.dec	2585	2659	forward 2	SP
20	368396.5.dec	2585	2668	forward 2	SP
20	368396.5.dec	1051	1137	forward 1	SP
20	368396.5.dec	1051	1128	forward 1	SP
20	368396.5.dec	748	813	forward 1	SP
23	330933.5.dec	3492	3551	forward 3	TM
23	330933.5.dec	2174	2239	forward 2	TM
23	330933.5.dec	2627	2677	forward 2	TM

TABLE 3

SEQ ID NO:	Template ID	Start	Stop	Frame	Domain Type
23	330933.5.dec	2502	2552	forward 3	TM
23	330933.5.dec	2940	3026	forward 3	SP
23	330933.5.dec	2592	2651	forward 3	SP
23	330933.5.dec	2502	2549	forward 3	SP
23	330933.5.dec	2502	2567	forward 3	SP
23	330933.5.dec	2502	2555	forward 3	SP
23	330933.5.dec	2502	2561	forward 3	SP

TABLE 4

SEQ ID NO:	Template ID	Component ID	Start	Stop
1	348736.2.oct	899043R1	1	569
1	348736.2.oct	899043R6	29	569
1	348736.2.oct	g3597108	267	583
1	348736.2.oct	899072H1	270	569
1	348736.2.oct	899043H1	278	569
1	348736.2.oct	g2907503	297	473
1	348736.2.oct	g2903890	297	744
1	348736.2.oct	g2818919	297	736
1	348736.2.oct	g2904085	297	740
1	348736.2.oct	g2563340	297	595
1	348736.2.oct	g2817010	297	677
1	348736.2.oct	187645R6	10	105
1	348736.2.oct	187645R1	10	105
1	348736.2.oct	187645F1	10	106
1	348736.2.oct	187645H1	10	105
2	025119.6.oct	g2177786	304	651
2	025119.6.oct	g2434481	338	650
2	025119.6.oct	1568642H1	364	579
2	025119.6.oct	1572584H1	364	556
2	025119.6.oct	g3785307	410	673
2	025119.6.oct	g4136446	228	630
2	025119.6.oct	4828163H1	241	511
2	025119.6.oct	g2177785	256	622
2	025119.6.oct	g4223734	260	664
2	025119.6.oct	g2177771	270	625
2	025119.6.oct	g4087706	286	673
2	025119.6.oct	g1193161	291	672
2	025119.6.oct	g4223735	302	673
2	025119.6.oct	g2177772	304	631
2	025119.6.oct	3528954H1	1	225
2	025119.6.oct	3457794H1	1	240
2	025119.6.oct	g4124162	92	520
2	025119.6.oct	g2270206	115	551
2	025119.6.oct	1712170F6	140	628
2	025119.6.oct	1712170H1	140	358
2	025119.6.oct	g3076605	187	673
2	025119.6.oct	1616212H1	153	384
2	025119.6.oct	6110945H1	179	272
2	025119.6.oct	g3229162	182	656
2	025119.6.oct	3597144H1	184	464
2	025119.6.oct	4304325H1	150	369
2	025119.6.oct	5108047H1	152	383
3	474539.1.oct	g3039648	1	494
3	474539.1.oct	g4224114	1	444
3	474539.1.oct	g2354920	12	366
3	474539.1.oct	g2575314	34	417
3	474539.1.oct	g788735	42	278
3	474539.1.oct	g2753248	62	194
3	474539.1.oct	g1833029	145	334
3	474539.1.oct	5442680H1	258	429

TABLE 4

SEQ ID NO:	Template ID	Component ID	Start	Stop
4	197170.1.oct	2522574H1	378	630
4	197170.1.oct	6327035H1	470	573
4	197170.1.oct	1451166F1	494	779
4	197170.1.oct	1451166H1	494	767
4	197170.1.oct	1496387H1	512	724
4	197170.1.oct	g2537634	591	978
4	197170.1.oct	5324664H1	699	862
4	197170.1.oct	3274337H1	729	979
4	197170.1.oct	788329H1	878	990
4	197170.1.oct	1515193H1	881	1092
4	197170.1.oct	1515121H1	881	1081
4	197170.1.oct	1728752H1	898	1080
4	197170.1.oct	4671552H1	945	1197
4	197170.1.oct	g3931972	967	1429
4	197170.1.oct	g3428451	969	1392
4	197170.1.oct	g4267134	971	1429
4	197170.1.oct	g4534659	974	1392
4	197170.1.oct	g4111935	987	1392
4	197170.1.oct	g3919391	994	1429
4	197170.1.oct	g3419001	995	1392
4	197170.1.oct	g3896452	999	1392
4	197170.1.oct	g4300782	1017	1392
4	197170.1.oct	g3988440	1017	1429
4	197170.1.oct	g2056736	1021	1392
4	197170.1.oct	3234275H1	1046	1305
4	197170.1.oct	5163595H1	1097	1328
4	197170.1.oct	g4330857	1133	1392
4	197170.1.oct	g4194622	1168	1392
4	197170.1.oct	g3931900	1174	1429
4	197170.1.oct	g3049130	1213	1317
4	197170.1.oct	g3096022	1233	1393
4	197170.1.oct	g3888959	1277	1392
4	197170.1.oct	483831H1	1283	1517
4	197170.1.oct	5108547H1	1287	1423
4	197170.1.oct	g2056134	14	522
4	197170.1.oct	2182319H1	40	232
4	197170.1.oct	3187785H1	58	365
4	197170.1.oct	3538506H1	153	378
4	197170.1.oct	3538506F6	153	533
4	197170.1.oct	2521850H1	225	433
4	197170.1.oct	6317859H1	1	256
4	197170.1.oct	2402368H1	230	487
4	197170.1.oct	5688629H1	236	490
4	197170.1.oct	6176756H1	236	512
4	197170.1.oct	3785815H1	241	485
4	197170.1.oct	g2835283	246	350
4	197170.1.oct	6179452H1	265	528
4	197170.1.oct	2758648H1	282	542
4	197170.1.oct	5901704H1	331	423
4	197170.1.oct	3616975H1	331	624

TABLE 4

SEQ ID NO:	Template ID	Component ID	Start	Stop
5	345638.1.oct	3524936H1	1221	1489
5	345638.1.oct	5395774T1	1288	1796
5	345638.1.oct	2452828F6	1197	1623
5	345638.1.oct	1439670T6	1289	1695
5	345638.1.oct	2452828H1	1197	1431
5	345638.1.oct	5539601H2	1215	1439
5	345638.1.oct	2270342R6	1338	1690
5	345638.1.oct	2270342H1	1338	1591
5	345638.1.oct	2270342T6	1338	1642
5	345638.1.oct	g4175458	1372	1736
5	345638.1.oct	g1154300	1380	1548
5	345638.1.oct	g2241560	1399	1691
5	345638.1.oct	g2318255	1412	1690
5	345638.1.oct	2671159T6	1467	1891
5	345638.1.oct	g703628	1476	1696
5	345638.1.oct	5588741H1	1523	1721
5	345638.1.oct	2968103H2	1624	1926
5	345638.1.oct	2825566H1	1634	1935
5	345638.1.oct	g765459	1656	1851
5	345638.1.oct	g982043	1667	1843
5	345638.1.oct	g3872249	1790	2138
5	345638.1.oct	g3934859	1821	2138
5	345638.1.oct	2160009F6	1824	2138
5	345638.1.oct	2160081H1	1824	2069
5	345638.1.oct	2842652H1	1862	2090
5	345638.1.oct	1980041R6	1865	2138
5	345638.1.oct	1980041H1	1865	2112
5	345638.1.oct	3642137H1	1	215
5	345638.1.oct	1439670H1	1	263
5	345638.1.oct	1438620H1	1	250
5	345638.1.oct	1439670F6	1	470
5	345638.1.oct	1438620F1	1	417
5	345638.1.oct	4509739H1	49	297
5	345638.1.oct	3361128H1	68	328
5	345638.1.oct	4977040H1	69	322
5	345638.1.oct	3471990H1	69	309
5	345638.1.oct	5863955H1	71	314
5	345638.1.oct	3074876H1	72	344
5	345638.1.oct	3764710H1	82	291
5	345638.1.oct	269902H1	104	450
5	345638.1.oct	g4332349	182	516
5	345638.1.oct	1953604H1	248	464
5	345638.1.oct	5988669H1	271	460
5	345638.1.oct	4970243H1	275	547
5	345638.1.oct	3519477H1	295	462
5	345638.1.oct	4970569H1	343	602
5	345638.1.oct	4598609H1	405	587
5	345638.1.oct	2671159H1	485	729
5	345638.1.oct	2671159F6	485	927
5	345638.1.oct	2671152H1	485	729

TABLE 4

SEQ ID NO:	Template ID	Component ID	Start	Stop
5	345638.1.oct	2275853H1	505	716
5	345638.1.oct	2509419T6	508	889
5	345638.1.oct	2509419H1	515	754
5	345638.1.oct	2509419F6	515	787
5	345638.1.oct	4088123H1	529	799
5	345638.1.oct	5369561H1	918	1159
5	345638.1.oct	g2219914	953	1178
5	345638.1.oct	5607505H1	1010	1237
5	345638.1.oct	5559742H1	1021	1275
5	345638.1.oct	778081H1	1034	1244
5	345638.1.oct	3593225H1	1081	1375
5	345638.1.oct	5395774H1	579	813
5	345638.1.oct	3227545H1	663	891
5	345638.1.oct	5951114H1	817	1146
5	345638.1.oct	5951256H1	817	1145
5	345638.1.oct	2365252H1	849	928
5	345638.1.oct	4728612H1	899	1189
5	345638.1.oct	g2835252	1874	2138
5	345638.1.oct	g703518	1926	2153
5	345638.1.oct	3517178H1	1951	2073
5	345638.1.oct	g1139412	2005	2131
5	345638.1.oct	5265442H1	2006	2185
6	408784.1.dec	g4525629	1	193
6	408784.1.dec	g4113520	1	353
6	408784.1.dec	g1873896	1	272
6	408784.1.dec	g4372237	1	389
6	408784.1.dec	5426002F6	1	317
6	408784.1.dec	5426002H1	1	253
6	408784.1.dec	6264541H1	41	268
6	408784.1.dec	6566729H1	58	397
6	408784.1.dec	6569375H1	191	630
7	246526.2.dec	g3422692	1172	1278
7	246526.2.dec	g698573	1173	1273
7	246526.2.dec	2905036H1	1213	1446
7	246526.2.dec	5314181H1	1215	1363
7	246526.2.dec	g1010382	1243	1518
7	246526.2.dec	2617856H1	1249	1492
7	246526.2.dec	1574434T6	1282	1812
7	246526.2.dec	3083880H1	1315	1444
7	246526.2.dec	981687H1	1315	1544
7	246526.2.dec	1400468H1	1320	1574
7	246526.2.dec	5137157H1	1323	1589
7	246526.2.dec	g883275	1331	1633
7	246526.2.dec	g1017973	1335	1672
7	246526.2.dec	g3360494	1336	2634
7	246526.2.dec	g981374	1336	1704
7	246526.2.dec	g776347	1386	1770
7	246526.2.dec	4568542H1	1385	1573
7	246526.2.dec	g2035159	1393	1656
7	246526.2.dec	1861916F6	1419	1979

TABLE 4

SEQ ID NO:	Template ID	Component ID	Start	Stop
7	246526.2.dec	1861916H1	1419	1695
7	246526.2.dec	g574012	1420	1616
7	246526.2.dec	4591933H1	1448	1710
7	246526.2.dec	1861162T6	1467	1863
7	246526.2.dec	1861162F6	1474	1901
7	246526.2.dec	1861162H1	1475	1798
7	246526.2.dec	3856851H1	1478	1761
7	246526.2.dec	5597738H1	1495	1704
7	246526.2.dec	5919136H1	1509	1777
7	246526.2.dec	2616733H1	1510	1748
7	246526.2.dec	g3228879	1517	1913
7	246526.2.dec	1363803F1	1544	1994
7	246526.2.dec	1363803H1	1544	1791
7	246526.2.dec	g1379338	1572	1905
7	246526.2.dec	g2341495	1580	1906
7	246526.2.dec	4854205H1	1588	1848
7	246526.2.dec	358373H1	1590	1808
7	246526.2.dec	4793209H1	1600	1887
7	246526.2.dec	g1009757	1605	1748
7	246526.2.dec	4836901H1	1607	1888
7	246526.2.dec	6603577H1	1631	2157
7	246526.2.dec	5294946H1	1648	1893
7	246526.2.dec	2289413H1	1662	1880
7	246526.2.dec	2749412H1	1676	1915
7	246526.2.dec	5114945H1	1689	1960
7	246526.2.dec	4223825H1	1696	1996
7	246526.2.dec	4220586H1	1698	1962
7	246526.2.dec	1611734H1	1712	1923
7	246526.2.dec	g847365	1729	2060
7	246526.2.dec	g844344	1734	2069
7	246526.2.dec	g783315	1734	1983
7	246526.2.dec	6321704H1	1734	1933
7	246526.2.dec	4161027H1	1756	2045
7	246526.2.dec	658192H1	1760	2002
7	246526.2.dec	g2027049	1762	2050
7	246526.2.dec	1931913T6	1774	1848
7	246526.2.dec	1482438H1	1781	1980
7	246526.2.dec	1647267F6	1781	2251
7	246526.2.dec	1647343H1	1781	2022
7	246526.2.dec	5853125H1	1791	2045
7	246526.2.dec	g1231286	1793	1908
7	246526.2.dec	2425258H1	1799	2041
7	246526.2.dec	3719040H1	1806	2061
7	246526.2.dec	1494991H1	1819	2038
7	246526.2.dec	g1243109	1824	2193
7	246526.2.dec	g890161	1843	2149
7	246526.2.dec	4583873H1	1853	1995
7	246526.2.dec	2129527H1	1862	2131
7	246526.2.dec	4654582H1	1862	2124
7	246526.2.dec	g893529	1861	2146

TABLE 4

SEQ ID NO:	Template ID	Component ID	Start	Stop
7	246526.2.dec	5548011H1	1877	2174
7	246526.2.dec	2289736H1	1892	2120
7	246526.2.dec	g783093	1892	2146
7	246526.2.dec	3627179H1	1909	2072
7	246526.2.dec	g1969337	1929	2200
7	246526.2.dec	g713248	1930	2224
7	246526.2.dec	g760987	1930	2223
7	246526.2.dec	g759715	1930	2128
7	246526.2.dec	g712677	1930	2066
7	246526.2.dec	3877847H1	1931	2040
7	246526.2.dec	1972266H1	1943	2200
7	246526.2.dec	g1331147	1961	2293
7	246526.2.dec	5024160H1	1968	2243
7	246526.2.dec	1647267T6	1985	2601
7	246526.2.dec	3666919H1	2009	2108
7	246526.2.dec	3083009H1	2013	2328
7	246526.2.dec	1861916T6	2022	2595
7	246526.2.dec	2635842H1	2027	2267
7	246526.2.dec	397443T6	2036	2604
7	246526.2.dec	758011H1	2076	2382
7	246526.2.dec	838848H1	2090	2223
7	246526.2.dec	5016390H1	2099	2373
7	246526.2.dec	2822525T6	2125	2609
7	246526.2.dec	2197506F6	2125	2630
7	246526.2.dec	2197506T6	2126	2604
7	246526.2.dec	2197506H1	2125	2388
7	246526.2.dec	1722149T6	2129	2604
7	246526.2.dec	789184H1	2131	2363
7	246526.2.dec	1722149F6	2147	2578
7	246526.2.dec	1722149H1	2147	2360
7	246526.2.dec	g3278490	1	326
7	246526.2.dec	g2834735	1	67
7	246526.2.dec	g1898302	1	297
7	246526.2.dec	1495040H1	1	239
7	246526.2.dec	g4188207	9	463
7	246526.2.dec	g5435815	9	468
7	246526.2.dec	1394569H1	9	247
7	246526.2.dec	2586482H1	17	247
7	246526.2.dec	2822525F6	18	467
7	246526.2.dec	2822525H1	18	231
7	246526.2.dec	2586451H1	17	271
7	246526.2.dec	2173361H1	24	286
7	246526.2.dec	g2900274	55	484
7	246526.2.dec	g2787983	55	333
7	246526.2.dec	g2752379	73	424
7	246526.2.dec	g2816800	73	321
7	246526.2.dec	g2910688	73	176
7	246526.2.dec	3493568H1	150	414
7	246526.2.dec	1951947H1	152	275
7	246526.2.dec	1698139H1	156	352

TABLE 4

SEQ ID NO:	Template ID	Component ID	Start	Stop
7	246526.2.dec	6164569H1	156	461
7	246526.2.dec	1317624H1	157	466
7	246526.2.dec	1264328H1	173	406
7	246526.2.dec	5676507H1	181	451
7	246526.2.dec	1574434H1	193	416
7	246526.2.dec	1574566H1	193	307
7	246526.2.dec	1574582H1	193	306
7	246526.2.dec	g2883855	194	339
7	246526.2.dec	4531546H1	218	468
7	246526.2.dec	827733R1	219	698
7	246526.2.dec	2643382H1	219	447
7	246526.2.dec	827733H1	220	460
7	246526.2.dec	3397104H1	248	494
7	246526.2.dec	g2035684	249	500
7	246526.2.dec	155203H1	250	456
7	246526.2.dec	079076R6	336	782
7	246526.2.dec	079076H1	336	511
7	246526.2.dec	582057H1	376	632
7	246526.2.dec	583160H1	376	628
7	246526.2.dec	1929684F6	405	864
7	246526.2.dec	1929684H1	405	652
7	246526.2.dec	1751939H1	423	671
7	246526.2.dec	3441286H1	432	667
7	246526.2.dec	716326H1	455	596
7	246526.2.dec	2666560H1	471	719
7	246526.2.dec	g2180026	470	845
7	246526.2.dec	2479324H1	548	786
7	246526.2.dec	2479137H1	548	780
7	246526.2.dec	397443R6	559	1154
7	246526.2.dec	5519145H1	566	713
7	246526.2.dec	6615322H1	603	1130
7	246526.2.dec	g1950420	645	919
7	246526.2.dec	1929684T6	647	1223
7	246526.2.dec	3926385H1	662	936
7	246526.2.dec	4321894H1	662	921
7	246526.2.dec	079076T6	670	1236
7	246526.2.dec	g764005	752	1013
7	246526.2.dec	g703547	752	976
7	246526.2.dec	2188887F6	762	1178
7	246526.2.dec	1240601H1	762	1034
7	246526.2.dec	2059609H1	762	1015
7	246526.2.dec	2188887H1	762	1015
7	246526.2.dec	2059609R6	763	914
7	246526.2.dec	1228511H1	765	1009
7	246526.2.dec	1228592H1	765	1006
7	246526.2.dec	2173361T6	773	1232
7	246526.2.dec	1592372H1	783	907
7	246526.2.dec	2693343H1	784	1031
7	246526.2.dec	401540H1	788	926
7	246526.2.dec	g1517119	788	1107

TABLE 4

SEQ ID NO:	Template ID	Component ID	Start	Stop
7	246526.2.dec	1348393H1	801	1020
7	246526.2.dec	g4896130	813	1276
7	246526.2.dec	g3078088	814	1280
7	246526.2.dec	g3899643	818	1271
7	246526.2.dec	g5393483	824	1271
7	246526.2.dec	g704340	825	1008
7	246526.2.dec	g1014339	825	1102
7	246526.2.dec	g4690086	830	1272
7	246526.2.dec	g3899645	834	1272
7	246526.2.dec	g1955328	834	1045
7	246526.2.dec	g3245222	838	1272
7	246526.2.dec	g2238047	866	1275
7	246526.2.dec	5951508H1	869	1197
7	246526.2.dec	5949994H1	869	1125
7	246526.2.dec	5949657H1	869	1168
7	246526.2.dec	5949857H1	869	1027
7	246526.2.dec	5950094H1	869	1025
7	246526.2.dec	g2728632	872	1280
7	246526.2.dec	g2458193	890	1272
7	246526.2.dec	1931913F6	906	1284
7	246526.2.dec	1931913H1	906	1167
7	246526.2.dec	g1219072	921	1270
7	246526.2.dec	817442H1	929	1171
7	246526.2.dec	030658H1	938	1110
7	246526.2.dec	032501H1	938	1203
7	246526.2.dec	g763947	956	1260
7	246526.2.dec	g4990684	960	1275
7	246526.2.dec	g704341	970	1275
7	246526.2.dec	g1516455	974	1271
7	246526.2.dec	g2842365	976	1277
7	246526.2.dec	g5540637	983	1272
7	246526.2.dec	3617427H1	993	1305
7	246526.2.dec	g5446082	992	1274
7	246526.2.dec	g2242042	999	1267
7	246526.2.dec	g5639130	1002	1273
7	246526.2.dec	g4089555	1004	1274
7	246526.2.dec	6495914H1	1016	1471
7	246526.2.dec	271761H1	1022	1253
7	246526.2.dec	2354615H1	1039	1260
7	246526.2.dec	g3154599	1039	1434
7	246526.2.dec	6313728H1	1043	1488
7	246526.2.dec	562956H1	1046	1270
7	246526.2.dec	562956R6	1046	1268
7	246526.2.dec	500870H1	1046	1246
7	246526.2.dec	562956T6	1046	1230
7	246526.2.dec	g5638746	1055	1272
7	246526.2.dec	g1274236	1096	1536
7	246526.2.dec	3573608H1	1133	1439
7	246526.2.dec	3567436H1	1155	1309
7	246526.2.dec	1579505H1	1159	1355

TABLE 4

SEQ ID NO:	Template ID	Component ID	Start	Stop
7	246526.2.dec	1579505F6	1159	1286
7	246526.2.dec	g1331027	2169	2640
7	246526.2.dec	g4533116	2174	2642
7	246526.2.dec	g3431339	2175	2634
7	246526.2.dec	g5392578	2188	2645
7	246526.2.dec	2188887T6	2189	2595
7	246526.2.dec	3702561H1	2206	2518
7	246526.2.dec	3432072H1	2205	2377
7	246526.2.dec	g4076803	2211	2643
7	246526.2.dec	g5395302	2213	2649
7	246526.2.dec	g4003630	2217	2643
7	246526.2.dec	g5631457	2220	2640
7	246526.2.dec	g3870470	2222	2643
7	246526.2.dec	g3899705	2229	2642
7	246526.2.dec	2021042H1	2232	2438
7	246526.2.dec	6405258H2	2235	2421
7	246526.2.dec	6156086H1	2240	2547
7	246526.2.dec	g713604	2247	2642
7	246526.2.dec	g4282562	2244	2634
7	246526.2.dec	g2752080	2244	2406
7	246526.2.dec	g1331098	2251	2659
7	246526.2.dec	1496240H1	2252	2473
7	246526.2.dec	g1224147	2253	2643
7	246526.2.dec	1496240T1	2252	2602
7	246526.2.dec	g3801920	2262	2648
7	246526.2.dec	2429495H1	2265	2499
7	246526.2.dec	g3094872	2269	2643
7	246526.2.dec	g1010383	2272	2640
7	246526.2.dec	g3701189	2279	2648
7	246526.2.dec	g2674626	2284	2646
7	246526.2.dec	g981375	2286	2642
7	246526.2.dec	g2279829	2294	2633
7	246526.2.dec	g883276	2302	2654
7	246526.2.dec	g3742404	2311	2644
7	246526.2.dec	6361538H2	2313	2431
7	246526.2.dec	g1219974	2315	2642
7	246526.2.dec	g1201439	2319	2648
7	246526.2.dec	g723228	2325	2645
7	246526.2.dec	g898941	2326	2629
7	246526.2.dec	g760988	2354	2635
7	246526.2.dec	g2659181	2353	2645
7	246526.2.dec	g2020840	2355	2643
7	246526.2.dec	g2559564	2358	2649
7	246526.2.dec	g846893	2365	2643
7	246526.2.dec	1986742H1	2364	2558
7	246526.2.dec	g2969330	2368	2639
7	246526.2.dec	g1018535	2384	2608
7	246526.2.dec	g782865	2387	2642
7	246526.2.dec	g566344	2388	2612
7	246526.2.dec	1598359H1	2413	2622

TABLE 4

SEQ ID NO:	Template ID	Component ID	Start	Stop
7	246526.2.dec	1598358H1	2413	2623
7	246526.2.dec	1679021H1	2416	2628
7	246526.2.dec	2696192H1	2425	2634
7	246526.2.dec	g1017889	2427	2644
7	246526.2.dec	2364484H1	2433	2646
7	246526.2.dec	g3092039	2445	2645
7	246526.2.dec	g704228	2444	2620
7	246526.2.dec	g2213054	2495	2643
7	246526.2.dec	g3840446	2494	2642
7	246526.2.dec	2770933H1	2517	2634
7	246526.2.dec	4830839H1	2526	2650
7	246526.2.dec	289634H1	2534	2634
7	246526.2.dec	1358265H1	2537	2815
7	246526.2.dec	g2837523	2592	2965
8	200488.5.dec	4043361H1	1	265
8	200488.5.dec	4043361F6	1	571
8	200488.5.dec	5400109H1	38	168
8	200488.5.dec	5620913H1	45	321
8	200488.5.dec	572762H1	45	303
8	200488.5.dec	g680776	46	174
8	200488.5.dec	6437310H1	55	635
8	200488.5.dec	4043361T6	118	718
8	200488.5.dec	g1618321	320	699
8	200488.5.dec	4880281H1	523	754
8	200488.5.dec	5949678H1	525	771
9	474878.1.dec	571127H1	1497	1715
9	474878.1.dec	2328233H1	1525	1780
9	474878.1.dec	2328233R6	1525	2032
9	474878.1.dec	g1940321	1531	1844
9	474878.1.dec	6157851H1	1534	1697
9	474878.1.dec	g3742402	1539	1852
9	474878.1.dec	g1940948	1544	1721
9	474878.1.dec	g3166966	1551	1979
9	474878.1.dec	6157772H1	1567	1806
9	474878.1.dec	778655H1	1578	1821
9	474878.1.dec	1581071H1	1581	1781
9	474878.1.dec	5099087H1	1590	1857
9	474878.1.dec	1314472H1	1591	1864
9	474878.1.dec	1784735H1	1595	1843
9	474878.1.dec	584498H1	1596	1932
9	474878.1.dec	1344492H1	1609	1851
9	474878.1.dec	4068471H1	1634	1802
9	474878.1.dec	506313H1	1678	1902
9	474878.1.dec	6108290H1	1679	1952
9	474878.1.dec	2097212H1	1685	1874
9	474878.1.dec	6485186H1	1688	2236
9	474878.1.dec	6266715H1	1690	2262
9	474878.1.dec	745544R6	1690	2036
9	474878.1.dec	745544H1	1691	1955
9	474878.1.dec	4882217H1	1715	1999

TABLE 4

SEQ ID NO:	Template ID	Component ID	Start	Stop
9	474878.1.dec	2014391H1	1723	1979
9	474878.1.dec	1979002H1	1754	2044
9	474878.1.dec	3780778H1	1765	2080
9	474878.1.dec	1383473T6	1767	2386
9	474878.1.dec	1912211H1	1784	2036
9	474878.1.dec	4953404H1	1787	2041
9	474878.1.dec	3593485H1	1786	2082
9	474878.1.dec	1704049H1	1799	2017
9	474878.1.dec	532564H1	1800	2020
9	474878.1.dec	2460229H1	1808	2034
9	474878.1.dec	3122555H1	1810	2116
9	474878.1.dec	1007753H1	1826	2127
9	474878.1.dec	4550034T1	1830	2386
9	474878.1.dec	745544T6	1843	2382
9	474878.1.dec	g749175	1851	2125
9	474878.1.dec	2201650H1	1852	2109
9	474878.1.dec	6357768H1	1860	1983
9	474878.1.dec	1906164T6	1895	2396
9	474878.1.dec	2082940H1	1899	2137
9	474878.1.dec	2081388H1	1899	2137
9	474878.1.dec	g1383678	1912	2339
9	474878.1.dec	1298690H1	1913	2163
9	474878.1.dec	1298690F1	1914	2323
9	474878.1.dec	6326213H1	1916	2217
9	474878.1.dec	4979876H1	1937	2206
9	474878.1.dec	839539H1	1938	2148
9	474878.1.dec	g2913007	1943	2424
9	474878.1.dec	6430283H1	1948	2410
9	474878.1.dec	g3003791	1946	2425
9	474878.1.dec	2302122T6	1962	2388
9	474878.1.dec	1855791T6	1964	2379
9	474878.1.dec	3178987H1	1970	2280
9	474878.1.dec	6321190H1	1972	2245
9	474878.1.dec	3482645T6	1984	2387
9	474878.1.dec	2260661T6	1991	2390
9	474878.1.dec	6326393H1	1995	2282
9	474878.1.dec	g3418836	2004	2425
9	474878.1.dec	g5659013	2008	2425
9	474878.1.dec	g3900513	2009	2425
9	474878.1.dec	2328233T6	2008	2387
9	474878.1.dec	g3988728	2012	2427
9	474878.1.dec	g3095324	2013	2432
9	474878.1.dec	g4072902	2016	2425
9	474878.1.dec	g1727223	2023	2425
9	474878.1.dec	g3597743	2024	2426
9	474878.1.dec	g2554182	2029	2426
9	474878.1.dec	g2397860	2031	2426
9	474878.1.dec	g1940832	2031	2425
9	474878.1.dec	334239H1	2033	2262
9	474878.1.dec	g1941153	2037	2425

TABLE 4

SEQ ID NO:	Template ID	Component ID	Start	Stop
9	474878.1.dec	g2465956	2046	2426
9	474878.1.dec	g3002018	2055	2426
9	474878.1.dec	g3052386	2060	2429
9	474878.1.dec	g658645	2060	2425
9	474878.1.dec	5021683H1	2061	2342
9	474878.1.dec	4646243H1	2062	2326
9	474878.1.dec	5021683T1	2064	2379
9	474878.1.dec	073688H1	2071	2326
9	474878.1.dec	073962H1	2071	2213
9	474878.1.dec	g1689373	2076	2413
9	474878.1.dec	g988331	2101	2435
9	474878.1.dec	g2183351	2100	2425
9	474878.1.dec	271231H1	2100	2298
9	474878.1.dec	g989410	2108	2419
9	474878.1.dec	g2047031	2107	2425
9	474878.1.dec	4219112H1	2108	2374
9	474878.1.dec	g564678	2112	2425
9	474878.1.dec	4202793H1	2125	2410
9	474878.1.dec	g2835238	2125	2425
9	474878.1.dec	1576547H1	2125	2289
9	474878.1.dec	g1312586	2129	2426
9	474878.1.dec	g4986384	2154	2429
9	474878.1.dec	780421H1	2162	2292
9	474878.1.dec	g749280	2167	2427
9	474878.1.dec	4717682H1	1	248
9	474878.1.dec	2604722H1	18	247
9	474878.1.dec	2260661R6	22	421
9	474878.1.dec	2260661H1	22	274
9	474878.1.dec	4795373H1	22	272
9	474878.1.dec	3102252H1	27	352
9	474878.1.dec	5037329H1	30	295
9	474878.1.dec	4530781H1	30	285
9	474878.1.dec	5400139H1	32	178
9	474878.1.dec	6604055H1	44	451
9	474878.1.dec	1258366H1	34	246
9	474878.1.dec	3510895H1	42	314
9	474878.1.dec	3465753H1	45	379
9	474878.1.dec	4114074H1	52	167
9	474878.1.dec	3649065H1	62	166
9	474878.1.dec	6138239H1	68	366
9	474878.1.dec	3750720H1	75	197
9	474878.1.dec	2960324H1	84	242
9	474878.1.dec	g651892	187	490
9	474878.1.dec	4989817H1	212	495
9	474878.1.dec	3482645F6	303	867
9	474878.1.dec	3482645H1	303	498
9	474878.1.dec	1395412H1	336	595
9	474878.1.dec	5393935H1	385	650
9	474878.1.dec	4797624H1	396	665
9	474878.1.dec	6541193H1	414	931

TABLE 4

SEQ ID NO:	Template ID	Component ID	Start	Stop
9	474878.1.dec	2490605H1	449	689
9	474878.1.dec	1344946F6	476	921
9	474878.1.dec	g5233250	495	696
9	474878.1.dec	3504674H1	497	772
9	474878.1.dec	3748060H1	512	807
9	474878.1.dec	g1727282	550	722
9	474878.1.dec	352603H1	629	831
9	474878.1.dec	2302122R6	636	1097
9	474878.1.dec	2302122H1	636	870
9	474878.1.dec	4177761H1	647	919
9	474878.1.dec	190033H1	673	890
9	474878.1.dec	359191H1	673	896
9	474878.1.dec	1855791F6	675	1208
9	474878.1.dec	1855791H1	675	874
9	474878.1.dec	4649538H1	723	971
9	474878.1.dec	5404524H1	732	873
9	474878.1.dec	g658646	828	1137
9	474878.1.dec	1906164F6	860	1103
9	474878.1.dec	1906164H1	860	961
9	474878.1.dec	5120370H1	901	1016
9	474878.1.dec	5120063H1	901	1198
9	474878.1.dec	022665H1	957	1302
9	474878.1.dec	2185728H1	975	1241
9	474878.1.dec	4886861H1	976	1278
9	474878.1.dec	6159129H1	982	1209
9	474878.1.dec	5104424H1	994	1263
9	474878.1.dec	010115H1	1008	1346
9	474878.1.dec	5048787H1	1018	1268
9	474878.1.dec	593263H1	1018	1249
9	474878.1.dec	g824550	1019	1318
9	474878.1.dec	5188638H1	1023	1338
9	474878.1.dec	1383473F6	1069	1564
9	474878.1.dec	1383473H1	1069	1312
9	474878.1.dec	1381362H1	1069	1297
9	474878.1.dec	3518142H1	1079	1403
9	474878.1.dec	5661759H1	1081	1343
9	474878.1.dec	4550002H1	1117	1352
9	474878.1.dec	713452H1	1133	1321
9	474878.1.dec	g668336	1149	1410
9	474878.1.dec	g573132	1149	1472
9	474878.1.dec	g696465	1150	1533
9	474878.1.dec	1898273H1	1196	1457
9	474878.1.dec	g988498	1197	1520
9	474878.1.dec	3525794H1	1198	1470
9	474878.1.dec	2266314H1	1199	1443
9	474878.1.dec	5175326H1	1211	1421
9	474878.1.dec	5597046H1	1270	1537
9	474878.1.dec	6514953H1	1272	1777
9	474878.1.dec	g1941526	1281	1686
9	474878.1.dec	1924150H1	1305	1544

TABLE 4

SEQ ID NO:	Template ID	Component ID	Start	Stop
9	474878.1.dec	4900790H1	1340	1520
9	474878.1.dec	1816879H1	1347	1608
9	474878.1.dec	5836742H1	1370	1643
9	474878.1.dec	2265560H1	1375	1637
9	474878.1.dec	3702961H1	1380	1675
9	474878.1.dec	1907523H1	1440	1684
9	474878.1.dec	g5100926	1444	1854
9	474878.1.dec	6551418H1	1446	2002
9	474878.1.dec	3958231H2	1463	1738
9	474878.1.dec	4543030H1	1484	1564
9	474878.1.dec	2801727H1	1493	1695
9	474878.1.dec	g3174029	2178	2429
9	474878.1.dec	g644901	2178	2425
9	474878.1.dec	408264H1	2186	2420
9	474878.1.dec	1417510H1	2187	2425
9	474878.1.dec	g4194592	2192	2429
9	474878.1.dec	1547442H1	2197	2378
9	474878.1.dec	g1383626	2210	2430
9	474878.1.dec	6569854H1	2225	2427
9	474878.1.dec	g824551	2233	2435
9	474878.1.dec	2366889H1	2272	2425
9	474878.1.dec	2371405H1	2272	2425
9	474878.1.dec	3481366H1	2278	2431
9	474878.1.dec	g4438805	2293	2425
10	335916.2.dec	6497614H1	1	488
10	335916.2.dec	6457162H1	45	466
10	335916.2.dec	3110489H1	81	346
10	335916.2.dec	2782031F6	241	655
10	335916.2.dec	2782031H1	241	498
10	335916.2.dec	g4622020	348	594
10	335916.2.dec	2508394F6	377	743
10	335916.2.dec	2508394H1	377	623
10	335916.2.dec	3253880H1	393	636
10	335916.2.dec	4753078H1	450	560
10	335916.2.dec	2664350H1	617	830
10	335916.2.dec	5841727H1	708	965
10	335916.2.dec	3345808H1	758	853
10	335916.2.dec	1664667F6	790	1241
10	335916.2.dec	1664667H1	790	1036
10	335916.2.dec	6495655H1	905	1341
10	335916.2.dec	1730823H1	960	1040
10	335916.2.dec	3294429H1	969	1226
10	335916.2.dec	3371239H1	1019	1259
10	335916.2.dec	2861953H1	1053	1330
10	335916.2.dec	3401194H1	1053	1278
10	335916.2.dec	2861953F6	1053	1558
10	335916.2.dec	3257620H1	1113	1251
10	335916.2.dec	867163H1	1133	1372
10	335916.2.dec	867163R6	1133	1401
10	335916.2.dec	g2324543	1269	1620

TABLE 4

SEQ ID NO:	Template ID	Component ID	Start	Stop
10	335916.2.dec	1627014H1	1488	1720
10	335916.2.dec	g1939354	1506	1766
10	335916.2.dec	g2107851	1506	1858
10	335916.2.dec	912981H1	1615	1747
10	335916.2.dec	2111286H1	1616	1863
10	335916.2.dec	3790008H1	1693	1809
10	335916.2.dec	1214420H1	1700	1936
10	335916.2.dec	3535232H1	1798	2072
10	335916.2.dec	3257037H1	1810	2064
10	335916.2.dec	3210776H1	1820	2024
11	040422.12.dec	3343947H1	1	210
11	040422.12.dec	3343947F6	1	398
11	040422.12.dec	4183830H1	23	207
11	040422.12.dec	4792750H1	25	295
11	040422.12.dec	3159520H1	27	304
11	040422.12.dec	3296383H1	28	279
11	040422.12.dec	5197324H1	29	284
11	040422.12.dec	5197324F6	29	299
11	040422.12.dec	g3341989	42	1400
11	040422.12.dec	5978581H1	51	292
11	040422.12.dec	3898429H1	52	272
11	040422.12.dec	5605234H1	53	276
11	040422.12.dec	5302780H1	53	291
11	040422.12.dec	3592605H1	64	359
11	040422.12.dec	3593031H1	64	368
11	040422.12.dec	g1727841	70	483
11	040422.12.dec	6552493H1	112	701
11	040422.12.dec	6557908H1	112	591
11	040422.12.dec	4051117H1	224	509
11	040422.12.dec	3293317H1	477	729
11	040422.12.dec	2928983H1	499	798
11	040422.12.dec	3032868H1	515	808
11	040422.12.dec	5570320H1	666	831
11	040422.12.dec	4418383H1	691	897
11	040422.12.dec	4747915H1	718	987
11	040422.12.dec	g3096317	720	1177
11	040422.12.dec	3343947T6	725	1356
11	040422.12.dec	4371455H1	742	1023
11	040422.12.dec	1978317T6	801	1359
11	040422.12.dec	1978317R6	811	1196
11	040422.12.dec	1978317H1	811	1110
11	040422.12.dec	g3037965	922	1400
11	040422.12.dec	482585T6	937	1380
11	040422.12.dec	5029812H1	937	1150
11	040422.12.dec	658005H1	937	1115
11	040422.12.dec	1610157T1	937	995
11	040422.12.dec	1610157T6	941	1360
11	040422.12.dec	g1046767	974	1300
11	040422.12.dec	g5113655	983	1401
11	040422.12.dec	g2161987	985	1403

TABLE 4

SEQ ID NO:	Template ID	Component ID	Start	Stop
11	040422.12.dec	g1046664	1016	1400
11	040422.12.dec	4146468H1	1040	1288
11	040422.12.dec	g1727662	1053	1397
11	040422.12.dec	g4149302	1084	1401
11	040422.12.dec	3219363H1	1117	1394
11	040422.12.dec	g3871333	1123	1399
11	040422.12.dec	g2784520	1173	1409
11	040422.12.dec	2346542F6	1191	1400
11	040422.12.dec	2346542H1	1191	1421
11	040422.12.dec	g3037903	1314	1400
12	977651.2.dec	2801809H1	207	469
12	977651.2.dec	g1267440	205	617
12	977651.2.dec	2910841H1	209	468
12	977651.2.dec	4045484H1	211	488
12	977651.2.dec	4639491H1	213	471
12	977651.2.dec	2182080H1	231	511
12	977651.2.dec	3154813H1	246	504
12	977651.2.dec	3873262H1	300	562
12	977651.2.dec	1459945H1	300	540
12	977651.2.dec	4635570H1	309	553
12	977651.2.dec	3254753H1	315	573
12	977651.2.dec	986038H1	339	571
12	977651.2.dec	1541940H1	350	575
12	977651.2.dec	4466419H1	356	598
12	977651.2.dec	4466417H1	359	606
12	977651.2.dec	151211H1	372	604
12	977651.2.dec	4981429H1	381	635
12	977651.2.dec	g728181	395	643
12	977651.2.dec	1748157H1	397	680
12	977651.2.dec	4219930H1	402	701
12	977651.2.dec	1574381H1	402	633
12	977651.2.dec	1574381F6	402	660
12	977651.2.dec	4464523H1	412	598
12	977651.2.dec	4906687H2	433	674
12	977651.2.dec	4044623H1	438	705
12	977651.2.dec	3037055H1	451	734
12	977651.2.dec	1977380H1	452	679
12	977651.2.dec	2115723H1	455	567
12	977651.2.dec	5185327H1	459	693
12	977651.2.dec	907607H1	529	680
12	977651.2.dec	g3076955	621	1092
12	977651.2.dec	g2946373	634	1091
12	977651.2.dec	g4003859	654	1096
12	977651.2.dec	g4893606	682	1091
12	977651.2.dec	g3400779	696	1099
12	977651.2.dec	g3214725	697	1091
12	977651.2.dec	g2537968	705	1096
12	977651.2.dec	g5152617	720	1092
12	977651.2.dec	g3597940	727	1105
12	977651.2.dec	g2670173	775	1090

TABLE 4

SEQ ID NO:	Template ID	Component ID	Start	Stop
12	977651.2.dec	g4072011	812	1094
12	977651.2.dec	g1802488	816	1093
12	977651.2.dec	g4195857	822	1096
12	977651.2.dec	g4195469	898	1094
12	977651.2.dec	1921146R6	1	443
12	977651.2.dec	1921146H1	1	216
12	977651.2.dec	827751H1	1	274
12	977651.2.dec	2294102H1	75	353
12	977651.2.dec	2786002H1	77	349
12	977651.2.dec	6357235H1	160	372
12	977651.2.dec	2495317H1	161	483
12	977651.2.dec	3648560H1	169	343
12	977651.2.dec	855978H1	169	401
12	977651.2.dec	2409671H1	169	410
12	977651.2.dec	5021802H1	169	446
12	977651.2.dec	4166987H1	170	286
12	977651.2.dec	2814612H1	169	487
12	977651.2.dec	2578951H1	174	383
12	977651.2.dec	6171520H1	174	467
12	977651.2.dec	3347246H1	175	433
12	977651.2.dec	3491814H1	178	448
12	977651.2.dec	3360455H1	182	466
12	977651.2.dec	5863129H1	189	248
12	977651.2.dec	4725591H1	192	453
12	977651.2.dec	4798920H1	192	425
12	977651.2.dec	4725558H1	192	407
12	977651.2.dec	g1012357	194	481
12	977651.2.dec	g4680704	194	1096
12	977651.2.dec	2793693F6	199	606
12	977651.2.dec	2793693H1	199	491
12	977651.2.dec	2860948H1	199	459
12	977651.2.dec	2760646H1	199	450
12	977651.2.dec	2889910H1	199	382
12	977651.2.dec	4541324H1	199	465
12	977651.2.dec	3325062H1	201	458
12	977651.2.dec	4675275H1	202	303
12	977651.2.dec	3741914H1	202	502
12	977651.2.dec	2738790H1	202	440
12	977651.2.dec	4547040H1	202	357
12	977651.2.dec	4800415H1	204	492
12	977651.2.dec	3150944H1	202	377
12	977651.2.dec	g1802603	203	599
12	977651.2.dec	3050095H1	203	489
12	977651.2.dec	2635706H1	204	471
12	977651.2.dec	2452359H1	204	454
12	977651.2.dec	2692134H1	204	453
12	977651.2.dec	2545415H1	204	453
12	977651.2.dec	3523020H1	205	542
12	977651.2.dec	1919594H1	204	361
12	977651.2.dec	2780137H1	204	449

TABLE 4

SEQ ID NO:	Template ID	Component ID	Start	Stop
12	977651.2.dec	6304468H2	205	725
12	977651.2.dec	5017869H1	205	494
12	977651.2.dec	3213669H1	205	443
12	977651.2.dec	3521891H1	205	380
12	977651.2.dec	3129806H1	204	515
12	977651.2.dec	2106050H1	206	453
12	977651.2.dec	g1164443	206	469
12	977651.2.dec	3603114H1	207	514
12	977651.2.dec	2909904H1	207	479
12	977651.2.dec	4387078H1	207	467
13	012432.5.dec	2610935H1	1	244
13	012432.5.dec	712941H1	20	161
13	012432.5.dec	4175484H1	20	318
13	012432.5.dec	3458411H1	25	281
13	012432.5.dec	3286928H1	25	273
13	012432.5.dec	3297142H1	24	263
13	012432.5.dec	2665744H1	23	257
13	012432.5.dec	804988H1	25	251
13	012432.5.dec	3983449H1	22	207
13	012432.5.dec	3286928F6	25	586
13	012432.5.dec	3458411F6	25	423
13	012432.5.dec	5070204H1	26	334
13	012432.5.dec	660788H1	25	277
13	012432.5.dec	3464584H1	26	214
13	012432.5.dec	5992614H1	26	322
13	012432.5.dec	5472074H1	27	277
13	012432.5.dec	4913558H1	28	302
13	012432.5.dec	593561H1	29	183
13	012432.5.dec	2718265H1	31	276
13	012432.5.dec	3463817F6	31	519
13	012432.5.dec	3463817H1	31	327
13	012432.5.dec	194287H1	32	223
13	012432.5.dec	3391154H1	34	281
13	012432.5.dec	3391454H1	34	278
13	012432.5.dec	3375131H1	37	270
13	012432.5.dec	2920915H1	40	310
13	012432.5.dec	5163335H1	58	292
13	012432.5.dec	g3401307	57	411
13	012432.5.dec	g1807207	103	238
13	012432.5.dec	597038H1	119	311
13	012432.5.dec	4343602H1	188	470
13	012432.5.dec	1216935H1	439	590
14	059263.6.dec	g4333810	446	906
14	059263.6.dec	5907201H1	1	308
14	059263.6.dec	g1809245	88	2109
14	059263.6.dec	4178992H2	116	368
14	059263.6.dec	1467979H1	620	818
14	059263.6.dec	1467979F6	620	951
14	059263.6.dec	3085763H1	625	929
14	059263.6.dec	4326394H1	480	678

TABLE 4

SEQ ID NO:	Template ID	Component ID	Start	Stop
14	059263.6.dec	6546375H1	449	937
14	059263.6.dec	5913060H1	536	833
14	059263.6.dec	6515415H1	575	1105
14	059263.6.dec	5924357H1	616	889
14	059263.6.dec	449317T6	1613	2067
14	059263.6.dec	3845518H1	1635	1913
14	059263.6.dec	g5431445	1665	2115
14	059263.6.dec	735396H1	1304	1545
14	059263.6.dec	4709292H1	1260	1515
14	059263.6.dec	735396R1	1304	1840
14	059263.6.dec	527201H1	1336	1585
14	059263.6.dec	2755840H1	1410	1664
14	059263.6.dec	5602808H1	1412	1676
14	059263.6.dec	3449574H1	1412	1526
14	059263.6.dec	6269421H1	1419	1777
14	059263.6.dec	445961F1	1498	2109
14	059263.6.dec	3166822H1	1073	1359
14	059263.6.dec	g2013303	1007	1262
14	059263.6.dec	6269333H1	1183	1811
14	059263.6.dec	338737H1	1246	1484
14	059263.6.dec	3885430H2	1252	1506
14	059263.6.dec	3637017H1	969	1261
14	059263.6.dec	4959483H1	1006	1259
14	059263.6.dec	6437085H1	639	1152
14	059263.6.dec	3566975H1	711	955
14	059263.6.dec	445961R6	715	1248
14	059263.6.dec	3162586H1	1520	1795
14	059263.6.dec	338360H1	1533	1650
14	059263.6.dec	4367573H1	1559	1832
14	059263.6.dec	449317H1	944	1113
14	059263.6.dec	5907575H1	947	1239
14	059263.6.dec	342416H1	960	1197
14	059263.6.dec	3162459H1	947	1231
14	059263.6.dec	g560331	1887	2109
14	059263.6.dec	1519675T6	1909	2059
14	059263.6.dec	g668542	634	903
14	059263.6.dec	6430603H1	639	1124
14	059263.6.dec	g668543	634	893
14	059263.6.dec	g900542	634	946
14	059263.6.dec	445961R1	715	1205
14	059263.6.dec	512782H1	715	967
14	059263.6.dec	2431467H1	715	893
14	059263.6.dec	3242035H1	749	988
14	059263.6.dec	5913544H1	785	1063
14	059263.6.dec	4193622H1	818	1094
14	059263.6.dec	4958901H1	857	1117
14	059263.6.dec	4439155H1	871	1144
14	059263.6.dec	449788H1	944	1104
14	059263.6.dec	g775766	273	616
14	059263.6.dec	4708214H1	275	550

TABLE 4

SEQ ID NO:	Template ID	Component ID	Start	Stop
14	059263.6.dec	2151592H1	281	553
14	059263.6.dec	g814279	319	720
14	059263.6.dec	5373649H1	333	554
14	059263.6.dec	4708510H1	183	301
14	059263.6.dec	5925904H1	242	453
14	059263.6.dec	g1173538	242	1318
14	059263.6.dec	g389367	252	666
14	059263.6.dec	g1950140	255	667
14	059263.6.dec	g615808	1853	2109
14	059263.6.dec	3937956H1	1859	2071
14	059263.6.dec	2906383H1	1823	2109
14	059263.6.dec	3421560H1	1827	2083
14	059263.6.dec	g3076896	1841	2109
14	059263.6.dec	5434173H1	1768	1998
14	059263.6.dec	g2324590	1793	2109
14	059263.6.dec	g317469	1795	2109
14	059263.6.dec	3843223H1	1805	2084
14	059263.6.dec	g2269635	1756	2110
14	059263.6.dec	g2388765	1761	2109
14	059263.6.dec	g2214360	1767	2109
14	059263.6.dec	445961T6	1716	2068
14	059263.6.dec	5079421H1	1738	1847
14	059263.6.dec	4944041H1	1744	2021
14	059263.6.dec	1453911F6	1748	2019
14	059263.6.dec	3846369H1	1673	1909
14	059263.6.dec	g828896	1675	2109
14	059263.6.dec	g3870013	1678	2109
14	059263.6.dec	3002426T6	1683	2069
14	059263.6.dec	g3307105	1688	2111
14	059263.6.dec	g389366	1701	2109
14	059263.6.dec	g3834908	1690	2108
15	196774.3.dec	4198864H1	366	645
15	196774.3.dec	6543639H1	1	536
15	196774.3.dec	5467282H1	349	610
15	196774.3.dec	5467289H1	349	605
15	196774.3.dec	6545364H1	383	952
15	196774.3.dec	3124504H1	596	882
15	196774.3.dec	2858708T6	720	1100
15	196774.3.dec	1656694T6	752	1086
16	233624.11.dec	2578538F6	1	480
16	233624.11.dec	2578538H1	1	187
16	233624.11.dec	4624394H1	26	149
16	233624.11.dec	2478423H1	54	282
16	233624.11.dec	g1999348	59	188
16	233624.11.dec	2136789F6	288	634
16	233624.11.dec	2136789H1	288	511
16	233624.11.dec	5350727H1	399	563
16	233624.11.dec	5350889H1	399	524
16	233624.11.dec	3639605H1	581	871
16	233624.11.dec	3765020H1	612	906

TABLE 4

SEQ ID NO:	Template ID	Component ID	Start	Stop
17	228585.3.dec	1740045R6	1839	2332
17	228585.3.dec	1739439H1	1839	2088
17	228585.3.dec	1740045H1	1839	2053
17	228585.3.dec	5849788H1	1839	1981
17	228585.3.dec	5374048H1	1849	2100
17	228585.3.dec	4723812H1	1855	2126
17	228585.3.dec	2288963H1	1877	2123
17	228585.3.dec	1373365H1	1895	2124
17	228585.3.dec	1595644F6	1900	2332
17	228585.3.dec	4341071H1	1900	2206
17	228585.3.dec	1595644H1	1900	2114
17	228585.3.dec	2245012H1	1903	2111
17	228585.3.dec	532797T6	1927	2525
17	228585.3.dec	1400814H1	1953	2236
17	228585.3.dec	3945768H1	1974	2247
17	228585.3.dec	6307190H1	1986	2542
17	228585.3.dec	4313085H1	1998	2282
17	228585.3.dec	1595644T6	2005	2530
17	228585.3.dec	1712978T6	2037	2530
17	228585.3.dec	1412604T6	2065	2548
17	228585.3.dec	620296T6	2077	2525
17	228585.3.dec	1942348R6	2079	2588
17	228585.3.dec	4312619H1	2078	2365
17	228585.3.dec	2123967T6	2092	2532
17	228585.3.dec	663135T6	2103	2524
17	228585.3.dec	g5689560	2116	5914
17	228585.3.dec	g4685449	2116	2557
17	228585.3.dec	g4984720	2116	2535
17	228585.3.dec	2570503H1	3742	3978
17	228585.3.dec	4722814H1	3806	3916
17	228585.3.dec	1949846H1	2251	2496
17	228585.3.dec	1949815H1	2251	2496
17	228585.3.dec	5904662H1	2255	2551
17	228585.3.dec	g819594	2266	2622
17	228585.3.dec	4768762H1	2279	2556
17	228585.3.dec	g517574	2128	2616
17	228585.3.dec	6360619H1	2122	2294
17	228585.3.dec	2400848H1	2127	2343
17	228585.3.dec	620296H1	2127	2334
17	228585.3.dec	4311031H1	2127	2317
17	228585.3.dec	5902549H1	2142	2436
17	228585.3.dec	1942348H1	2127	2347
17	228585.3.dec	5659857H1	2131	2307
17	228585.3.dec	5614086H1	2142	2422
17	228585.3.dec	5898857H1	2142	2416
17	228585.3.dec	5898671H1	2142	2410
17	228585.3.dec	1673835T6	2149	2524
17	228585.3.dec	5139434H1	2145	2412
17	228585.3.dec	6131287H1	2180	2445
17	228585.3.dec	5679165H1	3595	3673

TABLE 4

SEQ ID NO:	Template ID	Component ID	Start	Stop
17	228585.3.dec	2658040F6	3621	4130
17	228585.3.dec	3762503H1	3733	3990
17	228585.3.dec	6118313H1	1	579
17	228585.3.dec	4787759H1	1255	1490
17	228585.3.dec	g990857	1308	1644
17	228585.3.dec	g946099	1308	1455
17	228585.3.dec	g878889	1308	1405
17	228585.3.dec	532797R6	1322	1701
17	228585.3.dec	532797H1	1323	1525
17	228585.3.dec	5833867H1	1348	1619
17	228585.3.dec	3726741H1	1377	1671
17	228585.3.dec	1712978F6	1476	1889
17	228585.3.dec	1712978H1	1476	1694
17	228585.3.dec	3770873H1	1489	1788
17	228585.3.dec	5876837H1	1498	1783
17	228585.3.dec	663135R6	1574	2127
17	228585.3.dec	3147094H1	165	447
17	228585.3.dec	3593276H1	210	524
17	228585.3.dec	1412604F6	352	898
17	228585.3.dec	6121951H1	1695	2233
17	228585.3.dec	5690251H1	1700	1975
17	228585.3.dec	6173835H1	1711	1942
17	228585.3.dec	g990056	1708	2017
17	228585.3.dec	3600703H1	1721	2011
17	228585.3.dec	5689188H1	1780	2048
17	228585.3.dec	2907705H1	1798	2050
17	228585.3.dec	1412604H1	352	622
17	228585.3.dec	g677056	424	633
17	228585.3.dec	g672789	430	758
17	228585.3.dec	g892790	431	666
17	228585.3.dec	g775645	431	678
17	228585.3.dec	1297889H1	541	784
17	228585.3.dec	1297889F1	541	765
17	228585.3.dec	g4069788	2121	2560
17	228585.3.dec	g564864	2122	2474
17	228585.3.dec	g671393	2122	2359
17	228585.3.dec	g518101	2116	2524
17	228585.3.dec	g3693534	2116	2454
17	228585.3.dec	g519265	2116	2375
17	228585.3.dec	g615632	2116	2306
17	228585.3.dec	g4888013	2116	2516
17	228585.3.dec	5371718H1	602	850
17	228585.3.dec	663135H1	1574	1838
17	228585.3.dec	4716435H1	1580	1675
17	228585.3.dec	5579252H1	1619	1878
17	228585.3.dec	6121671H1	1652	2080
17	228585.3.dec	2006293H1	1673	1796
17	228585.3.dec	6122051H1	1693	2025
17	228585.3.dec	3614928H1	3171	3452
17	228585.3.dec	6308868H1	3322	3848

TABLE 4

SEQ ID NO:	Template ID	Component ID	Start	Stop
17	228585.3.dec	2775486H1	3344	3559
17	228585.3.dec	6131367H1	3561	3828
17	228585.3.dec	1954291H1	2639	2859
17	228585.3.dec	5859988H1	2644	2885
17	228585.3.dec	g2050587	2626	3105
17	228585.3.dec	g314160	2454	2782
17	228585.3.dec	g891612	2514	2615
17	228585.3.dec	2291482H1	2485	2601
17	228585.3.dec	g2140727	2547	2601
17	228585.3.dec	4013255H1	2601	2886
17	228585.3.dec	g274421	4639	4951
17	228585.3.dec	1450839H1	5713	5923
17	228585.3.dec	g389990	4628	4941
17	228585.3.dec	2658040H1	3900	4130
17	228585.3.dec	g2559863	2361	2497
17	228585.3.dec	2658040T6	2416	2533
17	228585.3.dec	3313954H1	2371	2595
17	228585.3.dec	2123967H1	2335	2605
17	228585.3.dec	5911041H1	2382	2618
17	228585.3.dec	861748H1	2361	2568
17	228585.3.dec	g796237	2293	2613
17	228585.3.dec	2123967F6	2315	2607
17	228585.3.dec	g876300	2295	2615
17	228585.3.dec	4577236H1	2327	2593
17	228585.3.dec	2413167H1	1193	1436
17	228585.3.dec	6060583H1	1142	1192
17	228585.3.dec	4759715H1	1157	1421
17	228585.3.dec	6296788H1	1171	1435
17	228585.3.dec	4228967H1	1205	1467
17	228585.3.dec	4060180H1	1187	1471
17	228585.3.dec	1902883H1	905	1155
17	228585.3.dec	3761073H1	924	1219
17	228585.3.dec	g698612	1012	1235
17	228585.3.dec	5576750H1	1048	1301
17	228585.3.dec	3024344H1	1055	1318
17	228585.3.dec	g876656	1062	1415
17	228585.3.dec	4758756H1	1066	1240
17	228585.3.dec	2918456H1	704	989
17	228585.3.dec	6478720H1	735	1254
17	228585.3.dec	4136187H1	746	1024
17	228585.3.dec	g878232	782	1137
17	228585.3.dec	1673835H1	812	1048
17	228585.3.dec	1673806H1	812	1037
17	228585.3.dec	4115301H1	878	1134
18	198840.3.dec	908528H1	903	1052
18	198840.3.dec	g1228717	895	1052
18	198840.3.dec	g2719009	928	1052
18	198840.3.dec	571865H1	792	999
18	198840.3.dec	2289267H1	772	980
18	198840.3.dec	g3050309	786	974

TABLE 4

SEQ ID NO:	Template ID	Component ID	Start	Stop
18	198840.3.dec	g1188260	548	769
18	198840.3.dec	534108F1	555	1052
18	198840.3.dec	5020606T1	563	1016
18	198840.3.dec	1741910H1	566	797
18	198840.3.dec	g1486798	570	979
18	198840.3.dec	969236H1	573	855
18	198840.3.dec	1322802H1	583	918
18	198840.3.dec	5674974H1	593	848
18	198840.3.dec	g4113601	595	974
18	198840.3.dec	g3674968	524	975
18	198840.3.dec	1913281H1	869	1056
18	198840.3.dec	g2837605	872	1052
18	198840.3.dec	533989H1	873	971
18	198840.3.dec	g1384851	836	983
18	198840.3.dec	2761374H1	847	1060
18	198840.3.dec	g677992	672	975
18	198840.3.dec	g1136907	688	983
18	198840.3.dec	g1040531	694	962
18	198840.3.dec	g2177843	737	1052
18	198840.3.dec	2937367H1	771	1047
18	198840.3.dec	667891H1	1	267
18	198840.3.dec	6154236H1	47	367
18	198840.3.dec	g4265077	639	974
18	198840.3.dec	3622345H1	649	710
18	198840.3.dec	g794629	806	983
18	198840.3.dec	1457869H1	818	1056
18	198840.3.dec	g670354	821	1052
18	198840.3.dec	1291302H1	829	1052
18	198840.3.dec	5880838H1	522	789
18	198840.3.dec	5883036H1	522	614
18	198840.3.dec	5881876H1	523	754
18	198840.3.dec	g4686131	524	979
18	198840.3.dec	4784050H1	510	756
18	198840.3.dec	g4833681	521	978
18	198840.3.dec	5882937H1	522	797
18	198840.3.dec	g556213	128	496
18	198840.3.dec	g643590	133	1228
18	198840.3.dec	5020606H1	157	433
18	198840.3.dec	132225H1	210	375
18	198840.3.dec	1715481T7	470	1026
18	198840.3.dec	5000186H2	492	752
18	198840.3.dec	4719977H1	88	351
18	198840.3.dec	2588384H1	598	849
18	198840.3.dec	g1471573	608	971
18	198840.3.dec	g1390212	639	1053
18	198840.3.dec	g1893732	634	978
19	082154.5.dec	g2904866	538	806
19	082154.5.dec	5991508H1	1	273
19	082154.5.dec	5512955H1	1	277
19	082154.5.dec	5512955F6	1	456

TABLE 4

SEQ ID NO:	Template ID	Component ID	Start	Stop
19	082154.5.dec	531353R6	236	593
19	082154.5.dec	2449285H1	356	594
20	368396.5.dec	g3801673	1	463
20	368396.5.dec	g5395804	1	469
20	368396.5.dec	g2818234	1	488
20	368396.5.dec	2827120H1	1	254
20	368396.5.dec	3295468H1	6	251
20	368396.5.dec	5585616H1	190	412
20	368396.5.dec	g2819673	278	415
20	368396.5.dec	3898288H1	341	610
20	368396.5.dec	388965H1	516	753
20	368396.5.dec	388965R6	517	893
20	368396.5.dec	386150H1	517	787
20	368396.5.dec	568049H1	625	881
20	368396.5.dec	5305447H1	676	951
20	368396.5.dec	840982H1	745	971
20	368396.5.dec	840982R1	745	1335
20	368396.5.dec	4761219H1	912	1196
20	368396.5.dec	5980174H1	942	1170
20	368396.5.dec	4245533H1	1075	1316
20	368396.5.dec	4245533F6	1075	1556
20	368396.5.dec	4245533T6	1076	1517
20	368396.5.dec	5543782H1	1075	1298
20	368396.5.dec	g2884672	1084	1428
20	368396.5.dec	3895077H1	1114	1393
20	368396.5.dec	4904654H2	1131	1400
20	368396.5.dec	1377847H1	1272	1511
20	368396.5.dec	1377895H1	1272	1512
20	368396.5.dec	3186570H1	1285	1543
20	368396.5.dec	5604406H1	1294	1575
20	368396.5.dec	2206040H1	1304	1551
20	368396.5.dec	5507836H1	1341	1562
20	368396.5.dec	3321275H1	1419	1694
20	368396.5.dec	4737695H1	1502	1750
20	368396.5.dec	g5634213	1503	1935
20	368396.5.dec	g5036229	1509	1924
20	368396.5.dec	1517189T6	1526	1932
20	368396.5.dec	3489604H1	1530	1809
20	368396.5.dec	476400H1	1561	1827
20	368396.5.dec	376804H1	1594	1835
20	368396.5.dec	388965T6	1682	2204
20	368396.5.dec	6158381H1	1761	2037
20	368396.5.dec	5597672H1	1767	2029
20	368396.5.dec	5346995H1	1877	2076
20	368396.5.dec	g3146868	1917	2323
20	368396.5.dec	g4268095	1925	2320
20	368396.5.dec	g2913803	2091	2349
20	368396.5.dec	6157520H1	2179	2296
20	368396.5.dec	4180926H1	2225	2492
20	368396.5.dec	6264422H1	2278	2766

TABLE 4

SEQ ID NO:	Template ID	Component ID	Start	Stop
20	368396.5.dec	4063588H1	2421	2659
20	368396.5.dec	040407H1	2457	2716
20	368396.5.dec	g2795909	2464	4447
20	368396.5.dec	g709369	2464	2783
20	368396.5.dec	g694288	2477	2841
20	368396.5.dec	g766394	2475	2770
20	368396.5.dec	g2787933	3045	3264
20	368396.5.dec	g1267085	3843	4149
20	368396.5.dec	g709370	4105	4447
20	368396.5.dec	g795730	4300	4460
21	349415.4.dec	1471808T6	3019	3286
21	349415.4.dec	1471808H1	3019	3223
21	349415.4.dec	1471808R6	3019	3411
21	349415.4.dec	4552537H1	3278	3514
21	349415.4.dec	859127T6	3424	3933
21	349415.4.dec	2113564T6	3432	3939
21	349415.4.dec	g3181534	3543	3975
21	349415.4.dec	g3804642	3555	3978
21	349415.4.dec	4933708H1	3600	3742
21	349415.4.dec	862833H1	3840	3978
21	349415.4.dec	3074415T6	3847	3974
21	349415.4.dec	g468825	1	4204
21	349415.4.dec	g533522	202	4072
21	349415.4.dec	2113564H1	462	718
21	349415.4.dec	5670744H1	677	844
21	349415.4.dec	g1125015	2400	3418
21	349415.4.dec	g499121	2465	3409
21	349415.4.dec	6246530H1	2798	2928
22	474778.3.dec	3028810H1	859	1044
22	474778.3.dec	818800H1	277	556
22	474778.3.dec	6164205H1	326	657
22	474778.3.dec	6164005H1	327	672
22	474778.3.dec	g4137809	508	953
22	474778.3.dec	3229375H1	2	267
22	474778.3.dec	1955494H1	2	201
22	474778.3.dec	g5446507	196	659
22	474778.3.dec	2431871H1	1	235
23	330933.5.dec	g766379	1791	2088
23	330933.5.dec	1809312T6	1787	2329
23	330933.5.dec	001808H1	2050	2413
23	330933.5.dec	g2107812	2061	2276
23	330933.5.dec	g5369874	2104	2517
23	330933.5.dec	3813723H1	2408	2712
23	330933.5.dec	5901494H1	2416	2718
23	330933.5.dec	1301085F6	2428	2830
23	330933.5.dec	5901773H1	2448	2718
23	330933.5.dec	5813401H1	1873	2202
23	330933.5.dec	g5231675	1818	2273
23	330933.5.dec	g2411104	1820	2269
23	330933.5.dec	g1613942	1940	2275

TABLE 4

SEQ ID NO:	Template ID	Component ID	Start	Stop
23	330933.5.dec	g2717074	1911	2265
23	330933.5.dec	g1189991	1914	2278
23	330933.5.dec	g4665381	1915	2373
23	330933.5.dec	5813077H1	1916	2202
23	330933.5.dec	g4333942	1918	2276
23	330933.5.dec	g2159566	1911	2287
23	330933.5.dec	5820737H1	1913	2202
23	330933.5.dec	g697258	1736	2083
23	330933.5.dec	g900697	1750	2088
23	330933.5.dec	5210011H1	1759	2027
23	330933.5.dec	2198429T6	1774	2325
23	330933.5.dec	3927974H2	1	160
23	330933.5.dec	5839714H1	1	260
23	330933.5.dec	g1812194	3	308
23	330933.5.dec	4137530H1	4	312
23	330933.5.dec	495251H1	6	171
23	330933.5.dec	495254R6	7	271
23	330933.5.dec	g1615840	8	394
23	330933.5.dec	2602191F6	12	534
23	330933.5.dec	2602191H1	12	303
23	330933.5.dec	493158H1	37	269
23	330933.5.dec	5674628H1	52	320
23	330933.5.dec	5185412H1	61	209
23	330933.5.dec	3297904H1	76	329
23	330933.5.dec	5867451H1	129	261
23	330933.5.dec	5867483H1	130	261
23	330933.5.dec	g714746	139	462
23	330933.5.dec	g1985631	175	569
23	330933.5.dec	191521H1	184	378
23	330933.5.dec	g1198777	206	510
23	330933.5.dec	5296614H1	221	484
23	330933.5.dec	6264549H1	221	641
23	330933.5.dec	3528325H1	347	637
23	330933.5.dec	g1442579	347	683
23	330933.5.dec	5924396H1	397	647
23	330933.5.dec	3054803H1	473	775
23	330933.5.dec	2910408H1	488	739
23	330933.5.dec	266409H1	519	911
23	330933.5.dec	266409R1	520	969
23	330933.5.dec	2289394R6	525	1015
23	330933.5.dec	2289394H1	525	697
23	330933.5.dec	492226R6	575	981
23	330933.5.dec	492226H1	575	833
23	330933.5.dec	3332086H1	626	870
23	330933.5.dec	5163228H1	692	945
23	330933.5.dec	g2159686	777	1093
23	330933.5.dec	2198429F6	824	1252
23	330933.5.dec	2198429H1	824	1074
23	330933.5.dec	3052435H1	841	1121
23	330933.5.dec	g2107811	990	1411

TABLE 4

SEQ ID NO:	Template ID	Component ID	Start	Stop
23	330933.5.dec	872721H1	1023	1277
23	330933.5.dec	4381555H2	1049	1321
23	330933.5.dec	2837978H1	1050	1297
23	330933.5.dec	2837978F6	1050	1570
23	330933.5.dec	3467189H1	1080	1323
23	330933.5.dec	2280035H1	1110	1373
23	330933.5.dec	g1186783	1111	1283
23	330933.5.dec	998207H1	1160	1423
23	330933.5.dec	3110065H1	1192	1485
23	330933.5.dec	1267448F1	1203	1611
23	330933.5.dec	1267448F6	1203	1750
23	330933.5.dec	1267448H1	1204	1442
23	330933.5.dec	900107H1	1224	1535
23	330933.5.dec	900107R1	1224	1726
23	330933.5.dec	g767718	1254	1925
23	330933.5.dec	3157251H1	1318	1607
23	330933.5.dec	771694H1	1341	1556
23	330933.5.dec	771694R1	1341	1897
23	330933.5.dec	1296960H1	1344	1644
23	330933.5.dec	g1740525	1360	1718
23	330933.5.dec	2848360F6	1362	1812
23	330933.5.dec	2848360H1	1362	1700
23	330933.5.dec	618579H1	1391	1625
23	330933.5.dec	2509950H1	1395	1707
23	330933.5.dec	4342862H1	1428	1778
23	330933.5.dec	5469096H1	1450	1712
23	330933.5.dec	5605680H1	1458	1685
23	330933.5.dec	3222642H1	1481	1787
23	330933.5.dec	g316443	1482	1755
23	330933.5.dec	5691913H1	1503	1805
23	330933.5.dec	5948153H1	1506	1807
23	330933.5.dec	5598313H1	1515	1778
23	330933.5.dec	g5397192	1519	1968
23	330933.5.dec	3578326H1	1536	1792
23	330933.5.dec	3236629H1	1536	1732
23	330933.5.dec	4111759H1	1580	1834
23	330933.5.dec	5821608H1	1950	2202
23	330933.5.dec	g4898000	1960	2374
23	330933.5.dec	1499114H1	1972	2230
23	330933.5.dec	5013907H1	1973	2251
23	330933.5.dec	1267448T6	1982	2478
23	330933.5.dec	g4268930	1984	2273
23	330933.5.dec	g5178020	2005	2285
23	330933.5.dec	g2432366	1884	2275
23	330933.5.dec	5822549H1	1895	2202
23	330933.5.dec	5821996H1	1896	2202
23	330933.5.dec	5817448H1	1898	2202
23	330933.5.dec	3720963H1	1899	2212
23	330933.5.dec	5819913H1	1900	2202
23	330933.5.dec	g1812081	1908	2275

TABLE 4

SEQ ID NO:	Template ID	Component ID	Start	Stop
23	330933.5.dec	2487759T6	1910	2483
23	330933.5.dec	2653278H1	1630	1869
23	330933.5.dec	g3917068	1878	2287
23	330933.5.dec	g1740526	1884	2277
23	330933.5.dec	266409F1	1839	2273
23	330933.5.dec	4328132H1	1849	2115
23	330933.5.dec	306108H1	1864	2216
23	330933.5.dec	g2000838	1871	2103
23	330933.5.dec	g5656759	1871	2278
23	330933.5.dec	2866509H1	3116	3215
23	330933.5.dec	g3756034	3222	3615
23	330933.5.dec	g953954	3232	3576
23	330933.5.dec	2612962F6	3254	3737
23	330933.5.dec	g1061429	3334	3547
23	330933.5.dec	463141H1	3409	3608
23	330933.5.dec	5015528H1	3416	3693
23	330933.5.dec	g1984806	3531	3896
23	330933.5.dec	2612962H1	3631	3737
23	330933.5.dec	4602495H1	3795	3925
23	330933.5.dec	5786860H1	1968	2275
23	330933.5.dec	707952H1	1970	2218
23	330933.5.dec	1809312H1	1597	1849
23	330933.5.dec	1809312F6	1597	2044
23	330933.5.dec	495254T6	1601	2236
23	330933.5.dec	6559994H1	1613	2178
23	330933.5.dec	6550957H1	1613	2200
23	330933.5.dec	5619308H1	1624	1896
23	330933.5.dec	963906H1	2186	2264
23	330933.5.dec	2042448H1	2203	2273
23	330933.5.dec	1840195H1	2208	2468
23	330933.5.dec	g4334376	2244	2644
23	330933.5.dec	5586733H1	2257	2473
23	330933.5.dec	492226T6	1796	2222
23	330933.5.dec	601199H1	1795	2035
23	330933.5.dec	477137H1	1798	2052
23	330933.5.dec	g2445135	1804	2273
23	330933.5.dec	g2946741	1811	2284
23	330933.5.dec	3972989H1	1817	2077
23	330933.5.dec	6045101J1	2133	2668
23	330933.5.dec	g2336490	2178	2367
23	330933.5.dec	1832323H1	2855	3080
23	330933.5.dec	g5365612	2890	3025
23	330933.5.dec	2487759H1	3036	3261
23	330933.5.dec	g2000839	2812	3146
23	330933.5.dec	5903656H1	2453	2718
23	330933.5.dec	g959363	2529	2823
23	330933.5.dec	1301085H1	2582	2830
23	330933.5.dec	2155586H1	2611	2807
23	330933.5.dec	g803672	2626	2784
23	330933.5.dec	2487759F6	2777	3261

TABLE 4

SEQ ID NO:	Template ID	Component ID	Start	Stop
23	330933.5.dec	3881086H1	1699	1966
23	330933.5.dec	g900413	1712	2083
23	330933.5.dec	463141T6	3042	3577
23	330933.5.dec	3980529H1	3814	3925
23	330933.5.dec	5568862H1	1648	1917
23	330933.5.dec	1303090H1	1650	1848
23	330933.5.dec	4620879H1	1652	1791
23	330933.5.dec	2327576H1	1663	1924
23	330933.5.dec	5613964H1	1968	2017
23	330933.5.dec	5793991H1	1968	2254
23	330933.5.dec	2581254H1	1591	1835
23	330933.5.dec	g4311841	1751	2206
23	330933.5.dec	761800H1	1752	2038
23	330933.5.dec	1678609H1	1752	1964
23	330933.5.dec	2289394T6	2298	2744
23	330933.5.dec	g3203353	2322	2638
24	998036.2.dec	1389466H1	1	184
24	998036.2.dec	1389427H1	1	173
24	998036.2.dec	799829H1	123	355
24	998036.2.dec	4700320H1	206	477
24	998036.2.dec	5444070H1	222	489
24	998036.2.dec	g4136758	865	1296
24	998036.2.dec	g2583504	932	1304
24	998036.2.dec	4524035H1	945	1209
24	998036.2.dec	4384305H1	842	984
24	998036.2.dec	4386159H1	842	1093
24	998036.2.dec	2915642H1	952	1237
24	998036.2.dec	2915616H1	952	1157
24	998036.2.dec	961104H1	955	1122
24	998036.2.dec	5843637H1	983	1211
24	998036.2.dec	2343721H1	993	1250
24	998036.2.dec	g3754162	1014	1457
24	998036.2.dec	896617H1	1061	1245
24	998036.2.dec	g4114679	856	1293
24	998036.2.dec	904525R6	236	649
24	998036.2.dec	904525H1	236	510
24	998036.2.dec	5610611H1	298	567
24	998036.2.dec	1969343R6	347	745
24	998036.2.dec	1969343H1	347	598
24	998036.2.dec	1603990H1	351	576
24	998036.2.dec	1603974H1	351	580
24	998036.2.dec	4772331H1	365	632
24	998036.2.dec	4994912H1	379	624
24	998036.2.dec	2438688H1	457	680
24	998036.2.dec	4383640H1	498	753
24	998036.2.dec	5906450H1	531	802
24	998036.2.dec	1350441H1	653	890
24	998036.2.dec	g3162658	666	1063
24	998036.2.dec	5623485H1	676	857
24	998036.2.dec	1969343T6	695	1254

TABLE 4

SEQ ID NO:	Template ID	Component ID	Start	Stop
24	998036.2.dec	3723695H1	765	949
25	999304.1.dec	2327457T6	1	364
25	999304.1.dec	2327449H1	4	248
25	999304.1.dec	2327457R6	13	402
25	999304.1.dec	6537441H1	147	499
25	999304.1.dec	5108773H1	196	254

TABLE 5

SEQ ID NO:	Template ID	Tissue Distribution
1	348736.2.oct	Cardiovascular System - 32%, Exocrine Glands - 29%, Hemic and Immune System - 29%
2	025119.6.oct	Unclassified/Mixed - 37%, Germ Cells - 31%
3	474539.1.oct	Embryonic Structures - 44%, Hemic and Immune System - 26%, Male Genitalia - 11%, Digestive System - 11%
4	197170.1.oct	Unclassified/Mixed - 48%, Pancreas - 10%, Digestive System - 10%
5	345638.1.oct	Liver - 17%
6	408784.1.dec	Hemic and Immune System - 57%, Female Genitalia - 21%, Male Genitalia - 14%
7	246526.2.dec	Germ Cells - 11%
8	200488.5.dec	Endocrine System - 100%
10	335916.2.dec	Male Genitalia - 44%, Cardiovascular System - 25%, Exocrine Glands - 25%
11	040422.12.dec	Urinary Tract - 100%
12	977651.2.dec	widely distributed
14	059263.6.dec	Hemic and Immune System - 69%, Respiratory System - 23%
15	196774.3.dec	Hemic and Immune System - 100%
16	233624.11.dec	Digestive System - 100%
17	228585.3.dec	Nervous System - 34%, Germ Cells - 11%
19	082154.5.dec	Cardiovascular System - 33%, Nervous System - 25%, Female Genitalia - 25%
20	368396.5.dec	Unclassified/Mixed - 28%, Hemic and Immune System - 23%
21	349415.4.dec	Skin - 28%, Musculoskeletal System - 25%, Exocrine Glands - 13%, Hemic and Immune System - 13%
23	330933.5.dec	Digestive System - 100%
24	998036.2.dec	Exocrine Glands - 25%, Hemic and Immune System - 25%, Nervous System - 24%
25	999304.1.dec	Digestive System - 50%, Female Genitalia - 30%, Male Genitalia - 20%

TABLE 6

Program	Description	Reference	Parameter Threshold
ABI FACTURA	A program that removes vector sequences and masks ambiguous bases in nucleic acid sequences.	PE Biosystems, Foster City, CA.	
ABI/PARACEL FDF	A Fast Data Finder useful in comparing and annotating amino acid or nucleic acid sequences.	PE Biosystems, Foster City, CA;	Mismatch <50%
ABI AutoAssembler	A program that assembles nucleic acid sequences.	PE Biosystems, Foster City, CA.	
BLAST	A Basic Local Alignment Search Tool useful in sequence similarity search for amino acid and nucleic acid sequences. BLAST includes five functions: blastp, blastn, blastx, tblastn, and tblastx.	Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410; Altschul, S.F. et al. (1997) Nucleic Acids Res. 25:3389-3402.	ESTs: Probability value= 1.0E-8 or less; Full Length sequences: Probability value= 1.0E-10 or less
FASTA	A Pearson and Lipman algorithm that searches for similarity between a query sequence and a group of sequences of the same type. FASTA comprises at least five functions: fasta, tfasta, fastx, ifastx, and ssearch.	Pearson, W.R. and D.J. Lipman (1988) Proc. Natl. Acad. Sci. USA 85:2444-2448; Pearson, W.R. (1990) Methods Enzymol. 183:63-98; and Smith, T.F. and M.S. Waterman (1981) Adv. Appl. Math. 2:482-489.	ESTs: fasta E value=1.06E-6; Assembled ESTs: fasta Identity= 95% or greater and Match length=200 bases or greater; fastx E value= 1.0E-8 or less; Full Length sequences: fastx score=100 or greater
BLIMPS	A BLocks IMProved Searcher that matches a sequence against those in BLOCKS, PRINTS, DOMO, PRODOM, and PFAM databases to search for gene families, sequence homology, and structural fingerprint regions.	Henikoff, S. and J.G. Henikoff (1991) Nucleic Acids Res. 19:6565-6572; Henikoff, J.G. and S. Henikoff (1996) Methods Enzymol. 266:88-105; and Attwood, T.K. et al. (1997) J. Chem. Inf. Comput. Sci. 37:417-424.	Score=1000 or greater; Ratio of Score/Strength = 0.75 or larger; and, if applicable, Probability value= 1.0E-3 or less
HMMER	An algorithm for searching a query sequence against hidden Markov model (HMM)-based databases of protein family consensus sequences, such as PFAM.	Krogh, A. et al. (1994) J. Mol. Biol. 235:1501-1531; Sonnhammer, E.L.L. et al. (1988) Nucleic Acids Res. 26:320-322.	Score=10-50 bits for PFAM hits, depending on individual protein families

TABLE 6

Program	Description	Reference	Parameter Threshold
ProfileScan	An algorithm that searches for structural and sequence motifs in protein sequences that match sequence patterns defined in Prosite.	Gribskov, M. et al. (1988) CABIOS 4:61-66; Gribskov, M. et al. (1989) Methods Enzymol. 183:146-159; Bairoch, A. et al. (1997) Nucleic Acids Res. 25:217-221.	Normalized quality score \geq GCG-specified "HIGH" value for that particular Prosite motif. Generally, score = 1.4-2.1.
Phred	A base-calling algorithm that examines automated sequencer traces with high sensitivity and probability.	Ewing, B. et al. (1998) Genome Res. 8:175-185; Ewing, B. and P. Green (1998) Genome Res. 8:186-194.	
Phrap	A Phils Revised Assembly Program including SWAT and CrossMatch, programs based on efficient implementation of the Smith-Waterman algorithm, useful in searching sequence homology and assembling DNA sequences.	Smith, T.F. and M.S. Waterman (1981) Adv. Appl. Math. 2:482-489; Smith, T.F. and M.S. Waterman (1981) J. Mol. Biol. 147:195-197; and Green, P., University of Washington, Seattle, WA.	Score = 120 or greater; Match length = 56 or greater
Consed	A graphical tool for viewing and editing Phrap assemblies.	Gordon, D. et al. (1998) Genome Res. 8:195-202.	
SPScan	A weight matrix analysis program that scans protein sequences for the presence of secretory signal peptides.	Nielson, H. et al. (1997) Protein Engineering 10:1-6; Claverie, J.M. and S. Audic (1997) CABIOS 12:431-439.	Score = 3.5 or greater
Motifs	A program that searches amino acid sequences for patterns that matched those defined in Prosite.	Bairoch, A. et al. (1997) Nucleic Acids Res. 25:217-221; Wisconsin Package Program Manual, version 9, page M51-59, Genetics Computer Group, Madison, WI.	

What is claimed is:

1. An isolated polynucleotide comprising a polynucleotide sequence selected from the group
5 consisting of:
 - a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:1-25,
 - b) a naturally occurring polynucleotide sequence having at least 90% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:1-25,
 - c) a polynucleotide sequence complementary to a),
 - 10 d) a polynucleotide sequence complementary to b), and
 - e) an RNA equivalent of a) through d).
2. An isolated polynucleotide of claim 1, comprising a polynucleotide sequence selected
from the group consisting of SEQ ID NO:1-25.
15
3. An isolated polynucleotide comprising at least 60 contiguous nucleotides of a
polynucleotide of claim 1.
4. A composition for the detection of expression of disease detection and treatment molecule
20 polynucleotides comprising at least one of the polynucleotides of claim 1 and a detectable label.
5. A method for detecting a target polynucleotide in a sample, said target polynucleotide
having a sequence of a polynucleotide of claim 1, the method comprising:
 - a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction
25 amplification, and
 - b) detecting the presence or absence of said amplified target polynucleotide or fragment
thereof, and, optionally, if present, the amount thereof.
6. A method for detecting a target polynucleotide in a sample, said target polynucleotide
30 comprising a sequence of a polynucleotide of claim 1, the method comprising:
 - a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides
comprising a sequence complementary to said target polynucleotide in the sample, and which probe
specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization
complex is formed between said probe and said target polynucleotide or fragments thereof, and
35 b) detecting the presence or absence of said hybridization complex, and, optionally, if
present, the amount thereof.

7. A method of claim 5, wherein the probe comprises at least 20 contiguous nucleotides.
8. A method of claim 5, wherein the probe comprises at least 60 contiguous nucleotides.
- 5 9. A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim 1.
10. A cell transformed with a recombinant polynucleotide of claim 9.
- 10 11. A transgenic organism comprising a recombinant polynucleotide of claim 9.
12. A method for producing a disease detection and treatment molecule polypeptide, the method comprising:
- a) culturing a cell under conditions suitable for expression of the disease detection and treatment molecule polypeptide, wherein said cell is transformed with a recombinant polynucleotide of claim 9, and
- 15 b) recovering the disease detection and treatment molecule polypeptide so expressed.
13. A purified disease detection and treatment molecule polypeptide encoded by at least one of the polynucleotides of claim 2.
- 20 of the polynucleotides of claim 2.
14. An isolated antibody which specifically binds to a disease detection and treatment molecule polypeptide of claim 13.
- 25 15. A method of identifying a test compound which specifically binds to the disease detection and treatment molecule polypeptide of claim 13, the method comprising the steps of:
- a) providing a test compound;
- b) combining the disease detection and treatment molecule polypeptide with the test compound for a sufficient time and under suitable conditions for binding; and
- 30 c) detecting binding of the disease detection and treatment molecule polypeptide to the test compound, thereby identifying the test compound which specifically binds the disease detection and treatment molecule polypeptide.
16. A microarray wherein at least one element of the microarray is a polynucleotide of claim 3.
- 35 3.

17. A method for generating a transcript image of a sample which contains polynucleotides, the method comprising the steps of:

- a) labeling the polynucleotides of the sample,
- b) contacting the elements of the microarray of claim 16 with the labeled polynucleotides of
- 5 the sample under conditions suitable for the formation of a hybridization complex, and
- c) quantifying the expression of the polynucleotides in the sample.

18. A method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a polynucleotide sequence of claim 1,

10 the method comprising:

- a) exposing a sample comprising the target polynucleotide to a compound, under conditions suitable for the expression of the target polynucleotide,
- b) detecting altered expression of the target polynucleotide, and
- c) comparing the expression of the target polynucleotide in the presence of varying amounts
- 15 of the compound and in the absence of the compound.

19. A method for assessing toxicity of a test compound, said method comprising:

- a) treating a biological sample containing nucleic acids with the test compound;
- b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at
- 20 least 20 contiguous nucleotides of a polynucleotide of claim 1 under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence of a polynucleotide of claim 1 or fragment thereof;
- c) quantifying the amount of hybridization complex; and
- 25 d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

10/089644

SEQUENCE LISTING

JC10 RJJG PCT/PTO 27 MAR 2002

<110> INCYTE GENOMICS, INC.
HODGSON, David M.
LINCOLN, Stephen E.
RUSSO, Frank D.
SPIRO, Peter A.
BANVILLE, Steven C.
BRATCHER, Shawn R.
DUFOUR, Gerard E.
COHEN, Howard J.
ROSEN, Bruce H.
SHAH, Purvi
CHALUP, Michael S.
HILLMAN, Jennifer L.
JONES, Anissa L.
YU, Jimmy Y.
GREENAWALT, Lila B.
PANZER, Scott R.
ROSEBERRY, Ann M.
WRIGHT, Rachel J.
CHEN, Wensheng
LIU, Tommy F.
YAP, Pierre E.
STOCKDREHER, Theresa K.
AMSHEY, Stefan
FONG, Willy T.

<120> MOLECULES FOR DISEASE DETECTION AND TREATMENT

<130> PT-1086 PCT

<140> To Be Assigned

<141> Herewith

<150> 60/156,565; 60/168,197

<151> 1999-09-28; 1999-11-30

<160> 25

<170> PERL Program

<210> 1

<211> 569

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 348736.2.oct

<400> 1

ggggatggaa	ccccttatct	caggatcaca	gcatagatat	ctatttgttt	atctgcctct	60
tggtgctgat	ggctatgtgt	catgatcagt	ggtcccatga	ggacacagtg	gcactagtgg	120
gcaaagtttc	tcctctgagt	tggggatcct	gggagaagga	ggatgggcaa	gggtagatat	180
gttggggaag	tggattgtgg	gtcttcagca	cggggccagca	cggggccattt	atgggtttcat	240
ctatccccat	cataacagag	cagtgtgacc	tttgaagacg	tggctgtaaa	cttttccttg	300
gaggaatgga	gtcttcttaa	tgaggctcag	ggatgcctgt	accatgatgt	gatgctggag	360
accttgacac	ttatatcctc	cctggtaagg	tactcatact	taactgtgac	ctgagttagt	420
ctctgcccc	cccctttatt	cctcttggtg	ataacgtctt	tctcacatca	ggactgtggc	480
acagcttcac	tctccaattc	tctggatcag	ttctgtgggt	ggtagtactg	agatacatgt	540
actgccctct	cctttccttg	agcagcccc				569

<210> 2

<211> 673

<212> DNA



<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 025119.6.oct

<220>

<221> unsure

<222> 6-7, 42, 46, 162

<223> a, t, c, g, or other

<400> 2

```
cttggnnccc gggccgggga ggctttctcg ggcgaggag gntccncagg cccaggccag 60
gccaggggag gcagccgac cgctgctggg gttgacagtt accatggcgc cgcctctggc 120
cccgctccct ccccgggacc caaacggggc cggaccggag tngagggaagc ccgggactgt 180
gagcttcgcy gacgtggccg tgtacttctc cccggaggag tggggctgtc tgcggcccgc 240
gcagaggggt ctgtaccggg acgtgatgca ggagacctac ggccacctgg gcgcgctcgg 300
attcccaggc cccaaaccag cctcatctc ttggatggaa caggagagtg aggcttggag 360
ccccgccgcc caggatcctg agaaggggga aagactggga ggagctcgga gaggagatgt 420
cccaaaccag aaggaagagg aaccggagga agtcccaaga gccaaagggc ctagaaaggc 480
tctgtgaag gagagtctg aagtgtgtgt ggaacgcaac cctgaccag ctattagcgt 540
ggccccggca cgggcacagc cacccaaaaa tgctgcctgg gacccgacca caggagcaca 600
gccccgggca cccataccca gcatggatgc tcaggccggc cagcggcgcc acgtgtgcac 660
ggactgcggc cgc
```

<210> 3

<211> 429

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 474539.1.oct

<220>

<221> unsure

<222> 416, 424

<223> a, t, c, g, or other

<400> 3

```
gggcgtgctc agcaaataca ccaacctcct ccagggtctg cagaacaggt acttcgtact 60
ggatttcgag gctggcatcc tgcagtattt tgtgaatgag caaagcaaac accagaagcc 120
tcgaggagtc ctgtctttat ctggagccat agtgctccctg agcgatgaag ctccccacat 180
gctgggtgtg tactctgcta atggagagat gtttaaactg agagctgctg atgcaaaaga 240
gaaacaattc tgggtgactc agcttcgagc ttgtgccaac taccacatgg aaatgaattc 300
taagagtgtc ccaagctccc gaagccgaag tctcactttg ctccccatg gaacacccaa 360
ttctgctctc cctgtagcc agagacacct cattgttggg ggcccccggt gttgtnacaa 420
tcangcatc
```

<210> 4

<211> 1517

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 197170.1.oct

<220>

<221> unsure

<222> 1428, 1440, 1452, 1498

<223> a, t, c, g, or other

<400> 4

```
tcccacctec ggggccctct ccttgcttcc cccccaccg ccggccaaga aggccaagct 60
gaaggccgcy ggtatggcca gccctgggg gaagcaggac ctctcgggcg ccgcagccgc 120
cggcattttc tgggcctctg atgtggagcc gtctctctc aacctctcct caggcccaga 180
```



```

gccagcacga gacatccgct gcgagttctg tggtagagttc ttcgagaacc gcaagggcct 240
ctcgagccac gcgcgctccc atctgcggca aatgggctgt accgagtggg acgtcaatgg 300
ctcgcccatc gacacgctgc gggagatcct gaagagacgg acccagtctc ggcttgggtg 360
acctcccaac ccaccagggc caagcccaaa agccctggcc aagatgatgg gcggcgcagg 420
tctctggcag tcaactggaag cccgcagccc ctgggacctt cacatctcac ccttggccaa 480
gaagttgcca ccaccaccgg gcagccccc tgggcaactca ccaactgcct ctctctctcc 540
tacggccccg aagatgttcc caggcctggc tgcacctctc ttgccaaga agctgaagcc 600
tgaacaaata cgggtggaga tcaagcggga gatgctgccc gggggccctc atgggggaact 660
gcacccatct gagggctcct gggggggcacc acgggaagac atgacacccc tgaacctgtc 720
gtcccgggca gagccgtgac gggacatccg ctgtgagttc tgcggcgagt tcttcgagaa 780
ccgcaagggc ctgtcagatc acgcgcgctc acacctgcgg cagatgggtg tgaccgagtg 840
gtccgtcaat ggttcgcccc tgcacacact gcgagagatc ctcaagaaga agtccaagcc 900
gtgcctcatc aagaaggagc caccggctgg agacctggcc cctgcccctg ctgaggacgg 960
gctcccccac gtggcccttg ggcccgtgca gtcccccact ccgctgtcgc ccttggctgg 1020
ccggccaggc aaaccaggtg caggggccgg cccaggttcc tctgtgagtc agcctgacgc 1080
ccatcatctg ggccaagccc tcagccactg gctacctggg ctcaagtggc gccaaagcggc 1140
ccctgcagga ggaccgcctc ctcccagcag aggtcaaggc caagacctac atccagactg 1200
aactgcccct caaggcaaag accttcatg agaagacctc ccactcctcc accgaggcct 1260
gctgcgagct gtgtggcctt tatttgaaaa ccgcaaggcc ctggccagcc acgcacgggc 1320
acacctgcgg cagttcggcg tgaccgagt gtgcgtcaat ggctcgccca tcgagacact 1380
gagcgagtgg atcaaacacc ggccccagaa ggtgggcgcc taccgcanct acatccaggn 1440
cgcccgccct tnaaccaaga gttcgcagtg ccggccatgg ccgtgacagt gacaagcngc 1500
cgccctggg gctggca 1517

```

<210> 5

<211> 2185

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 345638.1.oct

<220>

<221> unsure

<222> 2153, 2159, 2175

<223> a, t, c, g, or other

<400> 5

```

ggaggaggag gtggggctgg cgctgaagcc ggatccggat ccggtgctgt gcacactggg 60
ggggggagagt ccgacgcgcc tggctaggag cgccgaccgc agggcctcta cggaccttac 120
tagaaaaaat aaactgatg aaactcctat gtttgaccca agtctactca aagaagtggg 180
ctggagtcag aatacagcta cattttctcc agccatttcc ccaacacatc ctggagagg 240
cttggttttg aggcctcttt gtactgctga cttaaataga ggttttttta aggtattggg 300
tcagctaaca gagactggag ttgtcagccc tgaacaattt atgaaatctt ttgagcatat 360
gaagaaatct ggggattatt atgttacagt tgtagaagat gtgactctag gacagattgt 420
tgctacggca actctgatta tagaacataa atccatccat tctgtgcta agagaggagg 480
agtagaagat gttgttggtt gtgatgaatg cagaggaaag cagcttggca aattgttatt 540
atcaaccctt actttgctaa gcaagaaact gaactgttac aagattacce ttgaatgtct 600
accacaaaaa gtttggtttc ataaaaagtt tggatatact gtatctgaag aaaactacat 660
gtgtcggagg tttctaaagt aaaaatcttg taagaaaatt gtcaaagggg ctaatgctac 720
aaggctacac tcttctaga gttgaaatat tttgttgctg cagccgagtg acctccataa 780
atactggact gaaaaaacat tgtaatacta caagtataat gacatttaga agattacttt 840
gggctgggtg gacatgctgt gaatttagat tacaaaatgaa tattataaag gggatgattt 900
ttaaccaaag gaatatattt ttaacttgaa tcttttcttg cattgtattt ttctaaaagt 960
ttggcttctc ttcttggtag tcaagagtat gggtaataag gagttatatg tctgctatct 1020
gtgttgctca tttaaaaaaa gtatacattg aataaggctg tttatcacat gcataaaatt 1080
aaatatTTTT gtttcaaaga aacatctcaa tacacttagg ggtgtattgt ttcccacata 1140
ttaagtcagg gtggataaat tagttattat aactaaacat agtatagtc aacattcggt 1200
gatcccaata caggcaaaaa acctgggtcaa ccttttgaag tagaagaaat gaaaattact 1260
tgacaagatt aaaagtaaaa caatttaaat gttttactga aagtttatat agtatagtct 1320
atgtagataa aaagtaccac ttgtcttttc tgtgaattat gactattcat ttgttaaaaa 1380
tacctaagag caattatagt gggacatctt aggtcctctg taaacagtga attagcaaac 1440
ctcagcctat gtgtttctac cctgattttt ttcttttcat gggatatctg agcctctaag 1500
ttttttcaaa aatggagtat cacaaaattg agtgaaacac aatacttaat gtattgtact 1560
agattgccaa attcataaaa tgttaattga agcttttga tgtgattata atggcactat 1620
tctggtcatt atcctatttt gatttttatt aattttttta agttgaagaa ttaaatattt 1680

```



```

taatgggttct aatcttttgc attccatggt gcattaaacc tgttttatatg agtagtcttc 1740
tgttagaatc acatctgtgc ttttcttgag tctgctgttg aactattaga ttaagtcata 1800
attcataaaa ttttagttta atgtgctctt tgtaaaatga aattgtaaag aaaataccag 1860
tgttttctcat cccattgact cacaccacgt catctggatt ttggatttcc ctccatgcag 1920
ccagctatag ttggctttcc aaaacaacag aaatccttca ccaatagagt gcactactta 1980
cctgcttata gcctatacag acgaactgat ctgtccttcg tgaaacgcaa caaagctagt 2040
tctgtctttt cagaagtcct acaaccttga caaagagtag ttttatcagg taaatcctgg 2100
taattaaaaa cgcatgtttt taaaaattag cctggtaagg ccgggtgcag tgnctcagnc 2160
tcccaaagtg ctggnatgac aggtg 2185

```

<210> 6

<211> 397

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 408784.1.dec

<400> 6

```

ccagcccaca aggtctcttt tcttttttga tccattcaaa aattactcat tgcaaattcc 60
cgaaccatcc ggctcgggct ccttccctgg cgatggctgg ccgctgagcc atggctcagt 120
acggccaccc cagtcgcgtc ggcattggctg cgagagagga gctgtacagc aaagtcacc 180
cccggaggaa ccgccaacag cgccccggca ccatcaagca tggatcggcg ctggacgtgc 240
tctctcccat ggggttcccc agagcccgcg cacgaaaagc cttggcatcc acgggaggaa 300
gaagtgttca gacagcatgt gactgggtat tctcccatgt cggtgacccc ttctgggatg 360
acccctgcc cggggagtac gtcctctacc ctccgctc 397

```

<210> 7

<211> 2815

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 246526.2.dec

<400> 7

```

ccgggagagc tcgatgggct tctcctgcgc gccgcccggg gtctggccga gtccagagag 60
ccgcgccgcc tcgttccgag gagccatcgc cgaagcccga ggccgggtcc cgggttgggg 120
actgcagggg aaggcagcgg cggggcggcg ggagcccccac cggggtctgg gactggggaa 180
ctgcctccgg cttcacgatg ccagtatgga cagaatagct tatgatgctt atccccacc 240
accacttccg aaacattgag ccgaaaccag aatacctcca gccagagaag tgtgtccac 300
ccccctaccc tggctcctgtg ggaaccatgt ggtttatccg tgacggctgt ggcacgcct 360
gtgccatcgt tacctgggtt ctggctcctc atgcccaggt ctggttctc tttgtcatgc 420
tgattccatc tcgagactac gtgtatagca tcatcaacgg aattgtgttc aacctgctgg 480
ccttcttggc cctggcctcc cactgccggg ccattgctgac ggaccccggg gcagtgcaca 540
aaggaaatgc cactaaagaa ttcacgcaga gtttacagtt gaagcctggg caggtggtgt 600
acaagtgcc caaatgctgc agcatcaagc ccgaccgagc ccaccactgc agtgtttgta 660
agcgggtgat tcggaagatg gaccaccact gtccttgggt caacaactgt gtaggcgaga 720
acaaccagaa gtacttcgtc ctgtttacaa tgtacatagc tctcatttcc ttgcacgcc 780
tcatcatggt gggattccac ttctgcatt cgtttgaaga agattggaca aagtgcagct 840
ccttctctcc acccaccaca gtgattctcc ttatcctgct gtgctttgag ggcctgctct 900
tctcatttt cacatcagtg atgtttggga cccagggtgca ctccatctgc acagatgaga 960
cggaataga acaattgaaa aaggaagaga gaagatgggc taaaaaaca aaatggatga 1020
acatgaaagc cgtttttggc cacccttct ctctaggctg ggccagcccc tttgccacgc 1080
cagaccaagg gaaggcagac ccgtaccagt atgtggtctg aaggaccccg accggcatgg 1140
ccactcagac acaagtccac accacagcac taccgtccca tccgttctca tgaatgttta 1200
aatcgaaaaa gcaaaaacaac tactcttaaa acttttttta tgtctcaagt aaaatggctg 1260
agcattgcag agaaaaaaa aagtccccac attttatttt ttaaaaacca tcctttcgat 1320
ttcttttggg gaccgaagct gctctctttt ccttttaaaa tcaattctct ggcctctggt 1380
ttctctctgc tgtctgtctg gcatgactaa tgtagagggc gctgtctcgc gctgtgcca 1440
ttctactaac tgagtgcagc atgacgctgt gcgtggatgg aatagtctgg acacctggtg 1500
ggggatgcat gggaaagcca ggagggccct gacctccac tgcccaggag gcagtggcgg 1560
gctccccgat gggacataaa acctcaccga agatggatgc ttacccttg aggcctgaga 1620
agggcaggat cagaaggagc cttggcacag cgacctcatc ccccaagtgg acacggtttg 1680
cctgctaact cgcaaagcaa ttgcctgcct tgtactttat gggcttgggg tgtgtagaat 1740

```




```

gatttttgcgg gggagtgggg agaaagatga aagagggtctt atttgtattc tgaatcagca 1800
attatattcc ctgtgattat ttggaagagt gtgtaggaaa gacgtttttc cagttcaaaa 1860
tgccttatac aatcaagagg aaaaaaaatt acacaatttc aggcaagcta cgttttccct 1920
tgtttcatct gcttcctctc tcaccacccc atctccctct cttccccagc aagatgtcaa 1980
ttaagcagtg tgaattctga ctgcaatagg caccagtgcc caacacatac agccccacca 2040
tcatccccctt ctcatcttat aaacctcaaa gtggattcac tttctgatag ttaacccccca 2100
taaagtgtgca cgtacctgtg tcttatctat attttaacct gggagactgt tgtcctggca 2160
tggagatgac catgatgctg gggttacctc acagtcccca ccctttcaaa gttgacatat 2220
ggccatccca ttggccagaa tccacagaca cacctaagcc tgtggcactg ggacagaata 2280
gattttccat ttgagaggca cttcctgtgt cagtcttggt tgaaggaggt ggtgatgggtg 2340
gatagagggtg aaggaggtag ggagtgccct ccaagtgcaa aaataacaaa tatgattatt 2400
gaccatcggtg gaattctcac acattgattt gttttttaag caattgccag aaacccccct 2460
tttttagctt ttgcttgggg tgggggtagg agttaagggt tattcaatcc tgtcctgggt 2520
agggcgaaaag ttaatctagc catgtgattt ttcagaaaag taagtggaaac atgtgccac 2580
ttttcaattc tgtcagtgct tccacatgga aacaaaatgc aataaaattt ttccaaaacc 2640
tgttctgatt tagctctctc ttgaggtgtt acccttagtg ggaggccgac tatccacaat 2700
ctacttgagt tttctctggt tgggtgtttg ttccattgct ctgtctcttg aatgaggata 2760
ctttattttt tttgttttaa aatgcattta tggtcctctt cttgaaccag cttgc 2815

```

<210> 8

<211> 771

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 200488.5.dec

<220>

<221> unsure

<222> 7

<223> a, t, c, g, or other

<400> 8

```

ccgagangtg cagcgggcaca gctgtcgcgc cagtcgcaac agaagcaggt ccgaggcaca 60
gccgatccc gccatggagc agccgaggaa ggcggtggta gtgacgggat ttggcccttt 120
tggggaacac accgtgaacg ccagttggat tgcagttcag gagctagaaa agctaggcct 180
tggcgacagc gtggacctgc atgtgtacga gattccggtt gagtaccaaa cagtccagag 240
actcatcccc gccctgtggg agaagcacag tccacagctg gtggtgcatg tgggggtgtc 300
aggcatggcg accacagtca cactggagaa atgtggacac aacaagggct acaaggggct 360
ggacaactgc cgcttttgcc ccggctccca gtgctgcgtg gaggacgggc ctgaaagcat 420
tgactccatc atcgacatgg atgctgtgtg caagcgagtc accacgttgg gcctggatgt 480
gtcggtgacc atctcgagc atgccggcag gaaaaaaccc ttccctgcca aagggtactg 540
tgttttctgc cgccgaagga gggcccggtc cctccaggct cagtgtggct tctccctgac 600
ccccgcccta gaacttttgc cagtgccttt tctgaaactc ctgtgtcccg ggccccccag 660
gcgggagaag atattgccgga ttctgcctgg ggctgggctc taggagaccc caaatttgac 720
accacagaaa gcagataaaa cacttgaaat acgcagaaaa aaaaaaaag g 771

```

<210> 9

<211> 2431

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 474878.1.dec

<220>

<221> unsure

<222> 2427

<223> a, t, c, g, or other

<400> 9

```

ctgatttcga gtttccggtc aggttaggcc ggggggggtgc ggtcctggtc ggaaggaggt 60
ggagagtcgg gggtcaccag gcctatcctt ggcgccacag tcggccaccg gggctcgccg 120
ccgtcatgga gagcggagg cgccctcgc tgtgccagtt catcctcctg ggcaccacct 180
ctgtgggtcac cgccgccctg tactccgtgt accggcagaa ggccccgggtc tccaagagc 240

```



```

tcaagggagc taaaaaagtt catttgggtg aagattttaa gagtattctt tcagaagctc 300
caggaaaatg cgtgccttat gctgttatag aaggagctgt gcggtctgtt aaagaaacgc 360
ttaacagcca gtttgtggaa aactgcaagg gggtaattca gcggtcgaca cttcaggagc 420
acaagatggt gtggaatcga accaccacc tttggaatga ttgctcaaag atcattcacc 480
agaggacca cagagtggc tttgacctgg tgccccacga ggatggcgctg gatgtggctg 540
tgcgagtgtc gaagccccctg gactcagtg atctgggtct agagactgtg tatgagaagt 600
tccacccttc gattcagtc ttcaccgatg tcacggcca ctacatcagc ggtgagcggc 660
ccaaaggcat ccaagagacc gaggagatgc tgaaggtggg ggccaccctc acaggggttg 720
gcgaactggt cctggacaac aactctgtcc gcctgcagcc gcccaaacaa ggcattgcagt 780
actatctaag cagccaggac ttcgacagcc tgctgcagag gcaggagtcg agcgtcaggc 840
tctggaaggt gctggcgctg gtttttggct ttgccacatg tgccaccctc ttcttcattc 900
tccggaagca gtatctgcag cggcaggagc gcctgcgctt gcaagcagat gcaggaggag 960
ttccaggagc atgaggccca gctgctgagc cgagccaagc ctgaggacag ggagagctctg 1020
aagagcgctt gtgtagtgtg tctgagcagc ttcaagtctt gcgtctttct ggagtgtggg 1080
cacgtttgtt cctgcaccga gtgtaccgc gccttgccag agcccaagaa gtgccctatc 1140
tgcagacagg cgatcaccgc ggtgataccc ctgtacaaca gctaatagtt tggaaagccgc 1200
acagcttgac ctggaagcac cctgcccccc ttttcaggga tttttatctc gaggcctttg 1260
gaggagcagt ggtgggggta gctgtcacct ccaggatatga ttgagggagg aattgggtag 1320
aaactctcca gaccacgcc tccaatggca ggatgctgcc ttcccacct gagaggggac 1380
cctgtccatg tgcagcctca tcagagcctc accctgggag gatgccgtgg cgtctctctc 1440
caggagccag atcagtgtga gtgtgactga aaatgcctca tcacttaagc accaaagcca 1500
gtgatcagca gctcttctgt tcctgtgtct tctgtttttt tctggtgaat cgttgcttgc 1560
tctggacttg gtggaggact cagaggggag gaaaggctgg gcccgagta caacggatgc 1620
cttgggtgct gcctccgaag agactctgcc gcagcttttc ttcttttctc tcatgccccg 1680
ggaaacagtc tttcttcaga attgtcaggc tgggcaggtc aacttgtgtt cctttccctt 1740
cacctgcttg cctccttaac gcctgcacgt gtgtgtagag gacaaaagaa agtgaagtca 1800
gcacatccgc ttctgcccag atggtcgggg ccccgggcaa cagattgaag agagatcatg 1860
tgaagggcag ttggtcaggc aggcctcctg gtttcgccac tggccctgat ttgaactcct 1920
gccactggg agagctcggg gtggtccctg gttttccctc ctggagaatg aggcgcagag 1980
gcctgcctc ctgaaggacg cagtgtggat gccactggcc tagtgtcctg gcctcacagc 2040
ttccttgcaa ggctgtcaca aggaaaagca gccggctggc accctgagca tatgccctct 2100
tggggctccc tcattccagcc cgtcgcagct ttgacatctt ggtgtactca tgtcgcttct 2160
ccttggttta cccctccca gtattaccat ttgcccctca cctgcccctg gtgagccttt 2220
tagtgcaaga cagatggggc tgttttcccc cacctctgag tagttggagg tcacatacac 2280
agctcttttt ttattgccct tttctgcctc tgaatgttca tctctcgctc tcctttgtgc 2340
aggcgaggaa ggggtgccct caggggccga cactagtatg atgcagtgtc cagtgtgaac 2400
agcagaaatt aaacatgttg caaccanaaa a 2431

```

<210> 10

<211> 2064

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 335916.2.dec

<220>

<221> unsure

<222> 1377, 1387

<223> a, t, c, g, or other

<400> 10

```

ggactgttga cctgcagtgc tctctgttga caaagggtgt gagcagctgc tggaaagagga 60
ggtgtccttg aagacactgc ggccggcccc cctgtgccct tgggtccctg gctgcctaga 120
gagcctcacc cctggggcctt gggggccagg ctccaggact ctgactacct gccctcccc 180
agcctcagcg gctgcacctc ctcgtagta ctgatgcact gacctcgga cacagctggg 240
aggggttggg ggctgggtca tggctgtctc caggccccac ccaggctcct gagcctagaa 300
ggtgaaaaga ggactctcag gggctcacag gggctctcac tgcgtggttg ccttgccctc 360
ccttccccct cagcaggggtg cccggaagct ggaaccttgt tatctgggta attagtctca 420
gacctcgac tgaggccggc caggctcctg ggtgcctcc cataggttgt gcacctgac 480
cccgagaggg aggcgaggcg ctgcttgtcg acagctagag gctggcctgg ggagcaggtt 540
tgggggtccc tcccacactg ccctccctgc cccggcccat gcccccagg gctgcctggg 600
cctggttatt gtgtggggcc tcctgaccca gccaaaggga cgaagctctg ggaaggggat 660
gcccccgagg gtgccagtc agctagctcc ccacccctc aggccagcc ttgcccccaa 720
gtccccact ctgggtgcccc gagcagccct gtgggcaagc agccgcccgc atggccgagc 780
acctggagct gctggcagag atgcccattg tgggcaggat gagcacacag gaggcgctga 840

```



```

agcatgccca gaagcggcgc gccagcagg tgaagatgtg ggcccaggct gagaaggagg 900
cccaggggcaa gaaggggtcct ggggagcgtc cccggaagga ggcagccagc caaggggtcc 960
tgaagcaggt cctcttccct cccagtgttg tccttctgga ggcgctgcc cgaaatgacc 1020
tggaagaagt ccgccagttc cttgggagtg gggtcagccc tgacttgccc aacgaggacg 1080
gcctgacggc cctgcaccag tgctgcattg atgatttccg agagatgggt cagcagctcc 1140
tggaggctgg ggccaacatc aatgcctgtg acagtgagtg ctggacgcct ctgcatgctg 1200
cggccacctg cggccacctg cacctggttg agctgctcat cgccagtggc gccaatctcc 1260
tggcgggtcaa caccgacggg aacatgccct atgacctgtg tgatgatgag cagacgctgg 1320
actgcctgga gactgccatg gccgaccgtg gtaggcatca ccaggacag catcgangcc 1380
gcccggnccg tgccagaact gcgcatgctg gacgacatcc ggagccggct gcaggccgga 1440
gcagacctcc atgccccctt ggaccacggg ccacctgtgc acgtccaccc caacgggttc 1500
agcgagcggg cctgtgtgtg aacaccgagc cagcctgagc gctaaggacc aagacggctg 1560
ggagccgctg cagcccgagg cctactgggg ccagggtgct ggtggagctg ctctgtggcg 1620
acggggccga cctgaacgca aagtccttga tggacgagac gcccttgat gtgtgctggg 1680
acgaggaggt gcggggccaag ctgctggagc tgaagcacia gcacgacgcc ctctgctgg 1740
cccagagccg ccagcgctcc ttgctgcgcc gccgcaccte cagcgccggc agcccgggga 1800
aggtggtgag gcgggtgagc ctaaccacag gcaccgacct gtaccgcaag cagcagccc 1860
aggaggccat cgtgtggcaa cagccgccc ccaccagccc ggagccgccc gaggacaacg 1920
atgaccgcca gacaggcgca gagctcaggg cgccgcccc ggaggtgagc gcccgtccc 1980
tgtccgccc agcgcagggg tgggctggc tctgcccctg ttctctctcc gcttggaacc 2040
cctctgctt gtgtcaggaa tgggt                                     2064

```

<210> 11

<211> 1421

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 040422.12.dec

<220>

<221> unsure

<222> 913

<223> a, t, c, g, or other

<400> 11

```

cttgttggtg tgtgtagcgg cagtggccgc cggcggagca gtctgagccc gacgatgagg 60
ccgggggacgg gagctgagcg tggaggcctc atgggtgagtg aaatggagag ccctcctccc 120
tcgcaggggtc ctggggacgg ggagcggaga ttgtccggct caagcctctg ctccggctct 180
tgggtctctg ctgacggctt cctgaggaga cggccctcga tggggcaccg tggcatgcat 240
tatgccccaa tgggaatgca cctatgggtt cagagagcga atatgcctcc tgtacctcat 300
ggaatgatgc cgcagatgat gccccctatg ggagggccac caatgggaca aatgcctgga 360
atgatgtcgt cagtaatgcc tggaaatgat atgtctcata tgtctcaggc ttccatgcag 420
cctgccttac cgccaggagt aaatagtatg gatgtagcag caggtacagc atctggtgca 480
aaatcaatgt ggactgaaca taaatcacct gatggaagga cttactacta caacactgaa 540
accaaacagt ctacctggga gaaaccagat gatcttaaaa cacctgctga gcaactctta 600
tctaaatgcc cctggaagga atacaaatca gattctggaa agccttacta ttataattct 660
caaacaaaag aatctcgctg ggccaaacct aaagaacttg aggatcttga aggataccag 720
aataccattg ttgctggaag tcttattaca aaatcaaacc tgcattgcaat gatcaaagct 780
gaagaaagca gtaagcaaga agagtgcacc acaacatcaa cagccccagt ccctacaaca 840
gaaattccga ccacaatgag caccatggct cgtgccgaag cagcagctgc tgttgttgca 900
gcagcagcag cgngcagcac gagcagcagc tgcagccaat gctaattgct ccacttctgc 960
ttctaatact gtcagtggaa ctgttccagt tgttccctgag cctgaagtta cttccattgt 1020
tgctactgtt gtagataatg agaatacagt aactatttca actgaggaac aagcacaact 1080
tactagtacc cctgctattc aggatcaaag tgtggaagta tccagtaata ctggagaaga 1140
aacatctaag caagaaactg tagctgattt tactcccaa aaagaagagg aggagagcca 1200
accagcaaag aaaacataca cttggaatac aaaggaagag gcaaagcaag cttttaaaga 1260
attattgaaa gaaaagcggg taccatcgaa tgcttcatgg gagcaggcta tgaaaatgat 1320
tattaatgat ccacgatata gtgctttggc aaagttaagt gaaaaaaagc aagcctttaa 1380
tgcctataaa gtccagacag aaaaagaaaa aaaagggcgg c                                     1421

```

<210> 12

<211> 1096

<212> DNA

<213> Homo sapiens



<220>

<221> misc_feature

<223> Incyte ID No: 977651.2.dec

<400> 12

ggttccccgg	cctctcttgg	tcaggggtgac	gcagtagcct	gcaaacctcg	gcgcgtaggc	60
caccgcactt	atccgcagca	ggaccgcccc	cagccggtag	ggtgggctct	tcccagtgcc	120
cgcccagcta	ccggccagcc	tgcggctgcg	cagatctttc	gtggttctgt	caggggagac	180
ccttaggcac	tccggactaa	gatggcgggc	acggccaggg	cggggctggg	gagctgcggc	240
tgttgccgc	ggggctgcgc	aggcggttct	tgtcataagt	tgaagaatcc	atacaccatt	300
aagaaacagc	ctctgcatca	gtttgtacaa	agaccacttt	tcccactacc	tgcagccttt	360
tatcaccag	tgagatacat	gtttattcaa	acacaagata	ccccaaatcc	aaacagctta	420
aagtttatac	caggaaaacc	agttcttgag	acaaggacca	tggattttcc	caccccagct	480
gcagcatttc	gctccctctt	ggctaggcag	ttatttagga	ttgaaggagt	aaaaagtgtc	540
ttctttggag	cagatttcat	cactgtcaca	aaggaaaatg	aagaattaga	ctggaattta	600
ctgaaaccag	atatttatgc	aacaatcatg	gacttctttg	catctggctt	acccttggtt	660
actgaggaaa	caccttcagg	agaagcagga	tctgaagaag	atgatgaagt	tgtggcaatg	720
attaaggaat	tgtagatac	tagaatacgg	ccaactgtgc	aggaagatgg	aggggatgta	780
atctacaaag	gctttgaaga	tggcattgta	cagctgaaac	tccagggttc	ttgtaccagc	840
tgccctagtt	caatcattac	tctgaaaaat	ggaattcaga	acatgctgca	gttttatatt	900
ccggaggtag	aaggcgtaga	acaggttatg	gatgatgaat	cagatgaaaa	agaagcaaac	960
tcaccttaaa	ataatctgga	ttttctttgg	gcataacagt	cagacttggt	gataatatat	1020
atcaagtttt	tattattaat	atgctgagga	acttgaagat	taataaaaata	tgctcttcag	1080
agaatgataa	aaaaaa					1096

<210> 13

<211> 590

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 012432.5.dec

<400> 13

gggcggaaga	ggtgggctgg	tggaggcggg	gtcgagatgg	cggcgccttt	gaggattcag	60
agcgactggg	cgcaagcctc	caggaaggat	gaaggggagg	cctggctgag	ctgtcatccc	120
ccagggaaac	catctttgta	tggcagcctg	acttgtcaag	gaattggcct	agatggcatc	180
ccagaggtta	cagcttcaga	aggatttact	gtgaatgaaa	taaacaagaa	aagcattcat	240
atttcatgtc	caaaggaaaa	tgcattctct	aagtttttgg	caccatatac	tactttttcc	300
agaattcata	caaagagtat	aacatgcctg	gacatttcca	gcagaggagg	tcttggtgtg	360
tctttctagta	ctgacgggac	catgaaaatc	tggcaggctt	ccaatggaga	atcaggaga	420
gtattgggaa	ggacatgtgt	ttgatgtgaa	ttgttcagg	tttttcccat	caggccttgt	480
ggtcctgagt	gggggaatgg	atgccagct	gaagatatgg	tcagctgaag	atgctagctg	540
cgtggtgacc	ttcaaaggtc	acaaaggagg	tatcctggga	tacagccatc		590

<210> 14

<211> 2109

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 059263.6.dec

<400> 14

ccccctactg	ctacccacag	ggcccccaact	ccacctgtct	ccagacgagg	ccaactcctg	60
gccaagctta	ggggcacagc	ggaggcgctc	tgtttctgat	ttttctcgcc	ttccttgagg	120
atgcctgtgc	ttggaaggga	aggcagaaca	ttgcatcttg	gaacaaatct	gcttttgatc	180
atgcaaatga	atgcctggat	aatgtaggca	gactgtcaat	ttcaccagtt	agaaagaaag	240
agaaaagggg	gagaaattcc	ccatgacagc	gactgatgaa	gaatttcaat	agaaagctgc	300
tacttcagaa	aataagatca	tttgctgcga	atggagaaca	tctcaggcag	ccctgatgct	360
ccaccggctc	tgggcatcac	cagcgcccc	agggaaaaag	aaagaaatgg	gaaacagcat	420
gaaatccacc	cctgcgcctg	ccgagaggcc	cctgcccaac	ccggaggggac	tggatagcga	480
cttccttggc	cgtgctaagt	gactacccgt	ctcctgacat	cagccccccg	atattccgcc	540
gaggggagaa	actgcgtgtg	atttctgatg	aagggggctg	gtggaaagct	atttctctta	600
gcactggctg	agagagttac	atccctggaa	tatgtgtggc	cagagtttac	catggctggc	660



tggttgagg	cctgggcaga	gacaaggccg	aggagctgct	gcagctgcca	gacacaaagg	720
tcggctcctt	catgatcaga	gagagtgaga	ccaagaaagg	gttttactca	ctgtcgggtga	780
gacacaggca	ggtaaagcat	taccgcattt	tccgtctgcc	caacaactgg	tactacattt	840
ccccgaggct	caccttccag	tgcctggagg	acctggtgaa	ccactattct	gaggtggctg	900
atggcctgtg	ctgtgtgctc	accacgcect	gcctgacaca	aagcacggct	gccccagcag	960
tgagggcctc	cagctcacct	gtcaccttgc	gtcagaagac	tgtggactgg	aggagagtgt	1020
ccagactgca	ggaggacccc	gagggaacag	agaacccgct	tggggtagac	gagtcccttt	1080
tcagctatgg	ccttcgagag	agcattgcct	cttacctgtc	cctgaccagt	gaggacaaca	1140
cctcctttga	tcgaaagaag	aaaagcatct	ccctgatgta	tgggtggcagc	aagagaaaga	1200
gctcattctt	ctcatcacca	ccttactttg	aggactagcc	aagaacagac	acaatgggttc	1260
atgccccaaa	ggaacagaag	ttccaactat	tgcctgggat	cttgcgaaaa	gcgagggttc	1320
ctgatccctg	ggagcctcac	gtatttttaga	agccaagaga	agccacatgg	agactcaaat	1380
tcgcatcttc	tctatccaca	tcatgaccaa	aggaacccct	ccctggtgtc	tgatcagggc	1440
tgtggcatca	cgaacattg	gatcatgaca	tgtcgggcga	tgcttggaag	agcccagcat	1500
gtatgtatg	acacattgtg	tgtgtgggaa	ggacaaaggcc	actctcacia	gaaagggcac	1560
caggactgct	ctccaaggaa	ctggacctgt	ccagacagtt	acactccaag	gtcattggag	1620
agaacttctg	tatgggcaag	cctgagaggg	agaggaaaca	aaagctgtgt	cctggcagaa	1680
ggtctgggtt	tgcagatggg	tgccctgaat	ggaactactt	taactaatcc	atagggactt	1740
ctgggtatgt	ttcctctctt	tttaaaggaa	cttcgtgaca	ctaaacatta	gccccaaagg	1800
cttcttagcc	ttcaattggg	agataccttt	ggtctgtctc	tgcaccaaag	ccatatgggt	1860
ggaagtcaag	tggcctccct	ggttctgcag	agggccagaa	gaatgagaga	gaggaagact	1920
gctggcaggg	aaatcgagga	ggcgagacta	gaactgcacc	agcttccctg	atgtctgcag	1980
ccatggcttt	gcagcgcaga	cagagcttct	ctgggatgct	gggattcttg	cctgtatgaa	2040
tgcataag	attcatttat	tgcccgaata	ggcattgcat	taagtccctc	gtaagggtgc	2100
aggcaagcc						2109

<210> 15

<211> 1100

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 196774.3.dec

<220>

<221> unsure

<222> 1089

<223> a, t, c, g, or other

<400> 15

gggggtgacct	ggcttcagac	agctctgccc	ttgacctggg	gcaaatacact	ttcctgtgtg	60
ggccttgggt	ttctcattcg	tgaatgacca	gatcactaga	gccctggact	ctgactttgg	120
gtctccttct	tagtttttca	caggggaagc	tattgtgggt	tggteccctac	cccacagggc	180
ctgaggcaat	ctaacctccc	tgagagggtc	cctgcagcca	gttgccctgag	gctgagttga	240
tgtgtggggac	agcccaggag	gttccctggg	gtggtttagtc	tgtattcagg	gtttggaaga	300
gctgaagtga	agtgggcggg	gaagtggggg	agaggggtgc	agttctgcag	agaaacgtgg	360
gtgggtagca	gagggacctc	gaggctgcta	gtccaacctt	ctgagctctg	ggcctttaac	420
tgaacacaga	tccttgagga	tatggcacta	atggagattt	gggggctaac	tccaaacccc	480
tcactcacaa	agggagatgg	aggtccagat	agggcacctc	aagtcacaca	gaaccaggcc	540
tcctgcaccc	cgttcattgc	taatcccata	gcactgggct	atgagccctt	tgggactggg	600
agtcctccatg	gagtcacaac	aagccttcac	agggcagggg	tgggagggaa	ggggctcagg	660
ctgagtgggt	ttgtgtctcg	cagtttccca	gacagtcctg	gcccagctgg	atgcactgct	720
ggtcttccca	ggccaagtgg	ctcaactctc	ctgcacgctc	agccccagc	acgtcaccat	780
cagggactac	ggtgtgtcct	ggtaccagca	gcgggcaggc	agtgcacctc	gatatctcct	840
ctactaccgc	tcggaggagg	atcaccaccg	gcctgctgac	atccccgate	gattctcggc	900
agccaaggat	gaggcccaca	atgcctgtgt	cctcaccatt	agtcctgtgc	agcctgaaga	960
cgacgcggat	tactactgct	ctgtttggcta	cggctttagt	ccctaggggt	gggggtgtgag	1020
atgggtgcct	cccctctgcc	tcccatttct	gcccttgacc	ttgggtccct	tttaaacttt	1080
ctctgagcct	tgttccctc					1100

<210> 16

<211> 906

<212> DNA

<213> Homo sapiens

<220>



<221> misc_feature
 <223> Incyte ID No: 233624.11.dec

<220>
 <221> unsure
 <222> 75, 585
 <223> a, t, c, g, or other

<400> 16
 cgcttgtgga gctggtggcg gcgctccgca ggggctcggc tgttttccgc gcggcaggcg 60
 cggccatggc gcaantggga aagctgctca aggagcagaa gtacgaccgg cagctgaggc 120
 gattcctcca tacatttgac agctgtctgg gcccttatgg agcatacagt ggagtggaaa 180
 gatggatgct cagcaaacaa aaacaaatga agccaggttg tgggggtgatc atgggcaaga 240
 ggctttagaa tctgctcatg tttgcctaata aaatgcaaca gccacaggaa ctgaaattct 300
 taaaaacttg gtactaccag gtattgggtc gtttacaatt attgatggaa atcaggctcag 360
 cggagaagat gctggaaaca atttcttcct tcaaagaagc aagtatcggc aagaaccgag 420
 ctgaagctgc catggaattc ttacaagaat taaatagcga tgtctctgga agttttgttg 480
 aagagagtcc agaaaacott ctagacaatg atccctcatt tttctgtagg tttactgttg 540
 tagttgcaac tcagcttctt gaaagcactt cactacgctt agcanatgtc ctctggaatt 600
 cccagattcc tcttttgatc tgtaggacat atggactagt tgggttatatg aggatcatta 660
 taaaagaaca tccagtaata gaatctcatc cagataatgc attagaggat ctacgactag 720
 ataagccatt tcttgaactg agagaacatt ttcagtccta tgatttggat catatggaaa 780
 aaaaggacca cagtcatact ccatggattg tgatcatagc taaatattta gcacagtggg 840
 atagtgaaga attctaaaaa atgaaaatgg ggctccagaa gatgaagaga attttgaaga 900
 agctat 906

<210> 17
 <211> 5923
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 228585.3.dec

<220>
 <221> unsure
 <222> 3280
 <223> a, t, c, g, or other

<400> 17
 tcatcagcga tgacagtggg gtcggcgctg aagcactctg ggaccaggtc accatggagc 60
 accaggagct ggctttcaaaa gctggggacg tcatcgaagt gatggatgcc accaacagag 120
 agtgggtggtg gggccgggtc gccgatggcg agggctggtt tccagccagc ttcgttcggc 180
 tgagggtgaa tcaggacgag cccgcggatg acgacgcccc tctggccggg aacagcggag 240
 cggaggacgg cggggcggag gcgcagagca gcaaggacca gatgcggacc aacgtcatca 300
 acgagatcct cagcactgag cgggactaca tcaagcacct gcgcgacatc tgcgagggtc 360
 acgtccggca gtgccgcaag cgcgcagaca tgttcagcga ggagcagctg cgtaccatct 420
 tcgggaacat cgaggacatc taccgctgcc agaaggcctt cgtgaaggcc ctggagcaga 480
 ggttcaaccg cgagcgccca cacctgagcg agctgggtgc ctgcttctctg gagcatcaag 540
 ccgacttcca gatctactcg gactactgca ataaccaccc caacgcctgc gtggagctct 600
 cccggctcac caagctcagc aagtacgtgt acttcttcga ggctgcccgg ctgctgcaga 660
 agatgattga catctccctg gatggcttcc tgctgactcc ggtgcagaag atctgcaagt 720
 accctctgca gctggccgag ctgctcaaat acacgcaccc ccagcacagg gacttcaagg 780
 atgttgaagc cgcttgcac gccatgaaga acgtggccca gctcatcaac gagcggaagc 840
 ggagacttga gaacatcgac aagattgctc agtggcagag ctccatagag gactgggagg 900
 gagaagatct cttggtcagg agctcagaac tcatctactc gggggagctg actcgagtta 960
 cacagcctca agccaaaagc cagcagcgaa tgttctttct ctttgaccac cagctcatct 1020
 actgtaagaa ggacctgctc cgccgcgacg tgttgacta caagggccgg ctggacatgg 1080
 acggcctgga ggtggtggac ctggaggacg ggaaggacag agacctccat gtgagcatca 1140
 agaacgcctt ccggctgcac cgtggcgcca caggggacag ccacctgctg tgcaccagga 1200
 agcccagca gaagcagcgc tggctcaagg cctttgccag ggagagggag cagggtgcagc 1260
 tggaccagga gacaggcttc tccatcactg aactgcagag gaagcaggcc atgctgaatg 1320
 ccagcaagca gcaggtcaca gggaagccca aagctgttgg ccggccctgc tacctgacgc 1380
 gccagaagca cccagccctg cccagcaacc ggccccagca gcaggtcctg gtgctggcgg 1440
 agcccagggc gcaagccatt ctaccttctg gcacagcatc agccggctgg cacccttccg 1500
 caagtgaact ggtccctgcc tgacagcacc tgctgggcct tcttgccagt ggcccccagt 1560



ttttcttccc	cgaggccac	tcggcctggc	cttcctctgc	ctgcaagtga	gcagggatgg	1620
gctggggagt	tgcttgtgcc	accaagacgt	gccaggtctg	tactcctgtt	gtctttttcc	1680
ctgctcctgg	tgccctgaag	agaccagcaa	gggggcagac	cccgcactcg	ccacaccgcc	1740
gctgcagctt	gggccccatc	cgccctctgg	acctgtgtag	ggcctcactg	ctggagcggg	1800
gaaaccgcag	ctcagccag	gccagctgg	ggagaaggcg	ctacctgcgt	gggacctct	1860
tctctggaaa	cctaatectc	ctttcatttc	ctctgggcag	gactctctgg	ccttctgtgg	1920
cctgcaatgc	caggccatgt	gccccctctg	cctctagtct	tccaagtecc	cagcccgccc	1980
agtgggtgcca	ggcagcttgc	cacttgggag	ggcagaagcc	aggaattcca	cacccttgtg	2040
ttgccccgg	agccccccct	tcgcctccca	gccccctcaag	acaccgctgg	ctgctggaca	2100
ccctcttcac	ttgtgtgtgt	gtgtgtagcg	gaaaaggaca	agacgggtgca	gtcggctgca	2160
tactcccagt	cgggagtgtg	gtcagtctgc	ctgctgctga	atcctggggg	ctccacccca	2220
gctcgccagg	ccctggcttt	gctcctggcg	ccccttgcca	ggacagggcg	ccatctccac	2280
acaccgcgtg	cctgggctgg	gggtcaatcc	tgtgtgctga	gccacaaaat	tcggctctct	2340
tcttatggct	tctcacgctc	gtgagcgtaa	ggcaatcttc	tgtgtcacta	aaaatcaatt	2400
ctttttctcc	attggttggg	ggtagaaaaa	caagatgcca	aaatccaaac	aaaaccagga	2460
acgaggtggg	tctggaacta	accgcacagc	agcaggcaga	ctgaccacac	tcccgactgg	2520
gagtatgcag	ccgactgcac	cgtcttgtcc	ttctccgcta	cacacacaca	cacaagtga	2580
gaggggtgtcc	agcagccagc	ggtgtcttga	ggggctggga	ggcgaagggc	gggctccggg	2640
cgcaacacaa	gggtgtggaa	ttcctggctt	ctgcctccc	aagtggcaag	ctgcctggca	2700
ccactggccg	ggctggggag	ttggagaact	agagggcaga	ggggcacatg	gcctggcatt	2760
gcagggccaca	gaaggccaga	gagtctgtcc	cagaggaaat	gaaaggagga	ttaggtttcc	2820
agagaagagg	gtcccacgca	ggtagcgctt	tctccccagc	tgggcctggg	ctgagctgcg	2880
gtttccccgc	tcagcagtg	aggccctaca	caggtccaga	gggaggatgg	ggcccaagct	2940
gcagcggcgg	tgtggcgagt	gcggggctgt	ccccttgcct	ggtctcttca	ggccaccagg	3000
agcagggaaa	aagacaacag	gagtacagac	ctggcacgtc	ttgggtggcac	aagcaactcc	3060
ccagcccatc	cctgctcact	tgcaggcaga	ggaaggccag	gccgagtggg	cctcggggaa	3120
gaaaaactgg	gggccactgg	caggaaggcc	cagcaggtgc	tgtcaggcag	ggaccattca	3180
cttgcggaag	ggtgccagcc	ggctgatgct	gtgccagaag	gtagatgctt	gcgcctggct	3240
ccgccagcac	caggacctgc	tgctggggcc	gtgtgctggn	cagggctggg	tgcttctggc	3300
gcgtcaggta	gcagggccgg	ccaacagctg	aacagggaga	gacagcagag	ggtcatgggt	3360
gcccagggca	gagtgccacc	ccagctgttg	gggacagcat	ggggctcgtc	ccagggctct	3420
gcttcagagc	cgccgtagga	ggcagttttg	ccacacagga	cttgcctctg	gagagctgac	3480
cacatccaag	agctcaggct	gcctggggct	cttggcttgg	gcctggcctc	gctcctgagc	3540
ctgaagaggg	gggtggcctg	tgcaaaggca	tgtgatgttt	caggggcatg	gctctctgta	3600
gaaatgggga	aagcagctcc	atccctacac	caaccccaga	tgccctgtcag	gaaggaaacc	3660
tggggaaaca	agcattgtca	ccaatggccc	tgatctgggg	gagccaaggt	gttgagagta	3720
agaatgtcaa	ccataactg	accaggtct	ccccagtggc	cccttattac	caacctttgg	3780
gaacaaacag	ctgccaaaag	gcagtgggcc	ccccctcaggc	ctgggtggcta	cttggttggg	3840
ctttgtgggt	cagagaaggg	aatgatgtca	gcagggttaag	gaccgggcag	ccgaggaggt	3900
ggggctgctg	tcgcctacc	tttgggcttc	cctgtgacct	gctgcttgc	ggcattcagc	3960
atggcctgct	tcctctgcag	ttcagtgtat	gagaagcctg	tctcctggtc	cagctgcacc	4020
tgctccctct	ccctggcaaa	ggccttgagc	cagcgtgctc	tctgctcagg	cttctgggtg	4080
cacagcaggt	ggctgtcccc	tgtggcgcca	cgggtgagcc	ggaaggcggt	cttgatgctc	4140
acatggaggt	ctctgtcctt	cccgctctcc	aggctccacca	cctccaggcc	gtccatgtcc	4200
agccggccct	tgtagtacaa	cacgtcgccg	cggagcaggt	ccttcttaca	gtagatgagc	4260
tgggtggtcaa	agagaaagaa	cattcgtctg	tggtctttgg	cttgaggctg	tgttaactga	4320
gtcagctccc	ccagtagat	gagttctgag	ctcctgacca	agagatcttc	tcctccccag	4380
tcctctatgg	agctctgcc	ctgagcaatc	ttgtcgatgt	tctcaagtct	ccgcttccgc	4440
tcgttgatga	gctgggccac	gttcttcatg	gcatgcaagg	cggcttcaac	atccttgaag	4500
tcctctgtgt	gggggtgctg	gtatttgagc	agctcggcca	gctgcagagg	gtacttgagc	4560
atcttcttga	ccggagtcag	caggaagcca	tccagggaga	tgtcaatcat	ctctgcagc	4620
agccggcagg	cctcgaagaa	gtacacgtac	ttgctgagct	tgggtgagccg	ggagagctcc	4680
acgcaggcgt	tggggtgggt	attgcagtac	tccgagtaga	tctggaagtc	ggcttgatgc	4740
tccaggaagc	aggcaccag	ctcgtcagc	tgtgggcgct	cgcggttgaa	cctctgctcc	4800
agggccttca	cgaaggcctt	ctggcagcgg	tagatgtcct	cgatgttccc	gaagatggta	4860
cgcagctgct	cctcgtgtaa	catgtctgcg	cgcttgccgc	actgccggac	gtagccctcg	4920
cagatgtcgc	gcaggtgctt	gatgtagctc	cgctcagtcg	tgaggatctc	gttgatgacg	4980
ttgggtccgca	tctggctcct	gctgctctgc	gcctccgccc	cgcggtctcc	cgctccgctg	5040
ttcccgccca	gaggggctgc	gtcatccgcg	ggctcgtcct	gattcaccct	cagccgaacg	5100
aagctggctg	gaaaccagcc	ctcgccatcg	gcgaccgggc	cccaccacca	ctctctgttg	5160
gtggcatcca	tcacttcgat	gacgtcccca	gctttgaagc	ccagctcctg	gtcgtccatg	5220
gtgacatggg	cccagagtcg	ttcagcgcag	accacactgc	catcgctgat	gagctcattg	5280
atagccagct	gctccccacc	ccctccaggg	tggctgtagt	gggtggctgga	gctgtgcagg	5340
tcacatatac	ggctcctcct	gctccccact	tcgtcagcgc	agacagctgt	gtccagagct	5400
ccatcaggca	tggcagtgcc	tgggtgtgtg	cttgccagc	ccatgtgggt	cagtcctcgt	5460
ggagcactct	gggagagtgg	atggcttctt	ctaggagat	tcaaagactc	tggagaggtg	5520
atgactgtct	ttctccagca	cttgactcca	tctttgtgca	ctgccccat	gtgcagcctc	5580



```

ctttcgacgt gggcctgctt ctgcaacttc tttctctgtg tcttctccag ccacaggtca 5640
tccacactga cgggcgagcg gtgagggatg cccctaggct gtgaaggagc ctccccacgc 5700
acagtctctg cagagatgca gaggagggcc catgtcacca tgtcagtggt gaagcagggc 5760
ttctgggcag gctccatgtg gaacgccttc tgactgtgag agcaactggg cttctcacct 5820
gctggttctt cccagggcat gtggttctca ctcccaggaa ggtccctgag ccagggcact 5880
gtgccccaac cgcgcggacc ctggcctcct tcctgtctct ctt 5923

```

<210> 18
 <211> 1228
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 198840.3.dec

```

<400> 18
gccggcgagt gtgagcggcg cctgctcagg gtagatagct gagggcgggg gtggatgttg 60
gatggattag aaccatcaca cttggggccc ctgtttgcc gaggttgaac cacacccga 120
tgtggtgtaa aggaattcat tagccatgga tgtattcatg aaaggacttt caaaggccaa 180
ggaggggagt gtggctgctg ctgagaaaac caaacagggt gtggcagaag cagcaggaaa 240
gacaaaagag ggtgttctct atgtaggctc caaaaccaag gagggagtgg tgcattggtg 300
ggcaacagtg gctgagaaga ccaagagca agtgacaaat gttggaggag cagtggtgac 360
gggtgtgaca gcagtagccc agaagacagt ggaggagca gggagcattg cagcagccac 420
tggctttgtc aaaaaggacc agttgggcaa ggaagggtat caagactacg aacctgaagc 480
ctaagaaata tctttgctcc cagtttcttg agatctgtg acagatgttc catcctgtac 540
aagtgtcag ttccaatgtg cccagtcatt acatttctca aagtttttac agtgtatctc 600
gaagtcttcc atcagcagtg attgaagtat ctgtacctgc cccactcag catttcggtg 660
cttccctttc actgaagtga atacatggta gcagggtctt tgtgtgctgt ggattttgtg 720
gcttcaatct acgatgttaa aacaaattaa aaacacctaa gtgactacca cttatttcta 780
aatcctcact atttttttgt tgctgttgtt cagaagtgtg tagtgatttg ctatcatata 840
ttataagatt tttagggtgtc ttttaatatg actgtctaag aataatgacg tattgtgaaa 900
tttgtaata tatataatc ttaaaaaatg gtgagcatga aactatgcac ctataaatac 960
taaataatgaa attttaccat tttgcgatgt gttttattca cttgtgtttg tatataaatg 1020
gtgagaatta aaataaaacg ttatctcatt gcaaaaaatat tttattttta tcccatctca 1080
ctttaataat aaaaatcatg cttataagca acatgaatta agaactgaca caaaggacaa 1140
aaatataaag ttattaatag ccatttgaag aaggaggaat tttagaagag gttagagaaa 1200
tggaacatta accctacact cggaattc

```

<210> 19
 <211> 594
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 082154.5.dec

```

<400> 19
gtgctgtctt cagaaaagcg aggaccgggc ccgggagggtg aaagttaacac aagaactgaa 60
aaacattcaa gttgagcaga tgacaaaact tcaagccaaa catcaagcag aatgtgattt 120
gcttgaagat atgaggacat tcagtcagaa gaaggctgct attgaaagag agtatgcaca 180
gggtatgcag aagttggcta gtcaatacct gaagagagat tggcctggag taaaagctga 240
tgatcggaat gattacagga gcatgtatcc cgtttggaaa tcttttctcg agggaaacaat 300
gcaggtagcc cagtctcgga tgaatatatg tgaaaactat aaaaacttca tttctgagcc 360
tgcaaggaca gtgagaagct taaaagaaca gcaactaaaa aggtgtgtgg accagttgac 420
aaagatccaa actgaattac aagagacagt gaaagattta gctaaaggca aaaagaaata 480
ctttgagact gaacagatgg ctcatgcagt acgagagaaa gctgacatcg aggcaaaatc 540
taaacttagt ctttttcaat caagaatcag tttacagaag gcaagtgtaa agtt 594

```

<210> 20
 <211> 4447
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature



<223> Incyte ID No: 368396.5.dec

<220>

<221> unsure

<222> 23, 189, 307, 412, 414, 433, 435

<223> a, t, c, g, or other

<400> 20

ctgaggcggc	gcccggacgga	gcncctgcage	ggctgtgaca	ggctacgcaa	caggttcgcg	60
ggcgggcgcc	tgacgaccaa	gccagctgca	gtggcgccga	cgccggcaga	gcaggggtctc	120
cccgcgccctg	cccgcgcccc	ggctgcccgt	gctgaggggac	gcggagtcgc	gctgtgacgt	180
gccccggagng	cgccgagggc	gccagatggc	tgagagctag	caaggaaaac	tcaggaccat	240
gatggctcag	tttcccacag	ctatgaatgg	agggccaaac	atgtgggcta	ttacctctga	300
agaacgnact	aagcatgaca	ggcagttttg	ataacctcaa	accttcagga	ggttacataa	360
caggtgatca	agcacgtaat	tttttcttac	aatcagggtct	gccggcccct	gntnaagctg	420
aactatgggg	ttanacagac	ctaaacaagg	atgggaagat	ggatcagcaa	gagttctcca	480
tagctatgaa	aactcattca	aactgaagct	tacaaggcca	acagttgcct	gtggttctcc	540
ctcctattat	gaagcaaccc	cctatgtttt	ctccattaat	ttctgctcgt	tttggaatgg	600
gaagcatgcc	caatctgtcc	attcctcage	cattgcctcc	agctgcacct	ataacatcat	660
tgctcttgcc	gacttcaggg	accaaccttc	ctcccttaac	gatgccact	cccctagtgc	720
cttctgttag	cacatcatca	ttaccaaatg	gaaccgccag	tctcattcag	cttttaccac	780
ttccttattc	ttcttcaaca	ttgcctcatg	ggatcatctta	tagtctgatg	atgggaggat	840
ttggagggtgc	tagtatacag	aaagcgcagt	ctctgatgta	tttaggatct	agtagctcaa	900
cttctctcag	tgcttcaact	tcagggaact	cacccaagac	tgggacctca	gagtgggcag	960
ttctctgacc	tacaagatta	aaatatcggc	aaaaatttaa	tactcttgac	aaaagtatga	1020
gtggatatct	ctcaggtttt	caagctagaa	atgcccttct	tcagtcaaat	ctttctcaaa	1080
ctcagctggc	tactatttgg	actctggctg	acgttgatgg	tgatggacag	ctaaaagcag	1140
aagagtttat	tcttgcaatg	caccttactg	acatggccaa	agctggacag	ccattaccac	1200
tgactttacc	tcttgagctt	gttctcccat	ctttcagagg	aggaaagcaa	attgattcca	1260
ttaatggaaac	tctgccttca	tatcagaaaa	tgcaagaaga	ggagcctcag	aagaaattac	1320
cagttacttt	tgaggacaaa	cggaaagcca	actatgagcg	agggaaacatg	gagctggaaa	1380
agcgacgcca	agccttgatg	gagcagcaac	aaagggaggc	agaacgtaaa	gcccagaaag	1440
aaaaggaaga	gtgggaacga	aaacagagag	aattacaaga	acaagaatgg	aagaaacaac	1500
ttgaattaga	aaaacgctta	gagaagcaac	gggaatttga	gagacaacga	gaggaagaaa	1560
ggagaaaaga	catagaaaga	cgagaggcag	caaaacagga	acttgaacga	caacgtcgct	1620
tagaatggga	gagaattcgg	cgacaggagc	ttctcaatca	aaagaataga	gaacaagaag	1680
aaattgtcag	gttaaactct	aaaaagaaga	atcttcatct	tgagtggaa	gcactgaatg	1740
gcaaacatca	gcagatctca	ggcagacttc	aggatgtccg	actcaaaaag	caaactcaaa	1800
agactgagct	ggaagttctg	gataagcagt	gtgacttggg	aattatggaa	atcaagcaac	1860
ttcaacagga	acttcaggaa	tatcagaata	agcttatcta	tctggtacct	gagaagcaat	1920
tattaaatga	aagaattaaa	aacatgcagt	tcagtaacac	acctgattca	ggggtcagtt	1980
tacttcataa	aaaatcatta	gaaaaggaag	aattatgcca	aagacttaaa	gaacagttag	2040
atgctcttga	aaaagaaact	gcactctaagc	gttcagaaat	ggattctttt	aacaatcaac	2100
taaaggaact	gagagaaacc	tacaacacac	agcagttagc	ccttgaacag	ctttataaga	2160
tcaaacgtga	caagttgaag	gaaattgaaa	ggaaaagatt	agaactaatg	cagaaaaaga	2220
aactagaaga	tgagggctgc	aaggaaaagca	aagcaaggaa	aagaaaactt	atggaaagaa	2280
aatcttagaa	aggaggaaga	agaaaaacaa	aagcgactcc	aggaagaaaa	aacacaagaa	2340
aaaattcaag	aagaggaacg	gaaagctgag	gagaacaac	gtgagacagc	tagtgttttg	2400
gtgaattata	gagcattata	cccccttgaa	gcaaggaacc	atgatgagat	gagttttaat	2460
tctggagata	taattcaggt	tgatgaaaaa	accgtaggag	aacctgggtg	gctttatggt	2520
agttttcaag	gaaatttttg	ctggttttcca	tgcaattatg	tagaaaaaat	gccatcaagt	2580
gaaaatgaaa	aagctgtatc	tccaaagaag	gccttacttc	ctcctacagt	ttctttatct	2640
gctacctcaa	cttctcttga	accactttct	tcaaatcaac	cagcatcagt	gactgattat	2700
caaaatgtat	ctttttcaaa	cctaactgta	aatacatcat	ggcagaaaaa	atcagccttc	2760
actcgaactg	tgtccccctg	atctgtatca	cctattcatg	gacagggaca	agtggtagaa	2820
aacttaaaag	cacaggccct	ttgttcttgg	actgcaaaga	aagataacca	cttgaacttc	2880
tcaaaacatg	acattattac	tgtcttggag	cagcaagaaa	attgggtggt	tggggaggtg	2940
catggaggaa	gaggatgggt	tcccaaatct	tatgtcaaga	tcattcctgg	gagtgaagta	3000
aaacgggaag	aaccagaagc	tttgatgca	gctgtaaata	agaaacctac	ctcggcagcc	3060
tattcagttg	gagaagaata	tattgcactt	tatccatatt	caagtgtgga	acctggagat	3120
ttgactttca	cagaaggtga	agaaatatgt	gtgaccaga	aagatggaga	gtggtggaca	3180
ggaaagtattg	gagatagaag	tggaattttt	ccatcaaact	atgtcaaac	aaaggatcaa	3240
gagagttttg	ggagtgtctag	caagtctgga	gcatacaata	aaaaacctga	gattgctcag	3300
gtaacttcag	catatgttgc	ttctggttct	gaacaactta	gccttgcacc	aggacagtta	3360
atattaattc	taaagaaaaa	tacaagtggg	tggtggcaag	gagagttaca	ggccagagga	3420
aaaaagcgac	agaaaggatg	gtttcctgcc	agtcattgta	aacttttggg	tccaagtagt	3480
gaaagagcca	cacctgcctt	tcatectgta	tgtcagggtga	ttgctatgta	tgactatgca	3540



gcaaataatg	aagatgagct	cagttttctcc	aaggggacaac	tcattaatgt	tatgaacaaa	3600
gatgatcctg	attggtggca	aggagagatc	aacgggggtga	ctggtctctt	tccttcaaac	3660
tacgttaaga	tgacgacaga	ctcagatcca	agtcaacagt	ggtgtgctga	tctgcaaacc	3720
ctggacacaa	tgcagccaat	tgagaggaaa	agacagggtc	atattcatga	gctgattcag	3780
accgaagagc	ggtacatggc	tgaccttcag	ctcgtcgtcg	aggtagaggag	gctgctgctg	3840
gctagctctc	gggttatctg	ctgtctctca	tgagagatgg	tgggcatcag	actcagggtc	3900
gcctccacgc	agagtcaaag	caaggcatca	cttttgatgt	gtgaattcac	aaatagtgac	3960
ggaagctctc	acatccctcca	aatgctgtct	ctgcctgccg	gataatgctt	gagattgaaa	4020
gtctctaatg	agctctttcc	cccagatgag	gtcactcaga	gtgaagcggg	agaacaagag	4080
ggcattcgca	tggcttcggt	ggatgtggca	ggagcccat	caagggaagg	cgggtagaga	4140
gtggatggga	agggcctatg	gcagaccgta	ggttccttgg	atatttgctt	aatatctgtt	4200
ttacatctctg	acattttcat	aaactgggtat	ctctggagga	actgtgaaac	agtgaagtg	4260
ttcacctcat	ggttgatca	gtttggaaaa	cccaatggga	gcatattgta	aaatagttcc	4320
caaatatcat	atagctactg	tttgtttata	ccagtgcct	ctacgtgat	gacagctatc	4380
cttattcgag	tagcacttta	aaatgatttg	tgcttgagtg	aacaaaagaa	gactttccat	4440
ttctact						4447

<210> 21

<211> 4204

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 349415.4.dec

<400> 21

acgcaggcag	tgatgtcacc	cagaccacac	cccttcccc	aatgccactt	caggggggtac	60
tcagagtcag	agacttggtc	tgaggggagc	agaagcaatc	tcagaggat	ggcgggtccag	120
gctcagccag	gcatacaact	caggaccctg	agggatgacc	gaaggccccg	cccaccacc	180
cccaactccc	ccgacccccac	caggatctac	agcctcagga	cccccgctcc	aatccttacc	240
ccttgcccca	tcaccatctt	catgcttacc	tcacccccca	tccgatcccc	atccaggcag	300
aatccagttc	cacccctgcc	cggaaaccag	ggtagtaccg	ttgccaggat	gtgacgccac	360
tgacttgctc	attggaggtc	agaagaccgc	gagattctcg	ccctgagcaa	cgagcgacgg	420
cctgacgtcg	gctggaggaa	gccggccacg	gctcggtag	gaggcaaggt	aagacgctga	480
gggaggactg	aggcgggcct	cacctcagac	agagggcctc	aaataatcca	gtgctgcctc	540
tgctgccggg	cctggggccac	cccgacgggg	aagacttcca	ggctgggtcg	ccactacctc	600
acccgcgcga	cccccgccgc	tttagccacg	gggaactctg	gggacagagc	ttaatgtggc	660
cagggcgagg	ctgggttagaa	gaggtcaggg	cccacgtgt	ggcaggaatc	aagggtcagga	720
ccccgagagg	gaactgaggg	cagcctaacc	accaccctca	ccaccattcc	cgccccccaa	780
cacccaaccc	cacccccatc	ccccattccc	atccccaccc	ccacccttat	cctggcagaa	840
tccgggcttt	gccccctggt	tcaagtcacg	gaagctccgg	gaatggcggc	caggcacgtg	900
agtcctgagg	ttcacatcta	cggctaaggg	aggggaaggg	ttcggtatcg	cgagtatggc	960
cgttgggagg	cagcgaaagg	gcccaggcct	cctggaagac	agtggagtcc	tgaggggacc	1020
cagcatgccca	ggacaggggg	cccactgtac	ccctgtctca	aaccgaggca	ccttttcatt	1080
cggctacggg	aatcctaggg	atgcagaccc	acttcagcag	gggggttggg	cccagccctg	1140
cgaggagtc	tggggaggaa	gaagagggag	gactgagggg	accttgaggt	ccagatcagt	1200
ggcaaccttg	ggctggggga	tgctgggcac	agtggccaaa	tgtgctctgt	gctcattgct	1260
ccttcagggt	gaccagagag	ttgagggctg	tggtctgaag	agtgggactt	cagggtcagca	1320
gagggaggaa	tcccaggatc	tgacggggccc	aagggtgtacc	cccaaggggc	ccctatgtgg	1380
tggacagatg	cagtggctct	aggatctgcc	aagcatccag	gtgaagagac	tgagggagga	1440
ttgagggtag	ccctggggaca	gaatgcggac	tggggggccc	ataaaaatct	gccctgctcc	1500
tgctgttacc	tcagagagcc	tgggcagggc	tgctcagctga	ggtccctcca	ttatcctagg	1560
atcactgatg	tcagggaagg	ggaagccttg	gtctgagggg	gctgcactca	gggcagtaga	1620
gggaggctct	cagaccctac	taggagtggg	ggtgaggacc	aagcagtctc	ctcaccagg	1680
gtacatggac	ttcaataaat	ttggacatct	ctcgttgctc	tttccgggag	gacctgggaa	1740
tgtatggcca	gatgtgggtc	ccctcatggt	tttctgtacc	atatcaggta	tgtgagttct	1800
tgacatgaga	gattctcagg	ccagcagaag	ggagggatta	ggccctataa	ggagaaaggt	1860
gagggccctg	agtgagcaca	gaggggatcc	tccacccag	tagagtgggg	acctcacaga	1920
gtctggccaa	ccctcctgac	agttctggga	atccgtggct	gcgtttgctg	tctgcacatt	1980
gggggcccgt	ggattcctct	cccaggaaac	aggagctcca	ggaacaaggc	agtgaggact	2040
tggctcagg	cagtgtcctc	aggtcacaga	gtagaggggg	ctcagatagt	gccaacgggt	2100
aaggtttgcc	ttggattcaa	accaagggcc	ccacctgccc	cagaacacat	ggactccaga	2160
gcgcctggcc	tcacccctcaa	tactttcagt	cctgcagcct	cagcatgcgc	tgcccggtat	2220
taccctgagg	tgccctctca	cttctctcct	caggttctga	ggggacaggc	tgacctggag	2280
gaccagaggc	ccccggaggc	gcactgaagg	agaagatctg	taagtaagcc	tttgttagag	2340
cctccaaggt	tccattcagt	actcagctga	ggtctctcac	atgctccctc	tctccccagg	2400



```

ccagtgggtc tccattgccc agctcctgcc cacactcccg cctgttgccc tgaccagagt 2460
catcatgcct cttgagcaga ggagtcagca ctgcaagcct gaagaaggcc ttgaggcccc 2520
aggagaggcc ctgggcctgg tgggtgcgca ggctcctgct actgaggagc aggaggctgc 2580
ctcctcctct tctactctag ttgaagtcac cctgggggag gtgcctgctg ccgagtcacc 2640
agatcctccc cagagtccct agggagccct cagcctcccc actaccatga actacctct 2700
ctggagccaa tcctatgagg actccagcaa ccaagaagag gaggggccaa gcaccttccc 2760
tgacctggag tctgagttcc aagcagcact cagtaggaag gtggccaagt tgggttcattt 2820
tctgtccttc aagtatcgag ccaggggagcc ggtcacaaag gcagaaatgc tggggagtggt 2880
cgtcggaaat tggcagtaact tctttcctgt gatcttcagc aaagcttccg attcctttgca 2940
gctgggtctt ggcatcgagc tgatggaagt ggaccccatc ggccacgtgt acatcttttg 3000
cacctgcctg ggcctctcct acgatggcct gctgggtgac aatcagatca tgcccaagac 3060
aggcttctctg ataatcatcc tggccataat cgcaaaagag ggcgactgtg cccctgagga 3120
gaaaatctgg gaggagctga gtgtgttaga ggtgtttgag gggagggaag acagtatctt 3180
cggggatccc aagaagctgc tcacccaata tttcgtgcag gaaaactacc tggagtaccg 3240
gcaggctccc ggcatgtatc ctgcatgcta tgagtctctg tggggtccaa gggccctcat 3300
tgaaaccagc tatgtgaaag tcctgcacca tatggtaaag atcagtgagg gacctcgcat 3360
ttcctaccca ctctgcatg agtgggcttt gagagagggg gaagagttag tctgagcacg 3420
agttgcagcc agggccagtg ggaggggggtc tgggccagtg caccttccgg ggccccatcc 3480
cttagtttct actgectcct gtgacgtgag gccattctt cactctttga agcgagcagt 3540
cagcattctt agtagtgggt ttctgttctg ttggatgact ttgagattat tctttgtttc 3600
ctgttggagt tgttcaaagt ttctttttaa cggatgggtg aatgagcgtc agcatccagg 3660
tttatgaatg acagtagtca cacatagtgc tgtttatata gtttaggagt aagagtcttg 3720
ttttttactc aaattgggaa atccattcca ttttgtgaat tgtgacataa taatagcagt 3780
ggtaaaagta ttgtcttaaa attgtgagcg aattagcaat aacatacatg agataactca 3840
agaaatcaaa agatagttga ttctgtcctt gtacctcaat ctattctgta aaattaaaca 3900
aatatgcaaa ccaggatttc cttgacttct ttgagaatgc aagcgaaatt aaatctgaat 3960
aaataattct tctcttcac tggctcgttt cttttccgtt cactcagcat ctgtctctgtg 4020
ggaggccctg ggtagtagt ggggatgcta aggtaagcca gactcacgcc taccatagag 4080
gctgtagagc ctaggacctg cagtcataata attaaagtgg tgagaagtc tgagagtagt 4140
agaggaaatg taagagaggg gtgagggtgt ggcgctccgg gtagagtagt tggagtgtca 4200
gtgc 4204

```

<210> 22

<211> 1044

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 474778.3.dec

<220>

<221> unsure

<222> 231, 979, 984, 999, 1017, 1030-1031, 1037

<223> a, t, c, g, or other

<400> 22

```

cggaggagcg atctgcaggt ttccatgtca gagcccgatg gagaactgaa gattgccacc 60
tacgcacaaa ggccattgag acacttcgtg tagctggaag acaccaactt cctgacagga 120
gctttatttc atttgggatt tcaagtttac agatgggtatc ttctcaaaaag ttggaaaaac 180
ctatagagat gggcagtagc gaacccttct ccacgcgaga tgggtgacagg nggaggaaga 240
agaagcggag ggccggggcc actgactcct tgccaggaaa gtttgaagat atgtacaagc 300
tgacctctga attgcttggg gagggagcct atgccaaagt tcaaggtgcc gtgagcctac 360
agaatggcaa agagtatgcc gtcaaaatca tcgagaaaca agcaggggcac agtcggagta 420
gggtgtttcg agagggtggg acgctgtatc agtgtcaggg aaacaagaac attttggagc 480
tgattgagtt ctttgaagat gacacaaggt tttacttggg ctttgagaaa ttgcaaggag 540
gtacttaccg ttgagtatgt gtgtggactt ctgattaaga cccagggtgg tgatcatcca 600
tcatgaatcc cagagacttc caaaacgagt caagctaata aaaggatgaa ggacttaaaa 660
actgcccttg atttgggaga agggaggccg gagggaagga tgataattag cttttgagc 720
agcttagaat gtcacctgtg tgggtatttt ataaatgcct tttcattata ataggagtca 780
tatatagata catttagtca tcgatttata aatcccgttt tgacatgttc actgtttaac 840
tacattaatt atgggtgga agctctcaaa tacattgcga agtctagaaa ggctaaaaca 900
gaggagagga gggctctatt gtttgggaca cagaccaggg ataaagggga agcctgagaa 960
tgtgccatcc ttcagatgnt aagntgccat caccacana cataatcact gcggtgnata 1020
cttaagtgen ntctganata atga 1044

```

<210> 23



<211> 3925
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 330933.5.dec

<220>
<221> unsure
<222> 3742, 3746
<223> a, t, c, g, or other

<400> 23
ctggaccagg cgtgcaaate tctagaagat gacgggtgttc tttaaaacgc ttcgaaatca 60
ctggaagaaa actacagctg ggctctgcct gctgacctgg ggaggccatt ggctctatgg 120
aaaacactgt gataacctcc taaggagagc agcctgtcaa gaagctcagg tgtttggaac 180
tcaactcatt cctcccaatg cacaagtga gaaggccact gtttttctca atcctgcagc 240
ttgcaaagga aaagccagga ctctatttga aaaaaatgct gccccgattt tacatttatc 300
tggcatggat gtgactattg ttaagacaga ttatgaggga caagccaaga aactcctgga 360
actgatggaa aacacggatg tgatcattgt tgcaggagga gatgggacac tgcaggaggt 420
tgttactggg gttcttcgac gaacagatga ggctaccttc agtaagattc ccattggatt 480
tatccactcg ggagagacca gtagtttgag tcataccctc tttgccgaaa gtggaaacaa 540
agtccaacat attactgatg ccacacttgc cattgtgaaa ggagagacag ttccacttga 600
tgtcttgtag atcaagggtg aaaaggaaca gcctgtattt gcaatgaccg gccttcgatg 660
gggatctttc agagatgctg gcgtcaaagt tagcaagtac tggatctctg ggctctctaa 720
aatcaaagca gccacttttt tcagcactct taaggagtgg cctcagactc atcaagcctc 780
tatctcatac acgggaccta cagagagacc tcccaatgaa ccagaggaga cccctgtaca 840
aaggccttct ttgtacagga gaattattac aaggcttgcc gtcctactgg gcacaaccac 900
aggatgccct tcccaagag gtgagcccg aggtctggaa agatgtgcag ctgtccacca 960
ttgaactgtc catcacaaca cggaataatc agcttgacct gacaagcaaa gaagattttc 1020
tgaatatctg cattgaacct gacaccatca gcaaaggaga ctttataact ataggaagtc 1080
gaaaggtgag aaaccccaag ctgcacgtgg agggcacgga ggtctctcaa gccagccagt 1140
gcactttgct tatcccgag ggagcagggg gctcttttag cattgacagt gaggagtatg 1200
aagcgatgcc tgtggagggt aaactgctcc ccaggaagct gcagttcttc tgtgatccta 1260
ggaagagaga acagatgctc acaagcccca ccagtgagc agcagaagac aagcactctg 1320
agaccacact ttaggccacc ggtgggacca aaagggaaca ggtgcctcag cccctccaca 1380
agtgtcgtca gagggtcccc agggcatttt ctctgtcacc tgctttgcaa tcggcttcca ttagcgcag 1500
gcagtgcctc ccaaagtgtg ctctgtcacc tggccctcct aaacacggac tttcctcagg ctggttcaag 1560
ttttattttg gtgtgacggg tggccctcct gttttcttcc aaagtgcacac cacagtggag agcccacggt 1620
acggaaaagg actttcttct gtcctaggcc ctccatttcc tcttctttga aattccagga 1680
gggcttagcc tgcctaggcc ctgccttggc tatgtctagg ctccctcaca ggtgctgcta 1740
aagtgcattc ctgccttggc gtttagcttt tatttcagtt ctaacctcag tccagaaaca 1800
ttttgtgagc tccggctcct gtttagcttt gtttagcttt ctaacctcag tccagaaaca 1860
tatgtgaggt tggttccctc ttcagccacg gctacaatac cggaaaatgc tagtttttat 1920
ttattttttt aagtagtgct tccataatgg ttgtcatgag agccacctgg ggtacatggt 1980
gaaaacttat ttggggtcta ccccaaacct aataacccaa atttggggat ggggccagg 2040
aatatgcatt tttaaaaagt catctgccct tcccagggtga ttctgtaagt tgtccctcaa 2100
ctgtacttgg agaaatcgtg ttttaaagca gtatgccaca aagtattctg ctcatgtgcc 2160
cccaaaaagta ttttgaaaaa tcatgtatac cctcacccat ctaagttgat atctaaaatt 2220
ttatctaagt tggtatctaa aatttttcat gggaagttaa atagttgaca aagtatgtat 2280
ttgctgggtg cgtgtaataa ttgggtatttt aaaataaaaa ctgttacatc actattttaa 2340
acatatccag tacaatttaa atatcacaac aatttgacac ccttcattca tttataaaaa 2400
taaatgagct agttcttttag tagttaaaca tttcaaattg gcttttctcc ttctgtattt 2460
ccataccact tttcagccaa gaatcctatc ataagttaat ctattatgcc cgacatcttt 2520
taatcattca ccccatctat tctgtgcaac aaaaaatata aatggaaatt ttttttttag 2580
ctcttgcttt aagtgtttgt ttgttatctc agtccagaac caatattatc gtaattaat 2640
attggtatat aatgaaaacg gtattaatte ttggatgatt aaaagttttt ttattagaat 2700
gttcttttate ctaattagtt catttatcca agaatacatg aatgtgattt acagctgaga 2760
tggggttcaa cctcagctgt attccttgtt tctgtataga tgtaagcaca taaattcgat 2820
ggaatagaat tacgttaaca atgtttttac agttctttgg attcctttgg ttttttttag 2880
aagatcacag tgctctatca tcaagaatta ttaatgatga tctatcaact aacaaacaac 2940
ttgattagat tctccttttag tctgttgaac gcagagaact gaaatccacc tgatttacca 3000
tggctttgccc agccagtcac tagcaccatt tacttttact atcgtgaca ttttctttg 3060
ttcagtggcc ctgaggttct tacactctag ggggcagtcg accacaggaa gatagatcaa 3120
tgagggagga ttgcgagggg gaaggggagc aagcagagct ggcaggcctt agctacagc 3180
tctctctcag gcagatccct ttttaagata atacaccatg cccacacatc ccatggagag




```

agaccaatgc tttagtagat tacagaacag ctatgaaaag tccatgaatg aagatcacaa 3240
aaaggaaggc tttcttattt catactgtat tcttcagggt ggtaaaattt ctgcttttgg 3300
caaaaacata acagacgggt ccaaacatca gcataaagat cactcatccc ataccacca 3360
caggtaggga ggaaggatgc tgtagtatat gaaaacaaaa gttttcacct gagctgagag 3420
catttagcat atcgtgggtc tgtaacaata tcaaggacca gtgcagaatc tggctttctt 3480
ttctgatagg ctaccagtgt gtgtttatgt gtgtctatct tgtggttcta atcataatgg 3540
tacatataat tagggaagga tatggaagcc actttagaat cttattcatt tttaaatata 3600
aatatgcctt gtttcaaact ttgttttctt gattcagggt ttctttcctg tgagggcttg 3660
gtttccttat tgttgactgc tttgttcttt gccttgctct tccctataaa gcttgcattg 3720
aagacgttta atagtgaac tnaaanagag tcagctgagt gaggcttgct agccaaagct 3780
ggaatgctga gctatctgga ggagatccta ataaccat ttggggatgg ggccaggaa 3840
tctgcattgg gaagtcggcc acccttccca ggtgattggt tagtacaac tttttgacag 3900
attaatttca ctcaaatgca aagat 3925

```

<210> 24

<211> 1254

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 998036.2.dec

<220>

<221> unsure

<222> 36, 49, 61, 63, 77, 85

<223> a, t, c, g, or other

<400> 24

```

gcggcgctga gccgcgccgc cgccactgag gaagangccg gccagccnc cgccgcgtcc 60
ngnccctcgc gcttgntcc cagcncccc atcccggcgc cccaaccccc acgcccgcct 120
ccgccaaact tcacgtgcc tcggcgccgc ggcccggctc gacgccaatg gtggaggcca 180
tagtgaggtt tgactaccag gccagcacg atgatgagct gacgatcagc gtgggtgaaa 240
tcatacacia catcaggaag gaggatggag gctggtggga gggacagatc aacggcagga 300
gaggtttgtt cctgacaac tttgtaagag aaataaagaa agagatgaag aaagaccctc 360
tcaccaacia agctccagaa aagcccctgc acgaatgccc agtggaaact ctttgcgtgc 420
ttctgaaacg attttaagaa ccaataagag aggcgagcga cggaggcgcc ggtgccaggt 480
ggcattcagc tacctgcccc agaattgacga tgaacttgag ctgaaagttg gcgacatcat 540
agaggtggta ggagaggtag aggaaggatg gtgggaaggt gttctcaacg ggaagactgg 600
aatgtttcct tccaacttca tcaaggagct gtcaggggag tcggatgagc ttggcatttc 660
ccaggatgag cagctatcca agtcaagttt aagggaaaacc acaggctccg agagtgatgg 720
gggtgactca agcagcacca agtctgaagg tgccaacggg acagtggcaa ctgcagcaat 780
ccagcccaag aaagttaagg gagtgggctt tggagacatt ttcaaagaca agccaatcaa 840
actaagacca aggtcaattg aagtagaaaa tgactttctg ccggtagaaa agactattgg 900
gaagaagtta cctgcaacta cagcaactcc agactcatca aaaacagaaa tggacagcag 960
gacaaagagc aaggattact gcaaagtaat atttccatat gaggcacaga atgatgatga 1020
attgacaatc aaagaaggag atatagtcac tctcatcaat aaggactgca tcgacgtagg 1080
ctggtgggaa ggagagctga acggcagacg aggcgtgttc cccgataact tcgtgaagtt 1140
acttcaccg gactttgaaa aggaaggga tagacccaag aagccaccgc ctccatccgc 1200
tcctgtcatc aaacaagggg caggcaccac tgagagaaaa catgaaatta aaaa 1254

```

<210> 25

<211> 499

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 999304.1.dec

<400> 25

```

cggacgcgtg ggctaggccc ccagtgtgt cactctcacc catcctctc tacacatgtg 60
agatgtttca ggaccagtg gcctttgatg atgttgctgt gaacttcacc caggaggagt 120
gggctttgct ggatatttcc cagaggaaac tctacaagga agtgatgctg gaaactttca 180
ggaacctgac ctctgtagga aaaagttgga aagaccagaa cattgaatat gagtacaaa 240
acccaggag aaacttcagg agtctcatag aaaagaaagt caatgaaatt aagatgaca 300
gtcattgtgg agaaactttt acccaggttc cagatgacag gctgaacttc caggagaaga 360

```


aagcttctcc tgaaataaaa tcatgtgaca gctttgtgtg tggagaagtt ggcctaggta 420
actcatcttt taatatgaac atcagaggtg acattggaca caaggcctat gagtatcagg 480
aatatggacc gaagccata 499



(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
5 April 2001 (05.04.2001)

PCT

(10) International Publication Number
WO 01/23538 A3

(51) International Patent Classification?: C12N 15/00.
15/63, C07K 14/47, 16/00, C12Q 1/68, G01N 33/68

(21) International Application Number: PCT/US00/26085

(22) International Filing Date:
22 September 2000 (22.09.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/156,565 28 September 1999 (28.09.1999) US
60/168,197 30 November 1999 (30.11.1999) US

(63) Related by continuation (CON) or continuation-in-part
(CIP) to earlier applications:

US 60/156,565 (CIP)
Filed on 28 September 1999 (28.09.1999)
US 60/168,197 (CIP)
Filed on 30 November 1999 (30.11.1999)

(71) Applicant (for all designated States except US): INCYTE
GENOMICS, INC. [US/US]: 3160 Porter Drive, Palo
Alto, CA 94304 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): HODGSON, David,
M. [US/US]: 567 Addison Avenue, Palo Alto, CA 94301
(US). LINCOLN, Stephen, E. [US/US]: 725 Sapphire
Street, Redwood City, CA 94061 (US). RUSSO, Frank,
D. [US/US]: 1583 Courdillaeras Road, Redwood City, CA
94062 (US). SPIRO, Peter, A. [US/US]: 3875 Park Boule-
vard, Apt. B16, Palo Alto, CA 94306 (US). BANVILLE,
Steven, C. [US/US]: 604 San Diego Avenue, Sunnyvale,
CA 94086 (US). BRATCHER, Shawn, R. [US/US]:
550 Ortega Avenue, #B321, Mountain View, CA 94040
(US). DUFOUR, Gerard, E. [US/US]: 5327 Greenridge
Road, Castro Valley, CA 94552-2619 (US). COHEN,
Howard, J. [US/US]: 3272 Cowper Street, Palo Alto,
CA 94306-3004 (US). ROSEN, Bruce, H. [US/US]:
177 Hanna Way, Menlo Park, CA 94025 (US). SHAH,
Purvi [IN/US]: 859 Salt Lake Drive, San Jose, CA 95133
(US). CHALUP, Michael, S. [US/US]: 183 Alcanes
Drive, Apt. 6, Sunnyvale, CA 94086 (US). HILLMAN,
Jennifer, L. [US/US]: 230 Monrow Drive, #17, Mountain

View, CA 94040 (US). JONES, Anissa, L. [US/US]:
445 South 15th Street, San Jose, CA 95112 (US). YU,
Jimmy, Y. [US/US]: 37330 Portico Terrace, Fremont, CA
94536-7901 (US). GREENAWALT, Lila, B. [US/US]:
1596 Ballantree Way, San Jose, CA 95118-2106 (US).
PANZER, Scott, R. [US/US]: 965 East El Camino, #621,
Sunnyvale, CA 94087 (US). ROSEBERRY, Ann, M.
[US/US]: 725 Sapphire Street, Redwood City, CA 94061
(US). WRIGHT, Rachel, J. [NE/US]: 339 Anna Way,
Mountain View, CA 94043 (US). CHEN, Wensheng
[CH/US]: 210 Easy Street, #25, Mountain View, CA
94043 (US). LIU, Tommy, F. [US/US]: 201 Ottilia Street,
Daly City, CA 94014 (US). YAP, Pierre, E. [US/US]: 201
Happy Hollow Court, Lafayette, CA 94549-6243 (US).
STOCKDREHER, Theresa, K. [US/US]: 1596 Ontario
Drive, #2, Sunnyvale, CA 94087 (US). AMSHEY, Stefan
[US/US]: 1541 Canna Court, Mountain View, CA 94043
(US). FONG, Willy, T. [US/US]: 572 Cambridge Street,
San Francisco, CA 94134 (US).

(74) Agents: HAMLET-COX, Diana et al.: Incyte Genomics,
Inc., 3160 Porter Drive, Palo Alto, CA 94304 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW). Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM). European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE). OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
2 May 2002

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: MOLECULES FOR DISEASE DETECTION AND TREATMENT

(57) Abstract: The present invention provides purified disease detection and treatment molecule polynucleotides (mddt). Also encompassed are the polypeptides (MDDT) encoded by mddt. The invention also provides for the use of mddt, or complements, oligonucleotides, or fragments thereof in diagnostic assays. The invention further provides for vectors and host cells containing mddt for the expression of MDDT. The invention additionally provides for the use of isolated and purified MDDT to induce antibodies and to screen libraries of compounds and the use of anti-MDDT antibodies in diagnostic assays. Also provided are microarrays containing mddt and methods of use.

WO 01/23538 A3

